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  Summary 
I 
 
Summary 
 
The focus of the present study was the characterization of the hydroxyprostaglandin 
dehydrogenase 15-(NAD) (HPGD) in CD4+CD25+ regulatory T cells (Treg) concerning its 
regulation and role for the development and suppressive function of Treg cells. On the one 
hand, HPGD fulfills an important function in the metabolism of prostaglandins and is one of 
the major prostaglandin E2 (PGE2)-metabolizing enzymes. On the other hand, HPGD was 
reported to be a tumor suppressor. As enhanced numbers of Treg cells can be found in tumor 
tissue and PGE2 was shown to activate Treg cells and contributes to carcinogenesis, the 
expression of HPGD in Treg cells is of particular interest.  
HPGD expression was shown to be significantly higher expressed in human Treg cells 
compared to CD4+CD25- T cells (Tconv). Notably, HPGD expression was specific for naturally 
occurring Treg cells (nTreg) as HPGD was not upregulated during CD4+ T cell differentiation 
and even induced Treg cells (iTreg) do not show an enhanced HPGD expression. Furthermore, 
exclusively in nTreg cells, HPGD expression could be specifically modulated by different 
extracellular stimuli. Even minuscule amounts of IL-2 were sufficient to strongly upregulate 
HPGD expression. These data further support that HPGD belongs to the nTreg cell specific 
gene repertoire as low IL-2 receptor signaling also supports thymic development of Treg cells. 
Thus HPGD might represent a novel nTreg cell molecule that can be used to distinguish them 
from iTreg cells. Besides that, the dependency of HPGD expression on the extracellular 
microenvironment also indicates a tissue-specific expression and potential function of HPGD 
in the Treg cell.  
Taken together, the present study demonstrates that HPGD represents a novel gene, which is 
specific for human naturally occurring Treg cells. Although the relevance of HPGD for the Treg 
cell function remains to be elucidated, the present study indicates a tissue-specific role of 
HPGD in Treg cells and provides a basis for further research, to determine the role of Treg cells 
in the tumor microenvironment. 
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  Introduction 
1 
1 Introduction 
1.1 Regulatory T cells 
 
The mammalian immune system has many mechanisms to protect the body from external 
harmful pathogens such as bacteria, viruses and parasites. Moreover, the immune system 
regulates immunological homeostasis and protects the body from deleterious immune 
reactions against body-own tissue. The well-balanced regulation of immune responses results 
from interactions between the different immune cells in the body with T-lymphocytes playing 
a central role in the immune response. On the one hand, they can act as direct effector cells, 
on the other hand they can have regulatory functions to control and modulate the immune 
reactions and functions of numerous other cell types 1.  
 
1.1.1 Discovery of T cells with regulatory characteristics 
 
The first evidence for the existence of cells with immune regulatory features was provided by 
several studies in the seventies of last century. It was demonstrated that T cells could also 
depress immune responses and were required to induce tolerance. Tolerance could even be 
adoptively transferred to naïve recipients 2-6. Following studies supplied further evidence for 
the existence of a specialized T cell subset and suppressor T cells were later defined by anti-
Ly antisera, as Ly23+ (CD8+) T lymphocytes 7,8.  
In the eighties, however, the research into suppressor T cells was discontinued because of 
different reasons. Among other things was the indication that no coding region corresponding 
to the I-J region was displayed in the murine MHC gene 9,10. The I-J region was thought to 
encode the (soluble) I-J molecule, which was associated with the suppressive function of the 
T suppressor cells as a key suppressor molecule 11. 
In the early nineties the interest in suppressive T cells was revitalized. It could be 
demonstrated that BALB/c athymic nude (nu/nu) mice, inoculated with CD25+ depleted CD4+ 
T cell suspensions (CD4+CD25- T cells), developed severe autoimmune diseases such as 
thyroiditis, gastritis etc. The progression of the autoimmune disease could, however, be 
prevented by the reconstitution with CD4+CD25+ cells 12. These suppressive CD4+CD25+ T 
cells were called “regulatory T cells” and represent approximately 5-10 % of the peripheral 
CD4+ T cells in normal unimmunized adult mice 12.  
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1.1.2 Development of naturally occurring CD4+CD25+FOXP3+ regulatory T cells 
1.1.2.1 Development in the thymus 
 
Naturally occurring CD4+CD25+FOXP3+ regulatory T cells (nTreg) can be found in the 
thymus and the periphery of naïve mice 1,13 and have been isolated from peripheral blood, 
tonsils and thymus of healthy human 14,15. They are generated in the thymus, as it was shown 
that neonatal thymectomy at day 3 after birth leads to transiently reduced numbers of Treg 
cells and severe organ-specific autoimmune diseases in mice 1,16. Despite the fact that 
regulatory T cells suppress self-reactive T cells and limit their reactivity to self-antigens, it is 
likely that Treg cells display characteristics of self-specific cells and show elevated affinity for 
peripheral self-peptides 17-19. The reason for this is that Treg cells have been shown to require 
T cell receptor (TCR) stimulation to mediate their suppressive activities in vitro and to 
regulate organ-specific autoimmune diseases in vivo 18,19. It is remarkable that self-reactive 
Treg cell precursors are not depleted in the thymus, as is the rule with normal self-reactive T 
cells. Instead highly autoreactive Treg cells seem to differentiate into mature Treg cells. It has 
been demonstrated that CD4+CD25+ thymocytes with a high affinity TCR for self-peptide 
were more likely to develop into mature Treg cells than thymocytes that bear TCRs with a low 
affinity for self-antigen 20,21. Nonetheless the exact signaling events and genetic signatures 
that lead to the preference of Treg cells with high avidity for self-peptides remain to be 
elucidated22. The increased specificity for self-peptide though seems not to be a requisite for T 
cells to develop into Treg cells. This was demonstrated by means of a transgenic mouse model, 
in which the expression of a particular T cell epitope by the thymic stromal cells could be 
quantitatively and temporally controlled. The Treg cell differentiation and cell number 
occurred to be independent of the dose of T cell epitope 23. Instead CD4+CD25+ Treg precursor 
cells were rather more resistant to clonal deletion than CD4+CD25- T cells. This explains the 
enlarged amount of self-reactive cells within the CD4+CD25+ Treg cell population 23. Besides 
that additional molecules other than the TCR and other mechanisms may be involved in the 
development of Treg cells in the thymus, since it has been reported that mice deficient in B7-1/ 
B7-2-(B7-/-) or CD28 show reduced frequencies of CD4+CD25+ thymocytes compared to mice 
sufficient for B7 or CD28 24,25. Moreover, IL-2 appears to play an important role in the 
development and maintenance of Treg, as IL-2Rβ-deficient mice show a loss of functional Treg 
cells 26. Naturally occurring Treg constitutively express CD25, the alpha chain of the IL-2 
receptor, but are in contrast to conventional CD4+CD25- T cells (Tconv) unable to secrete IL-2 
27
. 
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1.1.2.2 Development of CD4+CD25+ regulatory T cells in the periphery and induced Treg cells 
 
The central role of the thymus in the development of CD4+CD25+ regulatory T cells is well 
established but it is not the only site for their formation. If the thymus was the only location 
for Treg cell development, the number of Treg cells in humans would due to thymic involution 
decrease with the advance of years. However, the Treg number does not decline but even 
increases with aging 28. Several studies with transgenic mice have demonstrated the peripheral 
generation of CD4+CD25+ Treg cells. Mice that were thymectomized at day 3 after birth 
showed a transient absence of Treg at first and later within 3 months the Treg numbers 
increased again to normal amounts 1. Another study used CD4+ T cells from OVA-specific 
DO11.10 TCR transgenic mice on a Rag-2 deficient background. These cells were transferred 
into BALB/c receptor mice with following intravenous or oral administration of antigen to 
induce peripheral tolerance. After tolerance induction TCR-transgenic CD4+CD25+ T cells 
emerged in tolerized animals with phenotypic characteristics similar to Treg cells 29,30. 
Obviously the new Treg cells were induced (iTreg) from the CD4+CD25- T cells pool towards a 
Treg cell phenotype. Similar results were obtained when mice were tolerized with antigen that 
was coupled to the monoclonal antibody (mab) against DEC205, which is an endocytic 
receptor highly expressed by dendritic cells (DCs) 31-33. The regulatory T cells generated in 
the periphery were termed ‘adaptive’ or ‘induced’ Treg cells (iTreg) and different 
subpopulations of these cells have been described by now.  
CD4+ T helper-3 T cells (TH3) can be induced by TGF-β in vitro or by antigen feeding in 
rodents in vivo. They lack FOXP3 expression but express TGF-β and suppress via TGF-β 
secretion 34. Besides that, CD4 positive type 1 regulatory T cells (Tr1) exist. They can be 
generated in vitro and in vivo in the presence of IL-10. Tr1 cells lack FOXP3 expression and 
mediate suppression via IL-10 secretion and TGF-β 35. Recently, it was shown that naïve 
human or mouse T cells can be induced in vitro towards the regulatory ‘iTR35’ cells by IL-35 
treatment. Their generation in vivo was induced under inflammatory conditions in the 
intestines of mice infected with Trichuris muris. These iTR35 cells did not express FOXP3 
and mediated suppression via IL-35 36.  
Furthermore, additional subpopulations of T cells with regulatory activities have been 
described like CD4+LAP+ T cells, that lack FOXP3 expression but express TGF-β receptor 
type II and the activation marker CD69, are hypoproliferative and exhibit IL-10 and TGF-β-
dependent suppressive activity in vitro 37. Moreover, there are different CD4 negative 
subpopulations with regulatory capacities including CD8+, CD4-CD8- (double negative 
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CD3+), γδ T cells and natural killer T (NKT) cells 38-41 . A summary of thymic and peripheral 
formation of Treg cells is given in Figure 1. 
 
 
Figure 1: Generation of FOXP3+ Treg cells in the thymus and in the periphery. 
Natural FOXP3+ Treg cells (nTreg) differentiate in the thymus and migrate to peripheral tissue. The 
differentiation of adaptive FOXP3+ Treg (iTreg) cells as well as FOXP3- iTreg (Tr1, TH3 and iTR35 cells) occurs in 
the periphery. Also TH effector cells such as TH1, TH2, TH9, TH17 etc. differentiate in secondary lymphoid 
tissue. The graphic was modified from Curotto de Lafaille et al. 2009 42. 
 
1.1.3 Immunological phenotype and features of regulatory T cells 
1.1.3.1 Surface molecules specifically expressed on naturally occurring regulatory T cells 
 
Naturally occurring CD4+CD25+FOXP3+ regulatory T cells (nTreg) are described as a subset 
of CD4+ T cells that show constitutively expression of CD25, the alpha chain of the IL-2 
receptor (IL-2R) 12. The IL-2R consists of three subunits, the α- (CD25, IL-2Rα), β- (CD122, 
IL-2Rβ) and γ-chain (CD132, IL-2Rγ). The β- and γ-chain are constitutively expressed on the 
cell surface. Upon antigen activation also the α-subunit is expressed and transported to the 
cell membrane. All three subunits need to be present so that the receptor gains a sufficient 
affinity of IL-2 43. In non-immunized, healthy mice CD25 expression can be used as a good 
marker for nTreg cells. However, CD25 is frequently found on all T cells upon activation 44.  
For this reason several studies were made to find other surface markers suitable for the 
characterization of nTreg. Different surface molecules have been proposed to be associated 
with the function, development or generation of CD4+CD25+FOXP3+ regulatory T cells. In 
addition to CD25 the most commonly used surface markers for nTreg are the cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4) 18,45, the interleukin-7 receptor-α-chain (CD127) 
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46,47
, the glucocorticoid-induced TNF receptor (GITR) 48,49 and lymphocyte activation gene-3 
(LAG-3) 50. But also other surface molecules like the nucleoside triphosphate 
diphosphohydrolase-1 (NTPDase 1; CD39) have been shown to be primarily expressed by 
immune-suppressive FOXP3+ regulatory T cells 51. The TGF-β latency-associated peptide 
(LAP) is expressed on the surface of activated mouse and human FOXP3+ Treg and it was 
shown that immunosuppression by cell-cell interactions is mediated via cell-surface bound 
TGF-β 52-54. The TNFR family members OX40 (CD134) and 4-1BB (CD137) have also been 
suggested to play a role in controlling the generation and activity of Treg cell, although they do 
not have a major role in homeostasis of nTreg in vivo 55-57. Recent studies have shown that 
GARP (or LRRC32), an orphan toll-like receptor composed of leucine-rich repeats, is highly 
expressed on activated nTreg in comparison to non-activated and activated non-Treg cells 52,58. 
However, these surface molecules can also be found on CD4+ T cells in different activation, 
differentiation and developmental states and up to now no specific surface molecule was 
identified to be unique for naturally occurring CD4+CD25+FOXP3+ Treg cells. 
 
1.1.3.2 The transcription factor FOXP3 – a master switch for development and function of Treg cells 
 
In 2003 the transcription factor FOXP3 (forkhead box P3), a member of the forkhead/winged-
helix family of transcription factors was described to be expressed in naturally occurring 
regulatory T cells and identified as lineage marker for nTreg 59-62. Previous studies initially 
described Foxp3 as the defective gene in the Scurfy mutant mouse. This mouse strain is an X-
linked recessive mutant that is lethal in hemizygous males within a month after birth. Scurfy 
mice exhibit fatal X-linked lymphoproliferation that is characterized by hyperactivation of 
CD4+ T cells, overproduction of proinflammatory cytokines and a multiorgan 
immunopathology 63. The immunodysregulation, polyendocrinopathy, enteropathy, X-linked 
(IPEX) syndrome is the corresponding disease in humans and is caused by a mutation within 
the FOXP3 gene. The IPEX syndrome is an X-linked recessive disorder that is caused by 
mutations in the FOXP3 gene located at Xq11.23-Xq13.3 of the X chromosome. Human 
individuals that suffer from IPEX develop various symptoms and diseases. These can be 
eczema, watery diarrhea, type I diabetes mellitus, excessive cytokine production and chronic 
inflammation, which lead to an early death 64-66.  
Though FOXP3 is not exclusively expressed in human nTreg, as recent works identified a 
transient expression of FOXP3 in activated human Tconv cells, which however does not 
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necessarily confer suppressive activity 67-69 as these FOXP3-expressing T cells did either exert 
suppressive activities 70,71 or not 68,69.  
In fact a high and stable expression of FOXP3 is required for the induction of suppressive 
activity in Tconv cells. This was demonstrated with the retroviral transduction of FOXP3 into 
FOXP3- non-regulatory CD4+ cells. They gained a fully functional Treg cell like phenotype; 
they became anergic, expressed Treg typical surface markers and showed suppression in vitro 
and in vivo. These observations demonstrate that FOXP3 is a highly specific marker for Treg 
cells and that it plays a role as master regulator because its expression is sufficient and 
necessary for the development of Treg 59-61.  
 
1.1.3.3 Anergy of regulatory T cells 
 
Naturally occurring Treg cells display specific characteristics and functions by which they can 
be characterized. On the one hand, nTreg cells can be identified by the expression of Treg-
associated surface molecules (see 1.3.1) and the expression of FOXP3 (see 1.3.2). On the 
other hand, although Treg cells require TCR activation for their functional activation, they 
possess an anergic phenotype and stay hypoproliferative towards CD3/CD28 engagement. 
Upon TCR stimulation Treg will not proliferate or produce IL-2 as for instance Tconv cells 
(effector T cells) 19,72,73. However, protocols have been developed for their in vitro expansion. 
The expansion is thereby performed via TCR/CD28 engagement in the presence of very high 
concentrations of IL-2 74. Furthermore, Treg cells were found to proliferate extensively in vivo 
in response to immunization, without losing their suppressive function in vivo, and they 
accumulated locally in response to transgenically expressed tissue antigen 75,76. 
The relationship between anergy and suppressive capacity needs to be further investigated. 
The anergic state in Treg can be abrogated by TCR stimulation in vitro combined with high- 
dose costimulation of IL-2 or CD28 and leads to a loss of the suppressive activity 77. Once IL-
2 and CD28 costimulation are removed, Treg cells regain their anergic state and suppressive 
activity 78. This was also observed in vivo 76. 
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1.1.3.4 Suppressive activity of regulatory T cells 
 
Another feature is their suppressive capacity in vitro and in vivo. nTreg show suppression of 
the proliferation and cytokine production of activated Tconv cells and of CD8+ T cells. But they 
can also suppress dendritic cells (DC), natural killer (NK) cells, natural killer T cells and B 
cells 18,78-80. Various potential suppression mechanisms and molecules that are used by Treg 
cells have been described.  
 
1.1.4 Different suppression mechanisms used by regulatory T cells 
 
Different suppression mechanisms have been demonstrated to be used by Treg cells to 
suppress the proliferation of Tconv cells and their effector cell functions. These mechanisms 
were shown to be cell-contact-dependent on the one hand. Treg cells were not able to suppress 
proliferation of Tconv cells when they were separated by a semi-permeable membrane from the 
Tconv 19,72. Further evidence for a cell-contact dependency proved that Treg failed to suppress 
B7-deficient T cells 81. On the other hand, also various cell contact-independent mechanisms 
have been described. Concerning the mode of action the suppression mechanisms can be 
divided into four main groups:  
a. Suppression by cytolysis  
b. Suppression by inhibitory cytokines 
c. Suppression by metabolic disruption 
d. Suppression by modulation of dendritic-cell (DC) maturation and function. 
 
1.1.4.1 Suppression by cytolysis 
 
Treg were shown to exhibit cytolytic activity to kill Tconv cells in a granzyme- or perforin-
dependent manner 82,83 Also B cells, NK cells and cytotoxic T lymphocytes have been shown 
to be killed in a granzyme-B-dependent and perforin-dependent manner by Treg cells 84,85. 
Furthermore, it was suggested that activated Treg induce apoptosis of Tconv cells through a 
TRAIL-DR5 (tumor-necrosis-factor-related apoptosis-inducing ligand-death receptor 5) 
pathway 86. Another study has shown that human and murine Treg upregulated galectin-1 
(LGALS1), which can induce T cell apoptosis and that galectin-1-deficient Treg had reduced 
regulatory activity in vitro 87. 
  Introduction 
8 
1.1.4.2 Suppression by inhibitory cytokines 
 
Besides cell-contact dependent suppression also cytokines like IL-10 or TGF-β seem to play 
an important role, as these cytokines possess immunosuppressive characteristics. However, in 
vitro studies with neutralizing antibodies against IL-10 and TGF-β revealed that IL-10 and 
TGF-β are not essential for the Treg cell function 18,19. Contrary to that these cytokines 
contribute to suppression in vivo, because IL-10 deficient Treg were unable to suppress 
inflammatory bowel disease (IBD) in a mouse model 88. Furthermore, blockade of the IL-10 
receptor (IL-10R) and neutralization of TGF-β did abolish Treg-mediated inhibition of the 
disease 45. Other studies suggest a crucial role for membrane-bound TGF-β. Membrane-
tethered TGF-β on Treg cells was shown to participate in a cell-cell contact-dependent 
suppression 54,89. 
Recent studies have identified IL-35 as another immunosuppressive cytokine. IL-35 is a novel 
member of the IL-12 heterodimeric cytokine family and is formed by pairing of the Epstein-
Barr virus-induced gene 3 (Ebi3) with p35 (Il12a). Natural FOXP3+ Treg cells were shown to 
produce predominantly immunosuppressive IL-35 and IL-35-deficient Treg were less 
suppressive in vivo (in controlling IBD) and in vitro (in a suppression assay) 90. 
 
1.1.4.3 Suppression by metabolic disruption 
 
The high expression of CD25 on nTreg and their inability to produce IL-2 themselves gave rise 
to the studies whether Treg cells ‘consume’ IL-2 in order to inhibit effector T cell responses. 
Cytokine deprivation led to apoptosis of dividing Tconv cells that need IL-2 to survive and was 
therefore proposed to be a prominent suppression mechanism used by Treg cells 19,91,92. 
However, other studies suggested that cytokine depletion is not a fundamental suppression 
mechanism of Treg. The relevance of IL-2 for immunosuppression was challenged by a study 
that used human Treg cells. It was demonstrated that IL-2 deprivation alone was not required 
for suppression of effector T cells 93. Therefore, the role of IL-2 deprivation as a suppression 
mechanism used by Treg needs to be further investigated. 
Besides IL-2 depletion, Treg cells have been reported to directly transfer cyclic adenosine 
monophosphate (cAMP) through membrane gap junctions into Tconv cells. Thereby 
intracellular cAMP levels in Tconv are upregulated, which finally lead to inhibition of T cell 
proliferation and IL-2 formation 94.  
  Introduction 
9 
Furthermore, Treg express the ectoenzymes CD39 (ectonucleoside triphosphate 
diphosphohydrolase 1) and CD73 (ecto-5’-nucleotidase). These ectoenzymes catalyze the 
generation of pericellular adenosine, which also suppresses effector T cell function through 
activation of the adenosine receptor 2A (A2aR) 51,95. 
 
1.1.4.4 Suppression by modulation of dendritic-cell (DC) maturation and function 
 
Treg cells have been shown to suppress effector T cell function by directly affecting these cells 
via cell-contact-dependent and -independent mechanisms. In addition, intravital microscopy 
revealed that Treg cells interact with dendritic cells (DCs) in vivo 96,97. Treg cells have been 
reported to modify the function of APCs especially DCs, that in turn leads to suppression of 
effector T cell functions 96,97. Treg may for example induce the down-modulation of CD80 and 
CD86 on DCs 98. Thereby the co-stimulatory molecule cytotoxic T-lymphocyte antigen 4 
(CTLA-4) plays an important role that is constitutively expressed on Treg cells 45. This was 
demonstrated by use of CTLA-4-specific blocking antibodies or CTLA-4-deficient Treg that 
suppression mediated via DCs was reduced 98,99. Moreover, Treg cells can induce the 
expression of immunosuppressive molecules like the tryptophan-degrading enzyme 
indoleamine 2,3-dioxygenase (IDO) in DCs. IDO is known to induce production of pro-
apoptotic metabolites from the catabolism of tryptophan. This leads to the suppression of 
effector T cells through a mechanism dependent on interactions between CTLA-4 and CD80 
and/or CD86 100,101. Other studies have reported that Treg can modulate and even block the 
maturation of DCs via a lymphocyte-activating gene 3 (LAG-3; CD223) mediated mechanism 
50,102
. Moreover, the molecule neuropilin-1 was found to prolong interactions with Treg cells 
and immature DCs 103. 
It has been suggested that the nTreg cell population maintains immunological tolerance and 
amplifies their suppressive function by the in vivo conversion of non-Treg into induced Treg 
cells (see also chapter 1.1.2.2). This induction process is also called ‘infectious tolerance’ and 
is shown to be cytokine-mediated, for instance by IL-10 or TGF-β 35,36,104,105 (see also chapter 
1.1.2.2). Natural Treg cells were shown to secrete IL-35 90. A recent study has shown that Tconv 
cells can be induced towards a T cell subset with regulatory activities called ‘iTR35’ cells by 
incubation with IL-35 in vitro 36. This conversion was also observed in vivo under 
inflammatory conditions in intestines infected with Trichuris muris and within the tumor 
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microenvironment. Thereby it was shown that approximately half of the regulatory 
microenvironment in the tumor consisted of ‘iTR35’ cells 36.  
In view of the plethora of suppressive mechanisms the question arises whether all these 
different molecules and mechanisms together are crucial for the Treg-cell function or whether 
single mechanisms exist that are used by all Treg-cells. The dependency on some single 
suppressive mechanism used by all Treg, is rather unlikely. So it was demonstrated that the 
abrogation of one suppression mechanism leads to a substantial but not a complete loss of the 
regulatory Treg-cell function. Otherwise the lack of a single molecule, for instance IL-10, 
would result in a scurfy-like phenotype. It is rather more presumable that Treg cells use 
different mechanisms of suppression depending on the type of target cell. Furthermore, 
different mechanisms may be required or may be more effective in different tissues 
compartments or for different diseases. Thereby, the mechanisms could also act in concert to 
enhance the suppressive efficacy. However, the exact interaction of the different mechanisms 
needs to be further investigated. 
 
1.1.5 Regulatory T cells in the tumor microenvironment 
 
Various studies have demonstrated the presence of regulatory T cells in tumor tissues as well 
as tumor-draining lymph nodes in rodents and also in cancer patients suffering from tumors in 
head and neck 106, lung 107, liver 108, in the gastrointestinal tracts 109, pancreas 110, breast tissue 
111
 and ovary tissue 112. Thereby increased numbers of Treg cells can be observed within the 
tumor tissue, which correlates with poor prognosis in patients with breast cancer 113, gastric 
cancer 109 and ovarian cancer 109,112. 
The question of how and why Treg cells are recruited to the tumor and are found in increased 
numbers in the tumor tissue is the focus of several studies. It is proposed that the proliferating 
and dying tumor cells provide large amounts of self-antigens that may attract and recruit Treg 
cells. Furthermore the inflammatory environment can also attract Treg to migrate to the tumor 
site 114. Besides that the tumor cells and tumor infiltrating macrophages produce chemokines 
like CCL22 that can recruit CCR4-expressing Treg cells 112,115. Finally it is proposed that 
FOXP3+ Treg cells are induced from non-Treg cells in the tumor microenvironment as a result 
of the high concentrations of tumor-derived TGF-β 116,117. 
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1.2 Interleukin-2 receptor signaling pathways 
 
Interleukin-2 is important for T cell proliferation, survival and programmed cell death and is 
primarily produced by activated T cells, which also represent the main target of IL-2 118-121. 
Besides, IL-2 is also important for other biological processes, like growth and differentiation 
of B cells 122, generation of lymphokine-activated killer cells 123, augmentation of natural 
killer cells 124 and proliferation and maturation of oligodendroglial cells 125. IL-2 consists of 
133 amino acids with a molecular mass of 15-18 kDa and mediates signaling via a multichain 
receptor complex 43. This interleukin-2 receptor (IL-2R) belongs to the type I cytokine 
receptor superfamily 118,119. It is composed of three subunits: the affinity-modulating subunit 
IL-2Rα (CD25) and the two signaling subunits IL-2Rβ (CD122) and IL-2Rγ (CD132) 126. 
Thereby the β- and γ-chain are constitutively expressed on the cell surface. Upon antigen 
activation also the α-subunit is expressed and transported to the cell membrane. All three 
subunits need to be present so that the receptor gains a sufficient affinity for IL-2 43. The 
binding of IL-2 to the IL-2R can activate a variety of different signaling cascades, which are 
depicted in a generalized overview in Figure 2. IL-2 can activate for instance the JAK/STAT-
signaling pathway. Phosphorylation of the cytoplasmic β- and γ-chain of the IL-2R provide 
docking sites for the janus kinases-1 and -3 (JAK1 and JAK3) 127,128, which are in turn 
autophosphorylated and thus provide docking sites for Signal Transducer and Activator of 
Transcription-5 (STAT-5). STAT5 is phosphorylated, which leads to dimerisation and nuclear 
translocation of STAT5 complexes, where they initiate transcription of target genes 129. 
Moreover, IL-2 can activate the PI3K/Akt-signaling pathway. Binding of IL-2 leads to 
activation of Phosphatidylinositol 3-kinase (PI3K). This leads to production of inositol 
phospholipids PtdIns (3,4,5)P3 and PtdIns(3,4)P2, which attract Akt (also known as Protein 
Kinase B, PKB) to the plasma membrane, where it is phosphorylated130. Akt in turn 
phosphorylates and thus activates IκB kinase (IKK), which is comprised of the catalytic 
subunits IKK-α and IKK-β and the regulatory subunit IKK-γ (NEMO)131-133. IKK 
phosphorylates the inhibitor of κBα protein (IκBα), which leads to ubiquitination of IκBα, its 
dissociation from nuclear factor κB (NF-κB, subunits p50 and p65) and eventual degradation 
of IκBα by the proteasome. The release of NF-κB allows its translocation to the nucleus 
where it initializes transcription132-134. The IL-2R can also activate the MAPK-signaling 
pathway as it binds spleen tyrosine kinase (Syk) and lymphocyte-specific protein tyrosine 
kinase (Lck), which are activated downstream of JAK1 and JAK3 135. This stimulates 
association of SHC (Src homology 2 domain containing) transforming protein 1(Shc), GRB2 
(Growth factor receptor-bound protein 2) and SOS (Son of sevenless homologs), which 
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further activate signaling via Ras (v-Ha-ras Harvey rat sarcoma viral oncogene homolog), Raf 
(v-Raf-1 murine leukemia viral oncogene homolog 1), MEK1/2 (Mitogen-activated protein 
kinase 1 and ; MEKs2) and ERK1/2 (Extracellular signal-regulated kinase 1 and 2; ERKs). 
This pathway leads to activation of the transcription factors such as Elk-1, c-Myc, c-Fos or c-
Jun/c-Fos (AP-1) 136-139. 
 
 
 
Figure 2: Generalized overview of different IL-2 signaling pathways. 
Binding of IL-2 to the IL-2R (subunits α, β and γ in orange) can activate different signaling cascades. IL-2 can 
activate the JAK/STAT-signaling pathway by activation of JAK1 and JAK3, resulting in the activation of 
STAT-5, its dimerisation and translocation to the nucleus where STAT5 initiates transcription of target genes. 
IL-2R signaling can also activate PI3K/Akt-signaling cascade, which leads to activation of Akt. Akt in turn 
activates IKK that phosphorylates IκBα. This results into the degradation of IκBα and the release of NF-κB, 
which can now translocate to the nucleus and initialize transcription. Phosphorylation of JAK1/JAK3 can also 
activate the MAPK-signaling pathways. SYK and LCK are activated, which leads to association of SHC, GRB2 
and SOS that further activate signaling via Ras, Raf, MEK1/2 (MEKs) and ERK1/2 (ERKs). This pathway leads 
to activation of the transcription factors such as Elk-1, c-Myc, c-Fos or c-Jun/c-Fos (AP-1).The graphic was 
modified from www.proteinlounge.com/Pathway/Default.aspx (01.05.2011). 
 
1.3 The hydroxyprostaglandin dehydrogenase 15-(NAD) 
1.3.1 Identification of HPGD as a prostaglandin metabolizing enzyme 
 
The NAD+-dependent 15-hydroxyprostaglandin dehydrogenase type-I (HPGD or 15-PGDH) 
maintains a crucial role in the metabolism of prostaglandins as it is considered as key 
catabolic enzyme, which controls their biological activity 140,141. The first evidence for the 
existence of a prostaglandin metabolizing enzyme was brought by Änggård and Samuelsson 
in 1964. They observed that lung homogenates from guinea-pigs converted prostaglandin E1 
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(PGE1) into the metabolites 13,14-dihydro-prostaglandin E1 and 13,14-dihydro-15-keto-
prostaglandin E1. The occurrence of metabolites was thereby not due to a non-enzymatic 
conversion, as boiled homogenates did not convert PGE1 into its metabolites 140. Two years 
later the same group reported the 11-fold purification of a specific prostaglandin 
dehydrogenase from swine lung 142. Since then HPGD was successful isolated from different 
tissues and organisms like human placenta 143,144, rabbit lung 145, rat kidney 146 and chicken 
heart 147. HPGD is ubiquitously expressed in mammalian tissues with the highest activities for 
HPGD detected in lung, kidney and placenta 141. 
 
1.3.2 Genomic location 
 
The HPGD gene encodes the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-
PGDH; HPGD; EC 1.1.1.141), an enzyme that belongs to the short-chain nonmetalloenzyme 
alcohol dehydrogenase protein family 148. Chromosomal localization of the human HPGD 
gene revealed that it maps to chromosome 4 with further location to the bands 4q34-q35149. 
The HPGD gene contains 7 exons and 6 introns and is approximately 31 kb long 150. The 
primary structure of the human HPGD was elucidated by peptide sequencing 148 and cDNA 
cloning 151. The open reading frame of the human enzyme type I codes for a protein of 
266 amino acids with a molecular weight (M.W.) of 28,975 Da 148,151. 
Initial studies on the gene transcription revealed two different mRNA species in human 
placenta, with 2.0 kb and 3.4 kb in length, indicating the existence of spliced variants or an 
alternative gene 152. Further investigation identified two truncated forms of the human HPGD 
variant 1 in HL-60 and TT cells 153,154. Variant 2 lacks thereby an alternate exon (the sixth 
exon) in the 3’ coding region. This smaller sequence codes for a predicted C-terminal-
truncated form of HPGD of 178 amino acids (19,28kDa) and has approximately 64 % identity 
with HPGD variant 1 153. The third variant is missing the fifth and sixth exon 154. The 
truncated variants seemed to be splicing isoforms of HPGD variant 1, because both showed 
N-terminal protein sequence homology but differed in the C-termini. However, both truncated 
variants are not likely to display enzymatic activity because they lack the catalytically 
essential amino acid residues Tyr 151 and Lys 155 155,156. The cDNAs for HPGD were also 
cloned from other species like mouse 157, rat [145] or guinea pig 158. The murine HPGD gene 
is approximately 11.3 kb in length and contains like the human gene seven exons and six 
introns and maps to chromosome 8 (8 B3.2;8) 157.  
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1.3.3 Protein structure and enzymatic activity 
 
Sequence alignments indicated that HPGD belongs to the short chain 
dehydrogenase/reductase (SDR) family 148,159. HPGD shows approximately 20 % homology 
compared to other short-chain dehydrogenases (SDRs) 159. The amino acid residues Tyr151, 
Lys155 and Ser138 have been demonstrated to be essential for the catalytic activity, because 
site-directed mutagenesis leads to a loss of enzymatic activity 155,156. Moreover, the residues 
Thr11 and Thr188 were found to be important for the interaction with NAD+ 160,161. The 
primary structures of HPGD from various species are largely homologous except for two 
regions, the C-terminal domain and the region from residue 205 to 224. HPGD forms a 
homodimeric protein to mediate its enzymatic function although it is also thought to be active 
as a monomer 162. 
HPGD plays a crucial role in the metabolism of prostaglandins (PGs), because it represents a 
major enzyme in the degradation of prostaglandins. Prostaglandins are rapidly inactivated in 
vivo by the β-oxidation of their 15-hydroxyl group into a 15-keto group, catalyzed by HPGD. 
The 15-keto-metabolite thereby represents the first step in the biological inactivation of PGs 
141,163
. The prostaglandins are then further metabolized by the 15-ketoprostaglandin ∆13-
reductase (15-13PGR), resulting in 13,14-dihydro-15-keto-prostaglandins the so called PG(A, 
D, F, E, M) 164.The 13,14-dihydro-15-keto-prostaglandins finally undergo β- and ω-oxidation 
to form a variety of metabolites that are excreted in the urine 163. Two different types of 
enzymes have been identified in human tissue that catalyze the oxidation of the 15-hydroxy 
group of prostaglandins: HPGD type I is described to be NAD+-dependent and uses basically 
prostaglandins and related eicosanoids as substrates 165. HPGD type II is NADP+-dependent 
but can also use NAD+ as cofactor. HPGD type II has a broader substrate specificity and 
approximately 20 % homology with the HPGD type I 165,166. This enzyme has also a much 
higher Km value for prostaglandins than the HPGD type I enzyme and does therefore not 
appear to contribute significantly to the catabolism of prostaglandins. HPGD type I is also 
believed to be the enzyme primarily involved in controlling the biological activities of 
prostaglandins and related eicosanoids 141,167. For this reason, only HPGD type I was 
considered in the present study and will be referred to as HPGD in the following. HPGD can 
use a variety of different prostaglandins as substrate, such as PGE1, PGE2, PGF1α, PGF2α, 
PGI2 and 6-keto-PGF1α. PGB2, PGD2 and TXB2, however, are poor substrates. Besides 
prostaglandins also the unsatureated fatty acids that contain a hydroxyl group at their ω-6 
position like 12-L-hydroxy-5,6,10-heptadecatrienoic acid (12-HHT); 15-
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hydroxyeicosatetraenoic acid (15-HETE); 5,15-dihydroxy-6,8,11,13-eicosatetraenoic acid 
(5,15-diHETE); 8,15-Dihydroxy-5,9,11,13-eicosatetraenoic acid (8,15-diHETE) and 
lipoxin A4 were reported to serve as substrates for HPGD 168-170 . 
 
1.3.4 Regulation of the HPGD gene expression 
 
The regulation of HPGD has been investigated by various studies in whole animals and also 
in isolated cells 163,167. The induction of HPGD expression and activity was first reported in 
dimethyl formamide treated HL-60 cells 171. Subsequently the induction of HPGD was also 
achieved by 1,25-dihydroxyvitamin D3 in human neonatal monocytes 149 and by treatment of 
humanerythroleukemia (HEL) cells with phorbol 12-myristate 13-acetate (PMA) 172. Also 
dimethyl sulfoxide (DMSO) could stimulate the enzyme activity 173. Besides that, also 
indomethacin increased HPGD mRNA expression in HL-60 cells 174. In contrast, HPGD 
expression and activity was sustained by glucocorticoids such as cortisol and dexamethasone 
172,175
 and treatment with IL-1β 176 or TNF-α. The effect of IL-1β could be reversed by the 
concurrent addition of the immunosuppressive cytokine IL-10 176. Similarly, the anti-
inflammatory cytokine IL-4 was also shown to stimulate HPGD activity in the human lung 
cancer cell lines A549, H358, H1435 and H460 177. Bile acids were also shown to inhibit 
HPGD transcription in human colon cancer cell lines 178.  
Besides that, several potential regulatory elements have been identified. The human promoter 
regions exhibit key regulatory elements such as Ets, CREB, AP-1, AP-2, GRE and Sp1, 
which may provide potential binding sites for these agents to initiate gene transcription 179,180. 
Recently, the forkhead transcription factor hepatocyte nuclear factor 3β (HNF3β) was shown 
to regulate HPGD expression, as HNF3β showed direct binding to promoter elements of 
HPGD in lung cancer cells 181.  
 
1.3.5 The role of HPGD in perinatal development and in cancer 
 
In addition to the role of HPGD in inflammation this protein maintains a crucial role in 
perinatal development. HPGD-deficient mice (Pgdh-/-) die shortly after birth because of the 
defective remodeling of the ductus arteriosus. Under normal conditions PGE2 levels are 
significantly reduced due to enhanced pulmonary HPGD activity in late gestation. This results 
in the closure of the ductus arteriosus 182. 
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Furthermore, HPGD seems to play an important role in cancer. This was demonstrated in a 
study that compared the protein expression profiles of normal bladder urothelium with that of 
63 transitional cell carcinomas of various histopathological grades and tumor stages. Among 
other protein biomarkers a loss of HPGD expression was associated with the progression of 
human bladder transitional cell carcinomas 183. Also in colon tumor samples, the median 
HPGD expression was at least 17-fold below the median HPGD expression of normal colon 
tissue 184. Similar results were found in primary breast tumors where HPGD was shown to be 
under-expressed 185 and in lung tumors where HPGD gene expression was found to be under-
presented 186. Moreover, experiments with a xenograft model where stable HPGD-transfected 
H358 lung cancer cells were injected into athymic mice, showed that tumor formation was 
markedly suppressed in mice injected with HPGD-transfected cells compared to empty-
vector-transfected cells. The suppression was thereby mediated by an antiangiogenic 
mechanism 181. In addition, an in vitro study with SW480 colorectal cells demonstrated that 
HPGD over-expression in these cells resulted in a decreased cell motility and invasive activity 
187
. These observations indicate a potential role for HPGD as tumor suppressor. 
 
1.4 Different methods of antibody generation  
 
The immune system produces antibodies with high specificity to their antigen by well-
directed selection processes. To mimic the processes of antibody generation in vivo, different 
methods were developed. One method to produce antibodies is performed by the repeated 
immunization of animals, for instance mice, rabbits, goats, horses etc. The animals are 
injected with an antigenic substance, for example (recombinant) protein or peptide together 
with a booster substance such as CFA (Complete Freud’s Adjuvant). The serum is isolated 
from these immunized animals and contains polyclonal antibodies specific for the antigenic 
substance 188,189. Antibodies obtained from serum can be produced relatively fast and with low 
costs. Disadvantageous of polyclonal antibodies is that they may contain large amounts of non 
specific and unspecific antibodies. Besides that, the products are highly dependable on donor 
blood availability, both in terms of quantity and suitability, resulting in considerable variation 
between batches. With the generation of hybridoma cells, which are produced by the fusion of 
murine B lymphocytes with myeloma cells, presented by Köhler and Milstein in 1975 190, a 
method to produce monoclonal antibodies was invented. The hybridoma technique can be 
expensive and time consuming because of screening for the right hybridoma clones. However, 
monoclonal antibodies from hybridoma clones have a high specific antigen recognition 190. 
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Moreover, an unlimited supply of a monoclonal antibody with defined and reproducible 
affinity and specificity is permitted once an appropriate hybridoma clone is identified 190. 
Besides that, other methods like the phage display technology have been developed. The 
phage display technology was invented when first murine antibody fragments from 
lymphocytes of immunized animals were obtained and expressed in E.coli, whereby either the 
variable region of the light (vL) or the heavy chain (vH) were used 191. Later on the display of 
peptides on filamentous phage was demonstrated by fusing the peptide of interest on to gene3 
of filamentous phage 192-194. The phage display technology is a relatively fast and simple 
method and less cost intensive to produce antibody fragments 192-194. 
 
1.5 Objectives 
 
The characteristics and functions of CD4+CD25+ regulatory T cells (Treg) have been 
extensively studied – yet further investigation is required to completely resolve how Treg cells 
mediate their suppressive activity especially in vivo and which molecules are actually 
involved in their development and function. Various molecules have been identified, such as 
the lineage specific transcription factor FOXP3, which regulates the transcription of many 
target genes in Treg. However, there are still unknown genes that are required for a complete 
regulatory phenotype of Treg cells.  
In order to identify novel target molecules involved in the development and function of Treg 
cells, global gene expression profiling was carried out to designate genes that are specifically 
expressed in Treg cells in comparison to CD4+CD25- T cells (Tconv) cells under different 
activation states. Thereby the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase 
type-I (HPGD), the major Prostaglandin E2 (PGE2)-metabolizing enzyme, was identified as 
one of the differentially expressed transcripts. The objective of the present study was the 
characterization of the role of HPGD in human Treg cells concerning its regulation and role for 
the development and suppressive function of Treg cells. Therefore, it should be investigated 
whether HPGD expression is specific for naturally occurring Treg cells or whether it can be 
also upregulated during T cell differentiation or the induction of adaptive Treg cells (iTreg). 
Moreover, the enzymatic activity of HPGD in Treg cells and its contribution to the Treg cell 
function should be examined. Besides, it was tested whether HPGD is a target gene of 
FOXP3. In addition, this study aimed at characterizing the influence of extracellular stimuli 
on the HPGD expression. Depending on these results, the underlying downstream signaling 
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pathways were further analyzed. Finally, it was investigated whether the observations made in 
the human could be transferred to the murine system.  
In conclusion the results of the present study could help to better understand the regulatory 
phenotype of Treg cells and provide a basis for future experiments to determine tissue-specific 
functions of Treg cells and their function in the tumor microenvironment. 
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2 Material and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
Name Manufacturer 
30 % Acrylamide/bis Solution 29:1 (3,3%) Bio-Rad Laboratories, München (DE) 
Agar Applichem, Darmstadt (DE) 
Agarose Applichem, Darmstadt (DE) 
Ammoniumacetate  Merck, Darmstadt (DE) 
Ammonium persulfate (APS) Sigma-Aldrich, St Louis (USA) 
Ampicillin Applichem, Darmstadt (DE) 
Bovine serum albumin (BSA) Sigma-Aldrich, St Louis (USA) 
β-Mercaptoethanol Applichem, Darmstadt (DE) 
Boric acid Sigma-Aldrich, St Louis (USA) 
Bromophenole blue Roth, Karlsruhe (DE) 
Calcium chloride-Dihydrat (CaCl2 ·2H2O) Merck, Darmstadt (DE) 
5,6-Carboxyfluorescein diacetate succinimidyl ester 
(CFSE) Sigma-Aldrich, München (DE) 
CD25+ Microbeads II Miltenyi Biotec GmbH, Bergisch-Gladbach (DE) 
CD45+ Microbeads Miltenyi Biotec GmbH, Bergisch-Gladbach (DE) 
CellFixTM BD Biosciences, Heidelberg (DE) 
Chloroform p.a. Applichem, Darmstadt (DE) 
Complete mini (Protease Inhibitor cocktail tablets) Roche Diagnostics, Basel (CH) 
1,4-Diazabicyclo[2.2.2]octan (Dabco) Sigma-Aldrich, St Louis (USA) 
Disodiumhydrogenphosphate-Dihydrate (Na2HPO4  
2H2O) Merck, Darmstadt (DE) 
Dulbecco’s Modified Eagle Medium (D-MEM) (High PAA Laboratories GmbH, Pasching 
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Glucose with L-Glutamine) (AT) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Müchen (DE) 
Dithiothreitol (DTT) Fermentas GmbH, St. Leon-Rot, (DE) 
Dynabeads® M-450 Tosylactivated Invitrogen Life Technologies, Karlsruhe (DE) 
Ethylendiamintetraacetate (EDTA) Sigma-Aldrich, St Louis (USA) 
Ethanol Roth, Karlsruhe (DE) 
Ethidiumbromide Applichem, Darmstadt (DE) 
Fc receptor blocking reagent Miltenyi Biotec GmbH, Bergisch-Gladbach (DE) 
Fetal calf serum (FCS) PAA Laboratories GmbH, Pasching (AT) 
Fluoromount-G Southern Biotech, Birmingham (US) 
Formaldehyde solution (37 %) Sigma-Aldrich, St Louis (USA) 
Gelatin from bovine skin Sigma-Aldrich, St Louis (USA) 
Gelatin from cold water fish skin Sigma-Aldrich, St Louis (USA) 
Gibco distilled water (RNase/ DNase free) Invitrogen Life Technologies, Karlsruhe (DE) 
Glacial acetic acid Roth, Karlsruhe (DE) 
D (+) Glucose Merck, Darmstadt (DE) 
GlutamaxTM (100 x) Invitrogen Life Technologies, Karlsruhe (DE) 
Glycine Applichem, Darmstadt (DE) 
Glycerol (87 %) p.a. Applichem, Darmstadt (DE) 
Goat serum (normal) DakoCytomation, Glostrup (DK) 
HEPES Applichem, Darmstadt (DE) 
Isopropanol for the molecular biology Applichem, Darmstadt (DE) 
Isopropanol p.A. Roth, Karlsruhe (DE) 
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Kanamycin Applichem, Darmstadt (DE) 
Laemmli buffer for SDS-PAGE (10 x) Serva Electrophoresis GmbH, 
Heidelberg (DE) 
Magnesiumchloride-Hexahydrate (MgCl2 ·6H2O) Applichem, Darmstadt (DE) 
Magnesium (MgSO4*7H2O) Merck, Darmstadt (DE) 
Methanol p.a. Roth, Karlsruhe (DE) 
Milk powder Roth, Karlsruhe (DE) 
MOPS Acros Organics, New Jersey (USA) 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) Applichem, Darmstadt (DE) 
NuPAGE® Transfer Buffer 20x Invitrogen Life Technologies, Karlsruhe (DE) 
Odyssey® Blocking Buffer Licor Biosciences, Bad Homburg (DE) 
Odyssey® Two-Color Molecular Weight Marker (10 – 
250 kDa) 
Licor Biosciences, Bad Homburg 
(DE) 
O’Range RulerTM 100+500 bp DNA-Ladder Fermentas GmbH, St. Leon-Rot, (DE) 
O’GeneRulerTM 1 kb Plus DNA-Ladder Fermentas GmbH, St. Leon-Rot, (DE) 
6x O’Range DNA loading dye Fermentas GmbH, St. Leon-Rot, (DE) 
Pancoll human (density 1.077 g/l) PAN Biotech GmbH, Aidenbach (DE) 
Paraformaldehyde Sigma-Aldrich, St Louis (USA) 
Penicillin/ Streptomycin Invitrogen Life Technologies, 
Karlsruhe (DE) 
Phosphate buffered saline (PBS) PAA Laboratories GmbH, Pasching (AT) 
Potassium chloride (KCl) Merck, Darmstadt (DE) 
Potassium dihydrogenphosphat (KH2PO4) Merck, Darmstadt (DE) 
Potassium hydrogen carbonate (KHCO3) Merck, Darmstadt (DE) 
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Potassium hydroxide (KOH) Merck, Darmstadt (DE) 
Prostaglandin E2 (PGE2) Sigma-Aldrich, St Louis (USA) 
Propidium Iodide (PI) Sigma-Aldrich, St Louis (USA) 
Re-Blot plus mild solution (Chemicon) Millipore GmbH, Schwalbach/Ts. (DE) 
Rosette Sep CD4+ T cell enrichment cocktail Stem Cell Technologies, London (GB) 
RPMI cell culture medium (1640) PAA Laboratories GmbH, Pasching (AT) 
Sandoglobulin ZLB GmbH, Springe (DE) 
Saponine powder Sigma-Aldrich, St Louis (USA) 
Sodium acetate Applichem, Darmstadt (DE) 
Sodium azide (NaN3) Roth, Karlsruhe (DE) 
Sodium dodecylsulfate (SDS) 10% solution Applichem, Darmstadt (DE) 
Sodium dodecylsulfate (SDS) powder Roth, Karlsruhe (DE) 
Sodium chloride (NaCl) Applichem, Darmstadt (DE) 
Sodium dihydrogenephosphate-monohydrate 
(NaH2PO4 · H2O) Merck, Darmstadt (DE) 
Sodium hydroxide (NaOH) Merck, Darmstadt (DE) 
Trichloroacetic acid Merck, Darmstadt (DE) 
Tris Applichem, Darmstadt (DE) 
Tris-HCl Applichem, Darmstadt (DE) 
Triton X-100 Applichem, Darmstadt (DE) 
Trizol® Reagent Invitrogen Life Technologies, Karlsruhe (DE) 
Tryptone Roth, Karlsruhe (DE) 
Trypan blue solution (0,4 %) Sigma-Aldrich, St Louis (USA) 
Trypsin/ EDTA 10x (0,05 %/ 0,02 %) Invitrogen Life Technologies, Karlsruhe (DE) 
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TurbofectTM in vitro Transfection Reagent Fermentas GmbH, St. Leon-Rot, (DE) 
Tween 20 Applichem, Darmstadt (DE) 
Yeast extract Applichem, Darmstadt (DE) 
X-vivo 15 cell culture medium Lonza, Verviers (B) 
 
2.1.2 Kits 
Name Manufacturer 
Amaxa Human T Cell Nucleofector® Kit Lonza Cologne AG, Köln (DE) 
BCA protein assay kit Thermo Scientific, Rockford (US) 
Cytofix/ CytopermTM BD Biosciences, Heidelberg (DE) 
CD4+CD25+ Regulatory T Cell Isolation Kit mouse Miltenyi Biotec GmbH, Bergisch-Gladbach (DE) 
FOXP3 Fix/Perm Buffer Set BioLegend, San Diego (USA) 
FOXP3 staining buffer set eBioscience, San Diego (USA) 
Gateway® LR ClonaseTM Enzyme Mix Invitrogen Life Technologies, Karlsruhe (DE) 
GeneJet Plasmid Miniprep kit Fermentas GmbH, St. Leon-Rot, (DE) 
LightCycler 480 Probes Master Roche Diagnostics, Basel (CH) 
Midi Plasmid HiSpeed Prep Qiagen, Hilden (DE) 
PKH-26 Red Fluorescent Cell Linker Kit Sigma-Aldrich, St Louis (USA) 
Prostaglandin E2 EIA Kit monoclonal 
Cayman Chemicals, Ann Arbor 
(USA) 
Prostaglandin E2 metabolite EIA Kit 
Cayman Chemicals, Ann Arbor 
(USA) 
Qia Quick Gel extraction kit Qiagen, Hilden (DE) 
Qia Quick PCR purification kit Qiagen, Hilden (DE) 
5x siRNA annealing buffer Dharmacon, Lafayette (USA) 
Transcriptor First Strand cDNA synthesis kit Roche Diagnostics, Basel (CH) 
Universal Probe Library Set Human Roche Diagnostics, Basel (CH) 
 
2.1.3 Cytokines 
Name Manufacturer 
Interleukin 1β, human recombinant (rhIL-1 β) Immunotools, Friesoythe (DE) 
Interleukin 2, human recombinant (rhIL-2) Chiron, Emeryville (USA) 
Interleukin 4, human recombinant (rhIL-4) Immunotools, Friesoythe (DE) 
Interleukin 6, human recombinant (rhIL-6) Immunotools, Friesoythe (DE) 
Interleukin-10, human recombinant (rhIL-10) Immunotools, Friesoythe (DE) 
Interleukin 12, human recombinant (rhIL-12) Immunotools, Friesoythe (DE) 
Interleukin 21, human recombinant (rhIL-21) Immunotools, Friesoythe (DE) 
Transforming growth factor beta, human 
recombinant (rhTGF-β) PeproTech EC Ltd., London (UK) 
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2.1.4 Enzymes 
 
All enzymes were purchased from Fermentas GmbH, St. Leon-Rot, (DE). Enzymes that are a 
component of a kit are not mentioned here. 
Enzyme name Function 
BamHI Restriction enzyme 
NotI Restriction enzyme 
NcoI Restriction enzyme 
XhoI Restriction enzyme 
BclI Restriction enzyme 
Pfu DNA Polymerase DNA Polymerase 
Shrimp alkaline phosphatase (SAP) Alkaline Phosphatase 
T4 DNA Ligase DNA Ligase 
 
2.1.5 Antibodies 
2.1.5.1 Antibodies for flow cytometry 
Antigen Clone Isotype Fluorophore Manufacturer 
Anti-human-CD3 SK7 IgG1κ APC-Cy7 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD3 SK7 IgG1κ FITC 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD3 UCHT1 IgG1κ Pe 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD4 SK3 IgG1κ FITC 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD4 SK3 IgG1κ Pe 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD4 SK3 IgG1κ Pe-Cy7 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD4 L200 IgG1κ PerCp-Cy5.5 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD8 SK1 IgG1κ APC 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD8 SK1 IgG1κ PerCP 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD8 SK1 IgG1κ Pe 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD14 MφP9 IgG1κ FITC 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD14 HCD14 IgG1κ Pe 
BioLegend, San Diego 
(USA) 
Anti-human-CD19 SJ25C1 IgG1κ APC BD Biosciences, Heidelberg 
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(DE) 
Anti-human-CD19 SJ25C1 IgG1κ Pe BD Biosciences, Heidelberg (DE) 
Anti-human-CD25 M-A251 IgG1κ APC BD Biosciences, Heidelberg (DE) 
Anti-human-CD25 M-A251 IgG1κ FITC 
BioLegend, San Diego 
(USA) 
Anti-human-CD25 M-A251 IgG1κ Pe 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD25 2A3 IgG1κ Pe-Cy7 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-
CD45RA L48 IgG1κ FITC 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-
CD45RA HI100 IgG2bκ Pe-Cy5 
BioLegend, San Diego 
(USA) 
Anti-human-
CD45RO UCHL1 IgG2bκ APC 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-
CD45RO UCHL1 IgG2bκ Pe 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-CD56 MY31 IgG1κ Pe 
BD Biosciences, Heidelberg 
(DE) 
Anti-human-
CD127 
hIL-7R-
M21 IgG1κ 
Alexa Fluor 
647 
BD Biosciences, Heidelberg 
(DE) 
FoxP3 206D IgG1κ Pe 
BioLegend, San Diego 
(USA) 
Isotype Control MOPC-21 IgG1κ 
Alexa Fluor 
647 
BD Biosciences, Heidelberg 
(DE) 
Isotype Control MOPC-21 IgG1κ Pe 
BD Biosciences, Heidelberg 
(DE) 
Isotype Control MOPC-21 IgG1κ FITC 
BD Biosciences, Heidelberg 
(DE) 
Isotype Control MOPC-21 IgG1κ PerCp-Cy5.5 BioLegend, San Diego (USA) 
Anti-mouse IgG  IgG1κ 
Alexa Fluor 
647 
Invitrogen Life 
Technologies, Karlsruhe 
(DE) 
 
2.1.5.2 Antibodies for Electrophoretic Mobility Shift Assay (EMSA) 
Antigen Clone Isotype Manufacturer 
Anti-human-FOXP3 259D/C7 IgG1κ BD Biosciences, Heidelberg (DE) 
Isotype control MOPC-21 IgG1κ BD Biosciences, Heidelberg (DE) 
 
2.1.5.3 Antibodies for Western blot analysis 
Name Species Manufacturer 
Anti-β-actin (primary antibody) mouse Chemicon, Temecula (US) 
Anti-mouse IgG IRDye 680 
(secondary antibody) goat Licor Biosciences, Bad Homburg (USA) 
Anti-mouse IgG, IRDye 800CW goat Licor Biosciences, Bad Homburg (USA) 
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(secondary antibody) 
 
2.1.5.4 Antibodies for coating of cell culture plates and beads 
Name Clone Manufacturer 
CD3  OKT-3 Janssen-Cilag GmbH, Neuss (DE) 
CD28  9.3 A kind gift of Dr. James L. Riley, University 
of Pennsylvania, Philadelphia (USA) 
CD28 28.2 BD Biosciences, Heidelberg (DE) 
MHC-I  W6/ 32 Lab-own hybridoma 
 
2.1.6 Inhibitors 
Name Alternate name Manufacturer 
HPGD-Inhibitor CK47A  
5-[[4-(ethoxycarbonyl)phenyl]azo]- 2-hydroxy-
benzeneacetic acid 
Cayman Chemicals, 
Ann Arbor (USA) 
NF-κB inhibitor 
BAY11-7082 
 
BAY11-7082 
3-[(4-methylphenyl)sulfonyl]-(2E)-
propenenitrile 
Cayman Chemicals, 
Ann Arbor (USA) 
NF-κB activation 
inhibitor  
 
6-Amino-4-(4-
phenoxyphenylethylamino)quinazoline 
Merck, Darmstadt 
(DE) 
JAK3 inhibitor Janex-1 
4-[(6,7-dimethoxy-4-quinazolinyl)amino]-phenol 
Cayman Chemicals, 
Ann Arbor (USA) 
PI3K inhibitor LY294002 
2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-
4-one 
Merck, Darmstadt 
(DE) 
STAT5 inhibitor STAT5 inhibitor 
N’-((4-Oxo-4H-chromen-3-yl)methylene) 
nicotinohydrazide 
Merck, Darmstadt 
(DE) 
MEK1 inhibitor PD98059 
2’-Amino-3’-methoxyflavone 
Merck, Darmstadt 
(DE) 
 
2.1.7 Oligonucleotides 
 
Primers were purchased from the manufacturer Sigma-Aldrich (Taufkirchen, DE). The 
selection of primers and probes for qRT-PCR were made with the tool ‘Universal Probe 
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Library Assay Design Center’ offered by Roche Diagnostics (https://www.roche-applied-
science.com/sis/ rtpcr/upl/index.jsp?id=UP030000; 07. October 2010). For Real-time PCR 
analysis probes were used from the Universal Probe Library Set Human provided (Roche 
Diagnostics, Basel, CH). Other oligonucleotides were purchased from Biomers.net GmbH 
(Ulm, DE). 
 
2.1.7.1 Primer for qRT-PCR 
Name Sequence Probe 
Human Beta-2 
microglobulin (B2M) 
forward: 5’-TTC TGG CCT GGA GGC TAT-3’ 
reverse: 5’-TCA GGA AAT TTG ACT TTC CAT TC-3’ (#42) 
Murine Beta-actin (β-
actin) 
forward: 5’-CTA AGG CCA ACC GTG AAA AG-3’ 
reverse: 5’-ACC AGA GGC ATA CAG GGA CA-3’ (#64) 
Human cAMP response 
element-binding 
protein (CREB) 
forward: 5’-CGG TGC CAA CTC CAA TTT AC-3’ 
reverse: 5’-ATT GCT CCT CCC TGG GTA AT-3’ (#86) 
Human CREB-Binding 
protein (CREBBP) 
forward: 5’-TGA ACA GCA TGG GCT CAG T-3’ 
reverse: 5’-CAT CAT GTT CGG AGG CTG A-3’ (#12) 
Human 
cAMPCCAAT/enhance
r-binding protein alpha 
(CEBPA) 
forward: 5’-GCA AAT CGT GCC TTG TCA T-3’ 
reverse: 5’-CTC ATG GGG GTC TGC TGT AG-3’ (#12) 
Human proto-oncogene 
protein c-fos (FOS) 
forward: 5’-AGG TCC GTG CAG AAG TCC T-3’ 
reverse: 5’-CTA CCA CTC ACC CGC AGA CT-3’ (#67) 
Human Forkhead box 
P3 (FOXP3) 
forward: 5’-ACC TAC GCC ACG CTC ATC-3’ 
reverse: 5’-TCA TTG AGT GTC CGC TGC T-3’ (#50) 
Human GATA binding 
protein 3 (GATA-3) 
forward: 5’- ACT ACG GAA ACT CGG TCA GG- 3’ 
reverse: 5’-GGT AGG GAT CCA TGA AGC AG-3’ (#36) 
Human 
Hydroxyprostaglandin 
dehydrogenase 15-
(NAD) 
forward: 5’-GGT TCC ACT GAT AAC AGA AAC CA-
3’ 
reverse: 5’-TTT GGT CAA TAA TGC TGG AGT G-3’ 
(#48) 
Murine 
Hydroxyprostaglandin 
dehydrogenase 15-
(NAD) 
forward: 5’-ATC GGA TTC ACA CGC TCA G-3’ 
reverse: 5’-TGG GCA AAT GAC ATT CAG TC-3’ (#46) 
Murine 
Hydroxyprostaglandin 
dehydrogenase 15-
(NAD) 
forward: 5’-GCA GGC GTG AAC AAT GAG A-3’ 
reverse: 5’-AAA CCA AGA TAG GTC CCA CTG A-3’ (#48) 
Murine hypoxanthine-
guanine 
phosphoribosyltransfer
ase (mHRPT1) 
forward: 5’-TGA TAG ATC CAT TCC TAT GAC TGT 
AGA-3’ 
reverse: 5’-AAG ACA TTC TTT CCA GTT AAA GTT 
GAG-3’ 
(#22) 
Human Interleukin ) 
(IL-9) 
forward: 5’-TGG ACA TCA ACT TCC TCA TCA-3’ 
reverse: 5’-TGC CCA AAC AGA GAC AAC TG-3’ (#4) 
Human RAR-related 
orphan receptor C 
forward: 5’-AGA AGG ACA GGG AGC AAG-3’ 
reverse: 5’-CAA GGG ACT ACT TCA ATT TGT G-3’ (#21) 
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(RORγt) 
Human T-box 21 (T-
bet) 
forward: 5’-GAC TCC CCC AAC ACA GGA G-3’ 
reverse: 5’-GGG ACT GGA GCA CAA TCA TC-3’ (#72) 
 
2.1.7.2 Primer for Cloning 
Name  Sequence 
HPGD forward (BclI) 5’-TAT GAT CAA CCA TGC ACG TGA ACG GCA AA-3’ 
HPGD 3’GFP reverse 
(XhoI) 5’-GCG GGG CTC GAG TTT ACT TGT ACA GCT CGT C-3’ 
HPGD reverse (NotI) 5’-TGC GCG GCC GCA TTG GGT TTT TGC TTG AAA TGG AGT-3’ 
HPGD forward (XhoI) 5’-ACT ACT CGA GAC CAT GCA CGT GAA CGG CAA AGT G-3’ 
HPGD reverse 
(BamHI) 5’-ATC AGG ATC CTC ATT GGG TTT TTG CTT GAA A-3’ 
 
2.1.7.3 Primer for Sequencing 
Name Sequence 
pDest EF1alpha forward 5’-TTA TGC GAT GGA GTT TCC CC-3’ 
pDest V5 reverse 5’-ACC GAG GAG AGG GTT AGG GA-3’ 
T7 promoter forward 5‘-TAA TAC GAC TCA CTA TAG GG-3‘ 
Bovine growth hormone (BGH) reverse 5’-TAG AAG GCA CAG TCG AGG-3’ 
CMV forward 5’-CGC AAA TGG GCG GTA GGC GTG-3’ 
pIRES reverse 5’-TAT AGA CAA ACG CAC ACC G-3’ 
 
2.1.7.4 Oligonucleotides for Electrophoretic mobility shift assay 
Name Sequence 5‘-Modification: IRDye 
HPGD forward 
FOXP3 BS 
5’ – TTC TAT GGA TAT TAT CAC TAT TTG 
TTT ACC CAT TTA TCT GTT AG – 3’ 
DY-681 
HPGD reverse 
FOXP3 BS 
5’ – CTA ACA GAT AAA TGG GTA AAC AAA 
TAG TGA TAA TAT CCA TAG AA – 3’ 
DY-681 
HPGD forward 
mutated FOXP3 
BS 
5’ – TTC TAT GGA TAT TAT CCC GGG GCC 
GCG GGC CAT TTA TCT GTT AG – 3’ 
DY-781 
HPGD reverse 
mutated FOXP3 
BS 
5’- CTA ACA GAT AAA TGG CCC GCG GCC 
CCG GGA TAA TAT CCA TAG AA – 3’ 
DY-781 
FKH forward 5’ – TCA AAA ATA TTG AAG TGT TAT CAC ATA CAC - 3' 
DY-781 
FKH reverse 5’ – GTG TAT GTG ATA ACA CTT CAA TAT TTT TGA – 3’ 
DY-781 
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2.1.8 siRNAs 
 
SiRNAs were purchased from Biomers.net GmbH, (Ulm; DE). 
Name Target Gene Sequence 
HPGD sense HPGD 5’-GCA CAG CAG CCG GUU UAU U-3’ 
HPGD antisense HPGD 5’-AAU AAA CCG GCU GCU GUG C-3’ 
FOXP3 sense FOXP3 5’-GCA CAU UCC CAG AGU UCC-3’ 
FOXP3 antisense FOXP3 5’-AGG AAC UCU GGG AAU GUG C-3’ 
Control sense Control siRNA 5’-UUC UCC GAA CGU GUC ACG U-3’ 
Control antisense Control siRNA 5’-ACG UGA CAC GUU CGG AGA A-3’ 
 
2.1.9 Buffers and solutions 
Name Contents 
ACK lysing buffer 
0,15 M NH4Cl, 10,0 mM KHCO3, 0,1 mM Na2EDTA, 
pH=7,2-7,4 adjusted with 1 N HCl, solution was sterile 
filtered 
Bead wash buffer 0.02 %w/v NaN3, 0,1 % w/v BSA in PBS, pH=7,4 
EMSA10 x loading dye 65 % (w/v) Sucrose, 10 mM Tris-HCl (pH7.5), 10 mM EDTA 
EMSA 10 x binding buffer 100 mM Tris, 500 mM NaCl, 10 mM DTT, pH=7,5 
EMSA buffer 2 25 mM DTT, 2,5 % Tween-20 
5 x Laemmli loading buffer  0,3 M Tris-HCl pH6,8; 50% glycerol, 25 % β-Mercaptoethanol, 2 % SDS, 0,01 % bromophenol blue 
LB-medium 5 g yeast extract, 10 g trypton, 5 g NaCl, ad 1 l H2O, pH=7,5 
Lysis buffer 
20 mM Tris-HCl pH=8, 10 % Triton X-100, 100 mM 
NaCl, 1 mM EDTA, 1 M DTT, a Complete Mini Protease 
inhibitor tablet 
MACS buffer 1 x PBS supplemented with 0,5 % BSA, 2 mM EDTA, pH=7,2 sterile-filtered 
Protein lysis buffer 1 % Triton-X 100, 0,1 NaCl, 1 mM EDTA, 1 mM DTT, 20 mM Tris-HCl pH=8 
Saponine buffer PBS supplemented with 0,5 % BSA, 0,01 % sodium azide 
solution and 200 mg saponine powder 
10 % separating gel 
2,01 ml H2Odest, 1,25 ml 1,5 M Tris-HCl (pH8,8), 50 µl 
10x SDS, 1,67 ml 30 % polyacrylamide, 16,65 µl 
10 % APS, 7 µl TEMED 
4 % native polyacrylamide gel 
(for 20ml) 
2.5 ml 40% polyacrylamide (Polyacrylamide-BIS ratio 
=29:1), 1 ml 1M Tris (pH=7,5), 3,8 ml 1 M Glycine, 80 µl 
0.5M EDTA, 13 ml H2O, 100 µl 10 % APS, 15 µl 
TEMED 
SOB-medium 
5 g yeast extract, 20 g trypton, 0,6 g NaCl, 0,2 g KCl ad 
1 l H2O, Medium was autoclaved and before use further 
supplemented with 10 ml of a 1 M MgCl2 solution and 
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10 ml of a 1 M MgSO4 solution 
SOC-medium SOB-medium was supplemented with sterile filtrated 1 M glucose solution to yield 20 mM glucose solution 
4,5 % stacking gel 
1,83 ml H2Odest, 0,83 ml 1M Tris-HCl (pH6,8), 25 µl 10 x 
SDS, 0,42 ml 30 % Acrylamide, 17 µl 10 % APS, 3,3 µl 
TEMED 
50 x TAE buffer 242 g Tris, 57,1 ml glacial acetic acid, 100 ml 0,5 M EDTA pH=8, ad 1 l H2O 
1 x TBE buffer 89 mM Tris-base, 89 mM Boric acid, 2 mM EDTA-NA2, pH=8,3 
10 x TGE buffer (1 liter) 30,3 g Tris, 142 g glycine, 37,2 g EDTA, add 1 l H2O 
10 x Tris/ glycine buffer 25 mM Tris, 192 mM glycine, pH=8,3 
TfB I solution 30 mM NaAc pH=6, 50 mM MnCl2x4H2O, 100 mM NaCl, 10 mM CaCl2, 15% glycerol 
TfB II solution 10 mM MOPS, 75 mM CaCl2, 10 mM NaCl, 15% glycerol 
Western blot transfer buffer (for 
semi dry blotting) 25 mM Tris, 192 mM glycine 
Western blot transfer buffer (for 
wet blotting) 4,8 mM Tris-Base, 3,9 mM glycine, 20 % methanol 
 
2.1.10 Peripheral blood samples 
 
Human blood samples from healthy donors were obtained in form of buffy coats from the 
Institute for Experimental Hematology and Transfusion Medicine of the University hospital of 
Bonn (Germany). Isolation of primary cells was approved by the local Ethics Committee. 
 
2.1.11 Eukaryotic cell lines 
 
Human embryonic kidney cells (HEK293) (DSMZ no: ACC 305) were purchased from the 
“Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH” (DSMZ; 
Braunschweig, Germany).  
 
2.1.12 Bacterial strains and genotype 
 
Chemically competent E.coli strains were obtained from Invitrogen Life Technologies, 
Karlsruhe (DE). 
E.coli strain Genotype 
DH5α F
-
 Φ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, mk+) 
phoA supE44 thi-1 gyrA96 relA1λ- 
TOP10 F- mcrA ∆(mrr-hsdRMS-mcrBC) 
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φ80lacZ∆M15∆lacX74recA1araD139∆(ara-leu)7697 galU galK rpsL 
endA1 nupG 
Stbl3 F
-
mcrB mrr hsdS20(rB-, mB-) recA13 supE44 ara-14galK2 lacY1 proA2 
rpsL20(StrR) xyl-5 –leu mtl-1 
 
2.1.13 Murine tissue samples 
 
Murine spleens from C57BL/6 and BALB/c mice were a kind gift of Dr. Zeinab Abdullah and 
Dr. Li-Rung Huang respectively from the team of Professor Percy Knolle, Institutes of 
Molecular Medicine and Experimental Immunology (IMMEI) Bonn (DE).  
 
2.1.14 Equipment 
Name Manufacturer 
AutoMACS Pro Separator Miltenyi Biotech, Bergisch-Gladbach (DE) 
Centrifuge Rotina 420R Hettich, Tuttlingen (DE) 
Centrifuge Mikro-200R Hettich, Tuttlingen (DE) 
Centrifuge AvantiTM J-20 XP Beckman Coulter, Brea (USA) 
Centrifuge 5810R Eppendorf GmbH, Hamburg (DE) 
Centrifuge 5815R Eppendorf GmbH, Hamburg (DE) 
CO2 Incubator 
Heraeus Christ Instruments, Düsseldorf 
(DE) 
Confocal Laser Scanning Biological FC1000 Olympus, Hamburg (DE) 
Dynal magnet MPC-S Dynal Biotech, Oslo (NO) 
Flow cytometer FACS CANTOTM BD Biosciences, Heidelberg (DE) 
Flow cytometer FACS LSR II Special Order 
System BD Biosciences, Heidelberg (DE) 
Flow cytometer / cell sorter FACS Aria BD Biosciences, Heidelberg (DE) 
Gene pulser XCellTM BioRad Laboratories, München (DE) 
Electroporator Amaxa, Köln (DE) 
Heating magnetic stirrer ARE Velp Scientifica, Usmate (I) 
Light microscope Eclipse TS100 Nikon, Tokio (J) 
Magnet MACS Multi Stand Miltenyi Biotech, Bergisch-Gladbach (DE) 
Mini-& MidiMACSTM Separation Units Miltenyi Biotech, Bergisch-Gladbach (DE) 
Microplate reader Infinite® M200  Tecan Austria GmbH, Grödig (AT) 
Mini-Protean Electrophoresis System Bio-Rad Laboratories, München (DE) 
Multi-Detection Microplate Reader Synergy HT 
Sirius 
BioTek Instruments, Bad Friedrichshall 
(DE) 
Neubauer chamber Roth, Karlsruhe (DE) 
Odyssey® Infrared Imaging System LI-COR Biosciences, Bad Homburg (DE) 
pH-meter S20-SevenEasyTM Mettler Toledo, Giessen (DE) 
Pipette Controller Accu Jet Plus Brand GmbH, Wertheim (DE) 
Pipette Multipette Plus Eppendorf GmbH, Hamburg (DE) 
Pipette Set Ergo One Starlab, Ahrensburg (DE) 
PowerPac HC Power Supply Bio-Rad Laboratories, München (DE) 
Real-time PCR system LightCycler 480 Roche Diagnostics, Basel (CH) 
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Roller Mixer SRT9D Stuart Bibby Scientific, Staffordshire (UK) 
Scale EL2001 Mettler Toledo, Giessen (DE) 
Analysis Scale MS104S Mettler Toledo, Giessen (DE) 
Spectrophotometer NanoDrop 2000 Thermo Scientific, Waltham (USA) 
Steril work bench BDK, Sonnbuhl (DE) 
Thermocycler T3000 Biometra GmbH, Göttingen (DE) 
Thermomixer comfort Eppendorf GmbH, Hamburg (DE) 
Trans-Blot Semi-Dry Transfer Cell Bio-Rad Laboratories, München (DE) 
Vortexer Velp Scientifica, Usmate (I) 
Water bath Memmert, Schwabach (DE) 
 
2.1.15 Disposables 
Name Manufacturer 
6-well tissue culture plates Sarstedt, Nürnbrecht (DE) 
12-well tissue culture plates Sarstedt, Nürnbrecht (DE) 
24-well tissue culture plates Sarstedt, Nürnbrecht (DE) 
48-well tissue culture plates Sarstedt, Nürnbrecht (DE) 
96-well tissue culture plates Sarstedt, Nürnbrecht (DE) 
10 cm plates Sarstedt, Nürnbrecht (DE) 
LightCycler 480 Multiwell Plate and sealing foil Roche Diagnostics, Basel (CH) 
0,5-2,0 ml reaction tubes Eppendorf GmbH, Hamburg (DE) 
0,2 ml PCR reaction tubes Eppendorf GmbH, Hamburg (DE) 
15 ml Falcon tubes Sarstedt, Nürnbrecht (DE) 
50 ml Falcon tubes Sarstedt, Nürnbrecht (DE) 
MACS LS columns (with plunger) Miltenyi Biotech, Bergisch Gladbach (DE) 
MACS LD columns (with plunger) Miltenyi Biotech, Bergisch Gladbach (DE) 
MACS MS columns (with plunger) Miltenyi Biotech, Bergisch Gladbach (DE) 
Nitrocellulose-membrane Hybond-C Extra GE healthcare, Piscataway (US) 
Parafilm Pechiney, Chicago (US) 
2, 5, 10 & 25 ml Pipettes Sarstedt, Nürnbrecht (DE) 
10, 200 & 1.000 µl Pipette tips Sarstedt, Nürnbrecht (DE) 
Pre-Separation Filters Miltenyi Biotech, Bergisch Gladbach (DE) 
10, 20, 100, 200 & 1.000 µl Filter Tips Starlab, Ahrensburg (DE) 
0,2 µm Sterile filter  Sartorius, Hannover (DE) 
50 ml Syringe Braun, Melsungen (DE) 
 
2.1.16 Software 
Name Manufacturer 
CorelDraw X3 Corel Corporation, CA 
dChip Free license, http://www.biostat.harvard.edu/complab/dchip/ 
FACSDivaTM BD Biosciences, Heidelberg (DE) 
FlowJo 7.5 and later Tree Star, Ashland (USA) 
KC4 plate reader software Biotek, Winooski (USA) 
LightCycler 480 software Roche Diagnostics, Basel (CH) 
Mayday 2.0 Free license, http://www.zbit.uni-tuebingen.de/pas/mayday 
Microsoft Office 2007 Microsoft Corporation, Redmond (USA) 
Odyssey V3.0 software Licor Biosciences, Bad Homburg (DE) 
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Statistical software package R 
(version 2.9.2) Free license, http://www.r-project.org 
Sigma Plot 10.0 Systat Software GmbH (DE) 
Vector NTI Invitrogen Life Technologies, Karlsruhe (DE) 
 
2.2 Methods 
 
Standard methods of the molecular biology were performed according to the guidelines and 
protocols of Current Protocols in Molecular Biology (Volume 3, 2000) if not otherwise stated. 
 
2.2.1 Prokaryotic cell culture 
2.2.1.1 Culture conditions and storage of E.coli 
 
Bacteria colonies were grown on LB-agar plates (see 2.1.9) containing the appropriate 
antibiotic (e.g. 100 µg/ml ampicillin or 50 µg/ml kanamycin) overnight at 37°C in an 
incubator. For long-term storage of transformed bacteria, a single colony was grown in 4 ml 
overnight culture with the appropriate selectable antibiotic and frozen in liquid nitrogen in 
1 ml LB-medium, supplemented with 0,5 ml 80 % sterile glycerol. 
 
2.2.1.2 Generation of chemically competent E.coli 
 
E.coli were made competent by means of the calcium chloride method. Therefore, 50 ml LB-
Medium were inoculated with 500 µl of an overnight culture and grown to a cell density of 
OD550nm=0,5-0,8. Bacteria were resuspended in 20 ml of sterile TfB I solution (see 2.1.9), 
incubated for 10 min on ice, centrifuged and resuspended in 10 ml of TfB II solution (see 
2.1.9) and finally frozen as 100 µl aliquots in liquid nitrogen and stored at -80°C. 
 
2.2.1.3 Transformation of E.coli 
 
Chemically competent E.coli (strains TOP10, DH5α or Stbl 3) were transformed using the 
heat shock method. Therefore, bacteria were thawn on ice, mixed with 1 to 5 µl (10 pg to 
100 ng) of vector DNA, incubated on ice for 30 min, subsequently heat-shocked at 42°C in a 
water bath for 90 sec (30 sec for TOP10) and incubated for another 2 min on ice. Afterwards 
bacteria were incubated for 60 min in 400 µl (250 µl for TOP10) pre-warmed SOC-medium 
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(see 2.1.9) at 37°C with shaking them at 300 rpm and then seeded agar plates containing the 
appropriate antibiotic. 
 
2.2.1.4 Plasmid-DNA extraction 
 
‘Mini’-plasmid extractions were performed by means of the isolation kit of the GeneJETTM 
Plasmid Miniprep Kit (Fermentas GmbH) according to the manufacturers’ instructions. 
‘Midi’-plasmid extractions were performed using the Qiagen HiSpeed Plasmid Midi Kit 
(Qiagen GmbH) according to the manufacturers’ instructions. ‘Maxi’-plasmid extractions 
were performed using the isolation kit Qiagen Maxi Plasmid Prep Kit (Qiagen GmbH) 
according to the manufacturers’ recommendations. The concentration of the isolated plasmids 
was measured with a spectrophotometer NanoDrop 2000. 
 
2.2.1.5 General cloning procedure  
 
For the present study different hydroxyprostaglandin dehydrogenase 15-NAD expression 
vectors were generated. The vector maps of plasmids used during the present study are listed 
in Appendix A. 
 
2.2.1.5.1 Preparative polymerase chain reaction (PCR) 
 
The HPGD gene was amplified in a polymerase chain reaction (PCR) with the reaction mix: 
Table 1: Preparative PCR reaction mix 
Reagent (stock concentration) Amount 
Template (cDNA) 0,25 µl (ca. 50pg – 500 ng) 
dNTPS (2 mM) 3,75 µl 
Primer forward (20 µM) 0,75 µl 
Primer reverse (20 µM) 0,75 µl 
10x PCR buffer (with MgSO4) 2,5 µl 
Pfu DNA Polymerase (2,5 u/µl) 0,25 µl 
H2O ultrapure Ad 25µl 
 
The PCR reaction was performed according to the following program: 
   Material and Methods 
35 
Table 2: PCR reaction program 
Incubation step Temperature Duration Cycles 
Initial denaturation 95°C 3 min 1 x 
Denaturation 95°C 45 sec 
35 x Annealing 56-66°C, depending on the primer pair sequence 30 sec 
Elongation 72°C 1-2 min  
Cooling 72°C 10 min 1 x 
 
The PCR products were loaded onto a 1,5 % agarose gel containing ethidium bromide 
(0,5 µg/ml), separated at constant 100 V for 1 h, the respective bands (at 800 bp) were excised 
and the PCR product was eluted with the Qiaquick gel extraction kit (Qiagen) according to the 
manufacturers’ instructions.  
 
2.2.1.5.2 Preparative restriction digest 
 
A double digest was performed with the purified PCR product and the circular vector for 
1 hour at 37°C with the respective restriction enzymes according to the manufacturers’ 
instructions. The vector DNA was additionally dephosphorylized with shrimp alkaline 
phosphatase (SAP) to prevent re-ligation. Table 3 gives an overview of the restriction 
enzymes used for each plasmid and corresponding insert. The digested DNA fragments were 
purified with the PCR Purification Kit (Fermentas) according to the manufacturers’ 
instructions and redissolved in a volume of 30 µl. 
 
Table 3: Survey of restriction enzymes used for the different plasmids and inserts 
Plasmid Insert 
Restriction enzymes 
for plasmid 
Restriction enzymes 
for insert 
pENTR4 GFP 3’ HPGD BamHI & NotI BclI & NotI 
pcDNA6/V5-His B HPGD BamHI & NotI BclI & NotI 
pcDNA6/V5-His B HPGD-GFP BamHI & XhoI BclI & XhoI 
pIRES2-AcGFP1 HPGD BamHI & XhoI BamHI & XhoI 
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2.2.1.5.3 DNA ligation 
 
Following the preparative digest and purification the digested DNA insert and the digested 
dephosphorylated plasmid were ligated at 22°C with T4 Ligase for 1 h. The reaction mix 
consisted of 2 µl vector DNA (~50 ng), 10 µl insert DNA (~500 ng), 2 µl 10x ligation buffer 
and 0,4 µl T4 ligase. 
 
2.2.1.5.4 Transformation in E.coli and plasmid extraction 
 
After ligation of insert and vector, 10 µl of the ligation approach were used for transformation 
in E.coli (strains TOP10 or DH5α) as described in 2.2.1.3 and plasmid extraction was 
prepared as described in 2.2.1.4. 
 
2.2.1.5.5 Control digest and DNA sequencing 
 
Purified plasmids were subjected to a control digest. The restriction enzymes were thereby 
chosen that specific fragments were created. The digested plasmid-bands were separated on a 
gel (see 2.2.1.5.1) and compared to a computer-simulated gel run with program Vector NTI 
(Invitrogen). Constructs that had performed positive restriction digest analysis were 
sequenced. Therefore 30 µl of plasmid solution (30-100 ng/µl) and 30 µl of forward and 
reverse primer (10 µM) were sent for sequencing to the company GATC biotech. 
 
2.2.1.5.6 Recombination 
 
pENTR4 constructs were used as entry clone for subsequent recombination reactions. 
Therefore, the Gateway® LR ClonaseTM Enzyme Mix (Invitrogen) was used according to the 
manufacturers’ recommendations. The reaction mix contained 100 ng/µl pENTR4 construct, 
150 ng/µl pLenti6/V5-Dest EF1α lentivector, 1 µl 5xLR Clonase reaction buffer, 1 µl Clonase 
and filled up to 5 µl with TE-buffer (pH 8). The reaction was performed at 25°C for 1 h and 
terminated by adding of 1 µl proteinase K for 10 min at 37°C. The recombination samples 
were transformed into the E.coli strain Stbl3 (see 2.2.1.3), plasmid was prepared (see 2.2.1.4) 
and control double digest as well as sequencing were performed with the constructs. 
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2.2.2 Eukaryotic cell culture 
2.2.2.1 Cell Culture 
 
All cells were maintained in an incubator at 37°C in an atmosphere humidified with 5 % CO2. 
Human embryonic kidney cells (HEK293) were cultured in Dulbecco’s Modified Eagle 
Medium (D-MEM), containing 4500 mg/L glucose and L-glutamine but no sodium pyruvate, 
supplemented with 10 % fetal calf serum, 5 % glutamax and 5 % penicillin/streptomycin. 
HEK293T cells were splitted every 2-3 as 1:5 or 1:6. Primary human lymphocytes were 
cultured in X-vivo 15 medium supplemented with 5 % glutamax. Cells were counted in a 
Neubauer-Counting chamber and were, therefore, diluted with trypan blue as 1:10 or 1:100, to 
distinguish dead from living cells. By means of the 4 engraved quadrates in each chamber the 
cell number per ml was calculated on the basis of the following formula: 
Cells/ml=Viable cells x chamber factor (here: 104) x dilution factor (e.g. 10 for 1:10 dilution) 
For cryoconservation cell lines were harvested when being 80 % confluent and frozen in the 
adequate cell culture medium supplemented with 10 % DMSO and 20 % FCS in a cell density 
of 3-10*106 cells per ml. Primary cells were frozen in FCS supplemented with 10 % DMSO. 
Frozen cells were thawn at 37°C in a water bath, washed with 20 ml normal cell culture and 
then used for normal cell culture. 
 
2.2.2.2 Transfection of eukaryotic cells via TurbofectTM Reagent  
 
HEK293 cells were transfected by using the TurbofectTM in vitro Transfection Reagent 
(Fermentas). The cells were seeded 24 h prior to transfection to yield 70 % confluency and 
were transfected according to the manufacturers’ instructions. After 8 h the transfection was 
stopped by substitution of the culture medium. Transgene expression was analyzed 24-48 h 
later and transfection efficiency was assessed by flow cytometry. 
 
2.2.2.3 Isolation of human Peripheral blood mononuclear cells 
 
Peripheral blood mononuclear cells (PBMC) were isolated by density-gradient centrifugation. 
Therefore, human peripheral blood obtained from buffy coats was diluted 1:3 with 1xPBS and 
overlaid on Pancoll. The centrifugation was performed at 900 x g for 30 min at 20°C without 
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break. After centrifugation the interphase containing the PBMC was carefully extracted and 
cells were washed with 1xPBS and counted before further processing. 
 
2.2.2.4 Isolation of human CD4+ T cells 
 
CD4+ T cells were isolated by combining human RosetteSep CD4+ enrichment cocktail and 
Pancoll density-gradient centrifugation. Human peripheral blood obtained from buffy coats 
was mixed with RosetteSep CD4+ T Cell enrichment cocktail (45 µl/ml blood) and was 
incubated for 20 min at RT with mixing every 5 min. Following the incubation the blood was 
diluted 1:3 with 1xPBS, overlaid on Pancoll and centrifuged at 900 x g for 30 min at 20°C 
without break. After centrifugation the CD4+ T cells containing interphase was carefully 
removed, cells were washed with 1xPBS and counted before further processing. The purity 
was checked by flow cytometric analysis and cells with 90 % purity were regularly obtained. 
 
2.2.2.5 Isolation of human CD4+ T cell populations 
 
CD4+ T cells were obtained as described in 2.2.2.4 Further separation into subpopulations was 
achieved by positive selection with magnetic activated cell sorting (MACS) using CD25 and 
CD45RA microbeads (Miltenyi Biotec, Bergisch Gladbach, DE). The cells were labeled with 
antibody-coupled microbeads (10 µl microbeads, 90 µl PBS per 107 cells) and separated on 
LS, MS or LD MACS columns in a magnetic field according to the manufacturers’ 
instructions (Miltenyi Biotec, Bergisch Gladbach (DE)). The following subpopulations were 
purified: regulatory CD4+CD25+ T cells, conventional CD4+CD25- T cells, naïve CD4+CD25-
CD45RA+ T cells and memory CD4+CD25-CD45RA-T cells. After purification cells were 
washed with PBS, counted and checked for purity by flow cytometry. Purities of 80-90 % 
were regularly obtained.  
 
2.2.2.6 Differentiation of primary human T cells  
 
Naïve CD4+CD25-CD45RA+ T cells (Tnaive) were isolated as described under 2.2.2.5 and were 
differentiated into different T helper cell subsets (TH1/2/9 or 17) or towards an induced Treg 
cell (iTreg) phenotype by incubation with CD3/CD28/MHC-I-coated beads (3 beads: 1 cell) 
together with an adequate cytokine mixture for 5 days. As controls untreated T cells (Tunstim) 
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or T cells only stimulated with CD3/CD28/MHC-I-coated beads (TH0) were used. Table 4 
shows the different cytokines that were used for differentiation and the respective 
restimulation on day 3: 
 
Table 4: Cytokines used for T cell differentiation 
T cell subset Cytokine mix after isolation Restimulation (day 3) 
TH1 
10 ng IL-12/ ml 
10 U IL-2/ ml 
10 ng IL-12/ ml & 
10 U IL-2/ ml 
TH2 20 ng IL-4/ ml 20 ng IL-4/ ml 
TH9 
20 ng IL-4/ ml 
1,0 ng TGF-β/ ml 
20 ng IL-4/ ml 
1,0 ng TGF-β/ ml 
TH17 
25 ng IL-21/ ml 
5,0 ng TGF-β/ ml 
25 ng IL-21/ ml 
5,0 ng TGF-β/ ml 
iTreg 
10,0 ng TGF-β/ ml 
300 U IL-2/ml 
10,0 ng TGF-β/ ml 
300 U IL-2/ml 
 
On day 5 cells were harvested and differentiation of the cells was controlled by qRT-PCR. 
Therefore, the upregulation of lineage specific transcription factors was controlled and 
compared to the expression of β2 microglobulin (B2M). TH1 cells were assessed for T-bet 
expression, TH2 for GATA-3, TH9 for Pu.1, TH17 for RORγt and iTreg cells for FOXP3 
expression. 
 
2.2.2.7 Isolation of murine CD4+ T cell populations 
 
Murine CD4+CD25+ regulatory T cells and conventional CD4+CD25- T cells were isolated 
from murine spleens of C57BL/6 and BALB/c mice, using a protocol modified from a method 
published by Kruisbeek 2001 195. The freshly removed spleens were extruded through a 
100 µm mesh to gain a single cell suspension. The cell suspension was further incubated for 
5 min in 5 ml/spleen ACK lysing buffer (see 2.1.9) with occasional shaking, to remove 
remaining red blood cells, and then cells were washed twice with RPMI. Further separation 
into Treg and Tconv cells was achieved by magnetic activated cell sorting (MACS) using the 
CD4+CD25+ Regulatory T Cell Isolation Kit mouse (Miltenyi Biotec, Bergisch Gladbach, 
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DE) according to the manufacturers’ instructions. The principle of this kit is a two step 
procedure which first enriches CD4+ T cells by depletion of unwanted cells and then 
positively selects CD25+ from the enriched CD4+ T cell fraction. Small aliquots of the 
purified cell populations were collected and purity was checked in flow cytometry. Purities of 
higher than 90 % were regularly obtained.  
 
2.2.2.8 Generation of synthetic, artificial antigen-presenting cells (aAPCs) 
 
An optimal activation of T cells requires the interaction of a specific antigen with the T cell 
receptor (signal 1) and concomitant costimulation (signal 2). These signals were mimicked 
in vitro by means of artificial antigen-presenting cells (aAPC), comprised of tosylactivated 
magnetic beads (Dynal Biotech, Oslo, Norway), which were coated with the following 
monoclonal antibodies: anti-CD3 (OKT3), anti-CD28 (9.3), anti-PD-1 (1-17), anti-CTLA4 
(ER5.3D6) and anti-MHC-I (W6/32). Thereby, suboptimal levels of anti-CD3 antibody (5 %) 
and suboptimal levels of anti-CD28 antibody (14 %) were coated on the beads together with 
either anti-MHC-I antibody (CD3/CD28/MHC-I) or with anti-PD-1 antibody 
(CD3/CD28/PD-1) or with anti-CTLA4 antibody (CD3/CD28/CDTLA4), which constituted 
the remaining 81 % of coated protein. This should guarantee that the bead is not completely 
coated with anti-CD3 and anti-CD28 to achieve a more physiological T cell activation. 
Magnetic beads were mixed with the designated antibodies (150 µg antibodies per ml beads), 
diluted in 0.1 M boric acid and incubated at 4°C overnight under constant rotation. 
Afterwards beads were washed four times with bead wash buffer (see 2.1.9) for 10 min at 
30°C and one time at 4°C overnight. The beads were then counted and stored in fresh bead 
wash buffer at 4°C. Before application in cell culture, aAPCs were washed three times with 
the appropriate culture medium to remove the sodium azide. The method was previously 
described by Chemnitz et al. 196. 
 
2.2.2.9 Flow cytometry 
 
Flow cytometry is a method to gain information about individual particles (e.g. cells) 
concerning size and granularity as well as qualitative and quantitative analysis of the 
expression of different surface markers. For routine surface staining, 2x105 – 5x105 T cells 
were stained in a volume of 100 µl PBS with 0.5 – 5 µl of each labeled antibody for 20 min at 
4°C. Cells were washed with PBS and measured immediately on a flow cytometer FACS LSR 
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II (Becton Dickinson, USA) or were stored until measurement at 4°C in the dark to minimize 
cell modifications or dye degradation. For overnight storage, cells were resuspended in 1 x 
CellFixTM. The antibodies with their respective conjugation that were used can be found in 
2.1.5.1. Cell viability was determined by staining cells with 1 µl propidium iodide (PI) 
(2 mg/ml) immediately before analysis. PI is a fluorescent molecule that enters only dead or 
dying cells. Data were analyzed with the FlowJo Software. 
 
2.2.2.10 Protocols for intracellular staining in flow cytometric analysis 
2.2.2.10.1 Intracellular FOXP3 staining  
 
Intracellular staining of FOXP3 in T lymphocytes was performed with the FOXP3 staining 
buffer set (eBioscience, USA) according to the manufacturers’ instructions. Typically 
1x106 cells were stained. Blocking was performed with after permeabilization with 2 % (2 µl) 
normal mouse or rat serum and cells were stained with 15 µl FOXP3 antibody or with the 
respective isotype control.  
 
2.2.2.10.2 Intracellular HPGD staining 
 
Intracellular staining of HPGD was performed either with the eBioscience FOXP3 staining kit 
described above, using HPGD antibody instead of FOXP3 antibody. In addition, intracellular 
HPGD staining was performed with the Cytofix/CytopermTM kit (BD, USA) according to the 
manufacturers’ instructions or with an approach based on a formaldehyde buffer for fixation 
and a saponine-based buffer for permeabilization modified from a method published by 
Assenmacher et al. 1994 197.  
For staining with the Cytofix/CytopermTM kit typically 5x105 cells were stained. Blocking 
was performed before and after permeabilization for 10 min at 4°C with irrelevant Ig 
(sandoglobulin 20 µg/ml) and cells were stained after permeabilization for 30 min at 4°C with 
either the unconjugated or the directly labeled HPGD antibody. Different HPGD antibody 
concentrations were used, with an initial stock solution of 0,25 mg/ml. The staining with the 
Alexa Fluor 647-labeled secondary antibody was performed for 30 min at 4°C, cells were 
washed with 1 x Perm/ Wash buffer and then subjected to flow cytometry within the next 
30 min. 
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For intracellular staining with the formaldehyde- and saponine-based buffers, 1x106 cells were 
washed with PBS, stained for 30 min at 4°C with the desired surface marker, washed with 
PBS and fixated at RT with 400 µl 4 % formaldehyde in PBS. After 20 min of fixation cells 
were washed with PBS and incubated for 10 min at RT with 400 µl 0,1 M glycine solution. 
Following that cells were washed with PBS, incubated 10 min at RT with 400 µl of 
0,5 %BSA/0,01 % sodium azide in PBS and then permeabilized for 30 min at RT in 100 µl 
saponine buffer (see 2.1.9), supplemented with additional 10 µl blocking serum (mouse or rat 
serum). Afterwards cells were stained for 20 min with HPGD antibody (unconjugated or 
labeled with Alexa Fluor 647) at RT. Then cells were washed with saponine buffer, incubated 
for 20 min at RT with the secondary antibody, washed again with saponine buffer and 
0,5 %BSA/0,01 % sodium azide in PBS and were finally measured in flow cytometric 
analysis within the next 30 min. 
 
2.2.2.11 Suppression assay 
 
A suppression assay was performed in order to investigate the suppressive function of Treg 
cells. Therefore, CFSE-labeled Tconv cells (see 2.2.2.11.1) were activated with 
CD3/CD28/MHC-I-coated beads (see 2.2.2.8) in a ratio of 1 cell: 3 beads. PKH-26-labeled 
Treg cells (see 2.2.2.11.2) were titrated to the Tconv in different ratios. After 72-96 h 
proliferation of the CFSE-labeled Tconv cells was measured by flow cytometry. 
 
2.2.2.11.1 CFSE staining of Tconv cells 
 
Tconv were stained with 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE), a green 
fluorescent cytoplasmic dye that covalently binds to intracellular macromolecules. With each 
cell division the CFSE-labeled macromolecules are equally segregated in such a way that each 
daughter cell contains half of the CFSE amount of the parent cell. This principle can be used 
to visualize proliferation and can be analyzed by flow cytometry 198. For CFSE staining 
1x107 cells/ ml were mixed with CFSE until a final concentration of 0,5 mM was reached and 
incubated for 8 min at RT by shaking it constantly. The reaction was stopped by adding 2 ml 
heat-inactivated FCS and 25 ml RPMI medium supplemented with 10 % FCS. Cells were 
washed again with 10 %FCS/RPMI, counted and resuspended in X-vivo 15 as 1x106 cells/ ml 
for further application.  
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2.2.2.11.2 PKH-26 staining of Treg cells 
 
Treg cells were stained with PKH-26, provided with the Red Fluorescent Cell Linker Kit 
(Sigma-Aldrich, USA) according to the manufacturers’ protocol. PKH-26 is a red fluorescent 
cell dye with long aliphatic tails that can be stably incorporated into lipid regions of the cell 
membrane 199. After staining, cells were washed with 10 %FCS/RPMI, counted and 
resuspended in X-vivo 15 as 1x106 cells/ ml for further application. 
 
2.2.2.12 siRNA knockdown 
 
SiRNA-mediated gene silencing was used to downregulate the expression of HPGD or 
FOXP3 in human Treg cells. Small interfering RNA duplexes (siRNA) are a class of double-
stranded RNA molecules with a length of typically 20-25 nucleotides and a base-paired 
structure characterized by two-nucleotide 3’overhangs. siRNAs are involved in RNA 
interference (RNAi) a mechanism that causes sequence-specific mRNA degradation of single-
stranded target RNAs without changing the transcription rate of the target gene 200,201. Single-
stranded siRNA was dissolved as 1.000 µM solution in sterile RNAse free water for storage at 
-80°C. For siRNA annealing 30 µl of each 500 µM single stranded siRNA were mixed 
together with 15 µl annealing buffer and was incubated for 1 min at 90°C, slowly cooled 
down to RT, heated again for 1 min at 90°C and then incubated of 1 hour at 37°C. The 
annealed siRNA was stored as 10 µl aliquots in -80°C. The knockdown of HPGD or FOXP3, 
respectively, was performed in freshly isolated CD4+CD25+ Treg cells (see 2.2.2.5). Therefore 
5-10x106 cells were mixed with 100 µl of Human T cell Nucleofector Solution and 5 µl of 
annealed siRNA, and cells were electroporated with an AMAXA electroporator for 5 sec with 
the Nucleofector program U14. Immediately after nucleofection cells were transferred into 
fresh, pre-warmed culture medium. After 24-48 h knockdown efficiency was assessed by 
qRT-PCR or flow cytometric analysis. The FOXP3 knockdown data was generated in part by 
Anne-Christine Flach, a former diploma student. 
 
2.2.2.13 Inhibitor assays 
 
Chemical inhibition of HPGD and intracellular signaling molecules in CD4+CD25+ T cells 
(Treg) was achieved by incubation for 24 h with specific inhibitors that target the respective 
molecule. All inhibitors were dissolved in DMSO according to the manufacturer’s 
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instructions. For inhibitor experiments, freshly isolated Treg (isolation see 2.2.2.5) were 
incubated as 1x106 cells/ ml with varying concentrations of the different inhibitors. As a 
control, Treg cells were incubated with DMSO alone. Notably, for experiments investigating 
the IL-2R signaling pathways, Treg cells were pre-incubated with the inhibitors for 60 min 
before additional costimulation with IL-2 was initiated, to avoid activation of the IL-2 
signaling pathway before the inhibitor achieves its complete effect. After 24 h of inhibitor 
treatment the cells were extensively washed with PBS and used for further applications in 
suppression assays, flow cytometry or qRT-PCR analysis. 
 
2.2.2.14 Immunofluorescence staining 
 
For immunofluorescence experiments 50.000 suspension cells were spun onto glass slides by 
centrifugation. Adherent cells were seeded into 8-well chamber slides as 3-4x104 cells/ well, 
transfected on the next day and subjected to immunofluorescence staining 24 h later. In 
general cells were fixated for 10 min with 4 % paraformaldehyde at RT, washed with PBS 
and permeabilized for 10 min in 0,1 % Triton-X 100 at RT. Then glass slides were washed 
with PBS and unspecific binding sites were blocked for 60 min at RT, either with 3 % BSA in 
PBS or with 1 % cold fish gelatin and 10 % goat serum in PBS. Afterwards cells were stained 
in a dark and humidified atmosphere for 1 h at RT with directly-conjugated or unconjugated 
antibodies against HPGD or FOXP3. After incubation for 1 h the slides were washed 
extensively with PBS and if the antibodies were unconjugated, the cells were further stained 
for 1 h at RT with the secondary antibody. All antibodies were diluted in PBS with dilutions 
varying from 1:100-1:1.000. Finally the glass slides were washed and stained for 10 min at 
RT with DAPI (4’6-Diamidino-2-phenylindole), diluted 1:3.000 in PBS. DAPI is used to stain 
the nucleus as it forms fluorescent complexes with natural double-stranded DNA. The slides 
were extensively washed with PBS and one drop of mounting medium and a cover slip were 
applied. The mounting medium was supplemented with 50 µg Dabco (1,4-
Diazabicyclo[2.2.2]octan) per ml mounting medium before usage, as additional bleaching 
protection. The glass slides were dried overnight in the dark at RT and analyzed on a confocal 
laser scanning microscope on the next day.  
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2.2.3 Molecular biological methods 
2.2.3.1 RNA isolation 
 
RNA was isolated with Trizol-Reagent® from Invitrogen Life Technologies according to the 
manufacturers’ instructions. This single-step method is based on an acid guanidinium 
thiocyanate-phenol-chloroform extraction, described by Chomczynski and Sacchi 202. The 
RNA quality and quantity were determined with a spectrophotometer Nano Drop 2000 
(Thermo Scientific, Waltham (USA).  
 
2.2.3.2 Quantitative real-time polymerase chain reaction (qRT-PCR) 
 
Gene expression of selected genes was analyzed using quantitative real-time polymerase 
chain reaction (qRT-PCR). Therefore, 100 ng to 1 µg RNA were reverse transcribed using the 
‘Transcriptor First Strand cDNA Synthesis’ kit (Roche) following the manufacturers’ 
instructions. The qRT-PCR reaction approach consisted of: 
- 4 µl template cDNA or water as control 
- 5 µl ready-to use reaction mix ‘LightCycler 480 Probes Master’ containing FastStart 
Taq DNA polymerase, dNTP mix and MgCl2 containing reaction buffer 
- 0,1 µl forward primer (20 µM stock solution) 
- 0,1 µl reverse primer (20 µM stock solution) 
- 0,1 µl appropriate Universal ProbeLibrary probe 
- 0,7 µl RNase/ DNase-free water 
Each reaction was run in duplicate in 96 well plates on the Real-time PCR system LightCycler 
480 with the program recommended by the manufacturer, see table 5. 
 
Table 5: Standard program for qRT-PCRs 
Program Temperature Acquisition mode Duration Ramp Rate Cycles 
Pre-incubation 95°C None 5 min 4.4 (°C/s) 1 x 
Amplification 
95°C 
60°C 
72°C 
none 
single 
none 
10 sec 
30 sec 
1 sec 
4.4 (°C/s) 
2.2 (°C/s) 
4.4 (°C/s) 
45 x 
Cooling 20°C None 30 sec 2.2 (°C/s) 1 x 
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2.2.3.3 Cell lysates and protein concentration 
 
Cells were harvested, washed with PBS and incubated for 30 min on ice with ice-cold lysis 
buffer (see 2.1.9) as 20 µl buffer/ 5x106 for T cells and 40 µl buffer/ 1x106 cells for cell lines. 
Cell debris were removed by centrifugation at 16.000 x g in a table centrifuge at 4°C and 
protein concentrations were determined, using the BCA protein assay kit (Thermo Scientific) 
according to the manufacturers’ instructions. The absorbance was measured at 562 nm and the 
protein concentration was calculated by comparing it with the absorbance of a standard curve. 
 
2.2.3.4 Sodium Dodecylsulfate-Polyacrylamid-Gelelektrophoresis of proteins (SDS-PAGE) 
 
The SDS-PAGE is a procedure to separate proteins according to their electrophoretic mobility 
203
. 15-50 µg of protein were mixed with laemmli loading buffer (5x) (see 2.1.9), incubated 
for 5 min at 95°C and then applied onto the electrophoresis gel, consisting of a 4,5 % stacking 
gel and a 10 % separating gel (see 2.1.9). The gel was run in Laemmli buffer for SDS-PAGE 
(1x) (see 2.1.1), protein bands were collected for 20 min at constant 100 V and separated for 
1-1,5 h at constant 180 V. After the run, the gel was transferred onto a nitrocellulose 
membrane using a semi-dry blotting or a wet-blotting system.  
 
2.2.3.5 Western Blot 
 
Western blotting was used to transfer protein, previously separated by SDS-PAGE, onto nitro 
cellulose membranes. For semi-dry blotting the protein transfer was carried out at 20-25 V for 
20-40 min. Wet-blotting was conducted at 100 V for 1.5 h. Membranes were blocked 1 h at 
RT in Licor blocking solution. For immunodetection the blot was incubated overnight at 4°C 
with the primary antibody, diluted in Licor blocking solution. Afterwards the blot was washed 
three times for 10 min with PBS + 0,1% Tween-20 (PBST) at RT and incubated for 1 h in the 
dark at RT with the secondary antibody that was diluted in Licor blocking solution at 1:5.000. 
The blot was washed three times with PBST, once with PBS and then the membrane was 
scanned on an Odyssey Imager. The secondary antibody was coupled to one of two different 
infrared dyes (IRdye), which allow near-infrared (NIR) fluorescence detection. The Odyssey 
Scanner images the membrane in two IR channels, with simultaneous laser excitation at 
680 nm and 780 nm. Emitted light is detected at 720 nm and 820 nm by two avalanche 
photodiodes and images are generated for each fluorescence channel. The expression of β-
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actin was analyzed to guarantee equal loading on the membrane and as a house-keeping 
protein, β-actin served to determine differences in protein expression. Membranes were 
stripped with Re-blot mild solution 1:10 diluted in PBS for 10 min at RT, blocked for 30 min 
at RT with Licor blocking solution and further proteins were detected. Membranes were 
stored at -20°C wrapped in an air-tight plastic foil. 
 
2.2.3.6 Electrophoretic mobility shift assay (EMSA) 
 
Protein-DNA-interactions were studied by electrophoretic mobility shift assay (EMSA). 
Synthetic oligonucleotides, labeled with infrared dyes, were diluted to a final concentration of 
20 pmol/µl and 5 µl of reverse oligonucleotide and 5 µl forward oligonucleotide were mixed 
and then annealed by incubation at 100°C for 3 min, followed by slowly cooling it down to 
RT. Annealed oligonucleotides were diluted 1:200 with H2O (‘oligonucleotide working 
solution’) and stored at -20°C for further application. For the binding reaction the following 
components were mixed together and incubated for 20 min at RT in the dark: 
- 1 µl EMSA 10x binding buffer (see 2.1.9) 
- 2 µl EMSA buffer 2 (see 2.1.9) 
- 1 µl oligonucleotide working solution 
- 5 µg FOXP3 recombinant protein 
- Optional: 1 µl of competitor oligonucleotide working solution 
- Optional: 1 µl of antibody for supershift reaction (FOXP3 or isotype control)  
- Add sterile ddH2O to 10 µl 
Afterwards the samples were mixed with 1 µl EMSA 10x loading dye (see 2.1.9), loaded onto 
a 4% native separation gel (see 2.1.9) and run at 10 V/ cm for about 40 min in 1xTGE buffer 
(see 2.1.9). 
 
2.2.3.7 Enzymatic activity assay of HPGD 
 
The enzymatic activity of the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase was 
assessed in human Treg and Tconv cells, which were stimulated for 24 h with IL-2. The 
enzymatic activity was determined by means of a radioactive assay that measures the transfer 
of tritium from 15(S)-[15-3H]PGE2 to glutamate by coupling HPGD with glutamate 
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dehydrogenase 178,204,205. The assay was performed by Professor Andrew J. Dannenberg and 
Dr. Kotha Subbaramaiah, Department of Medicine and Weill Cornell Cancer Center (Cornell 
University), 525 East 68th St., Rm.F-206, New York, NY 10065 (USA). 
 
2.2.3.8 Whole-genome gene expression of human T, B and NK cells as well as monocytes 
 
For the present study the gene expression data from former projects was used. The microarray 
data can be accessed under GSE15390. Data generation and analysis was conducted by Dr. 
Susanne Schmidt and Dr. Michael Mallmann as well as by the former group members Dr. 
Sabine Claßen and Dr. Daniela Eggle. Details concerning sample processing, data collection, 
data assessment and statistical analysis can be obtained from the Ph.D. thesis of Dr. Sabine 
Claßen and Dr. Daniela Eggle. In brief PBMCs and CD4+ T cell populations were isolated 
from human peripheral blood as described under 2.2.2.3 to 2.2.2.5. Human CD19+ B 
lymphocytes, CD3+ T lymphocytes and CD14+ monocytes were isolated from PBMCs by 
positive selection with magnetic activated cell sorting (MACS), using CD19, CD3 or CD14 
microbeads (Miltenyi Biotec, Bergisch Gladbach, DE) and NK cells with the human NK cell 
isolation kit (Miltenyi Biotec, Bergisch Gladbach, DE) according to the manufacturers’ 
instructions. RNA isolation and quantification were performed as described in 2.2.3.1. The 
amplification, labeling and hybridization of the samples were performed on Illumina WG6 
Sentrix Bead Chips V1 or V3, respectively, according to the manufacturers’ instructions 
(Illumina) using an Illumina Bead Station. The data were analyzed with the Bioconductor for 
the statistical software R (http://www.r-project.org). Gene expression values were quantile 
normalized. In brief, differentially expressed genes in human CD4+ T cell populations were 
identified by a combined t-test/fold change analysis with the following criteria: fold change ≥ 
2, absolute difference in signal intensity between group means ≥ 100 and p-value ≤ 0.05. A 
detailed description can be found in the Ph.D. thesis of Dr. Daniela Eggle. 
 
2.2.4 Statistics 
 
Statistical analysis of the sample data was performed with the free software package R 
(version 2.12.1, www.r-project.org). Given that sample values belonging to one group are not 
inevitably distributed normally, sample data were tested beforehand for normal distribution 
using the Shapiro-Wilk test. Normally distributed sample values were subjected to the 
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student’s t-test. The Wilcoxon signed-rank test was applied to data showing no normal 
distribution. If not otherwise mentioned student’s t-test was used for analysis of statistical 
significance. Differences between sample groups were thereby assumed as statistically 
significant when the p-value was below 0.05 (p < 0.05). Analysis of variance between more 
than two sample groups was tested with a one-way ANOVA test. No variance between the 
sample groups was assumed when the p-value was above 0.05 (p > 0.05). 
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3 Results 
3.1 Identification of HPGD as differentially expressed in human Treg cells 
 
In order to identify novel target molecules involved in the development and function of 
human regulatory T cells, global gene expression profiling was carried out. In contrast to 
previous approaches from other groups 206,207 the present study integrated Treg and Tconv cells 
in the resting state as well as cells under activating or inhibiting conditions. Furthermore, 
T cells were used from healthy individuals as well as patients suffering from chronic 
lymphocytic leukemia (CLL). By the use of Tconv cells under different conditions, genes could 
be excluded that were unspecifically upregulated in Treg cells. Thus it was assured to identify 
only genes being specifically expressed in Treg cells in comparison to Tconv cells. Global gene 
expression profiling of human CD4+ T cells, CD4+CD25- T cells (Tconv), regulatory 
CD4+CD25+ T cells (Treg) and expanded regulatory CD4+CD25+FOXP3+ T cells (expanded 
Treg), isolated from peripheral blood of healthy individuals or cancer patients (CLL) was 
performed as described in the methods section (see 2.2.3.8). The cells were either left 
untreated (resting) or incubated with different stimuli (activated). In total 34 different 
experimental conditions (summarized in Appendix B) with 2 – 4 replicates of each condition 
were assessed. In Figure 3, a generalized overview of the experimental setup for the gene 
expression profiling approach is given.  
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Figure 3: Generalized overview of the experimental setup for the global gene expression profiling.  
Human CD4+ Teff cells (Teff), CD4+CD25- Teff cells (Teff) and CD4+CD25+ Treg cells (Treg) were isolated from 
peripheral blood of healthy (H) donors or cancer patients (CLL) in order to identify genes specifically expressed 
in Treg cells. CD4+CD25- Teff cells (A-D) were either used directly as CD4+CD25- Teff cells (D) or were 
additionally further separated according to their expression of CD25 into CD4+CD25low Teff cells (A), 
CD4+CD25int. Teff cells (B), CD4+CD25low-int. Teff cells (C). CD4+CD25+ Treg cells were either used directly for 
following stimulation experiments or were additionally expanded with rapamycin (exp-Rapa) or without (exp) 
before they were used for further treatment. All cells were either rested (unstimulated) for 0-26 h or were 
stimulated (activated) with different substances for up to 26 h (indicated as 0 h, 8 h, 12 h, 18 h, 19 h, 20 h, 24 h 
or 26 h). The cells were stimulated with 1 µg/ml anti-CD3 (CD3), 1 µg/ml anti-CD3 in the presence of 20 U IL-
2/ml (CD3+IL-2), with beads coated with anti-CD3/MHC-I (CD3), anti-CD3/CD28/MHC-I (CD3/CD28), with 
beads coated with anti-CD3/CD28/PD1 (CD3/CD28/PD1), with beads coated with anti-CD3/CD28/CTLA4 
(CD3/CD28/CTLA4), with beads coated with anti-CD3/CD28/MHC-I in the presence of 30 ng/ml TGF-β 
(CD3/CD28+TGF-β), with beads coated with anti-CD3/CD28/MHC-I in the presence of 1 µM PGE2 
(CD3/CD28+PGE2) or with beads coated with anti-CD3/CD28/MHC-I in the presence of 50 ng IL-10/ml 
(CD3/CD28+IL-10). In total, 34 different experimental conditions were used, which are summarized in 
Appendix B. Gene expression was assessed using whole genome microarrays  
 
The gene expression values were normalized with the quantile method and differentially 
expressed genes were identified as described in the Ph.D. thesis of Dr. Daniela Eggle, a 
former group member. A group of 41 genes could be identified that were significantly 
differentially expressed in Treg compared to Tconv among all experimental conditions. One of 
the differentially expressed transcripts was the hydroxyprostaglandin dehydrogenase 15-
(NAD) (HPGD or 15-PGDH). HPGD plays an important role in the metabolism of 
prostaglandins and is one of the major prostaglandin E2 (PGE2)-metabolizing enzymes 163,167. 
In Figure 4, the average gene expression of these 41 differentially expressed genes across 34 
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experimental conditions (summarized in Appendix B) is visualized. The graphic was 
generated with pre-analyzed data that was normalized with the quantile method (therefore see 
also methods 2.2.3.8). Before visualization, the average gene expression was Z score 
transformed (mean=0, standard deviation=1). HPGD belongs to the group of genes that show 
a higher expression in Treg cells but a lower expression in Tconv during all experimental 
conditions (Figure 4). 
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Figure 4: Differentially expressed genes in Treg compared to Tconv cells. 
Visualization of the average gene expression values of genes that were identified to be differentially expressed 
in Treg cells compared with Tconv. Gene expression was assessed in 34 different experimental conditions 
(denoted on top of the diagram), which are summarized in Appendix B. The abbreviations for the different cell 
types and experimental conditions are consistent with Figure 3. The different genes are indicated by their gene 
symbol on the right side of the graphic. Pre-analyzed data, normalized by the quantile method, was used to 
create the graphic. The average gene expression values were further processed using Z score transformation. 
Expression values are color-coded. A high gene expression is depicted in red color, low expression in blue 
color, respectively. The microarray data can be accessed under GSE15390. The graphic was created with dChip 
software 208. 
 
In addition to Figure 4, the HPGD expression is shown separately in Figure 5 A in 
comparison to FOXP3 expression across the 34 different experimental conditions 
(Figure 5 B). A high HPGD expression was detected in CD4+CD25+ Treg cells, whereas a low 
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HPGD expression was observed in CD4+CD25- Tconv cells. Notably, the expression pattern of 
HPGD was similar to the expression of FOXP3. 
 
 
Figure 5: High expression of HPGD and FOXP3 in Treg compared to Tconv cells. 
The average gene expression of (A) HPGD or (B) FOXP3 respectively, was obtained by DNA microarray 
experiments. Human CD4+ T cells, CD4+CD25- T cells (Tconv), regulatory CD4+CD25+ T cells (Treg) and 
expanded regulatory CD4+CD25+ T cells (expanded Treg) were therefore isolated from human peripheral blood 
of healthy or cancer patients (CLL) and either left untreated or incubated up to 24 h with different stimuli. 
34 different experimental conditions with 2-4 replicates of each condition were analyzed. The 34 conditions are 
consistent with those described in Figure 3 and are summarized in Appendix B. The graphic was created with 
pre-analyzed data, which was normalized with the quantile method. The layout was adapted from a graphic 
originally designed by Prof. Dr. J. L. Schultze.  
 
Remarkably, the high HPGD expression in Treg cells appears to be more Treg-specific than for 
instance the expression of the molecules CTLA4 or CD127 (shown in Figure 6 A or 
Figure 6 B), which are commonly used as surface markers to characterize and discriminate 
Treg cells. 
 
 
Figure 6: Differential gene expression of CTLA4 and CD127 in Treg compared to Tconv cells. 
The average gene expression of (A) CTLA4 or (B) CD127 respectively, was obtained by DNA microarray 
experiments. Data were analyzed and processed as in Figure 5. The layout was adapted from a graphic 
originally designed by Prof. Dr. J. L. Schultze.  
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Next, qRT-PCR of Treg and Tconv cells purified from human peripheral blood was performed 
to assess the relative mRNA expression of HPGD in Treg cells. Consistent with the microarray 
data, qRT-PCR revealed a significantly higher HPGD mRNA expression in Treg cells 
compared to Tconv cells (Figure 7). HPGD expression in Tconv cells was reduced by a factor of 
eight compared to Treg cells.  
 
 
Figure 7: Differential expression of HPGD in human 
Treg compared to Tconv cells. 
Human CD4+CD25+ Treg and CD4+CD25- Tconv were 
purified from human peripheral blood and relative HPGD 
mRNA expression, compared to B2M expression was 
assessed by qRT-PCR. Samples are normalized to Treg 
cells. Data represent mean values and standard deviations 
of ten independent experiments. Statistically significant 
differences are marked with an asterisk (* p < 0.001). 
 
 
HPGD mRNA expression was furthermore analyzed in resting Treg or Tconv cells over a period 
of 72 h to investigate possible variations in unstimulated cells. Therefore, Treg or Tconv cells 
were purified from human peripheral blood, cultured in vitro without additional stimulus for 
12 h, 24 h, 48 h and 72 h and HPGD mRNA expression was assessed by qRT-PCR (Figure 8). 
Although a strong decrease of HPGD mRNA expression was observed already after 12 h in 
untreated Treg cells, HPGD mRNA expression in Treg was significantly higher for all time 
points compared to Tconv cells. HPGD mRNA expression in Tconv cells remained relatively 
constant over 72 h. These data show that the HPGD expression is specific for Treg cells, as 
HPGD expression remains constantly higher in Treg compared to Tconv cells, although HPGD 
expression declines in resting Treg cells over time.  
Taken together, this indicates that there might be external influences that maintain high levels 
of HPGD expression in Treg cells in peripheral blood that are not present in in vitro culture 
conditions.  
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Figure 8: HPGD expression in Treg and Tconv cells over 
time.  
Human CD4+CD25+ Treg and CD4+CD25- Tconv were 
purified from human peripheral blood and relative HPGD 
mRNA expression, compared to B2M expression, was 
assessed by qRT-PCR at different time points (0 h, 12 h, 
24 h, 48 h & 72 h). Samples are normalized to Treg cells 
(0 h). Mean values and standard deviations of five 
independent experiments are shown. Statistically 
significant differences are marked with an asterisk (* p < 
0.05). 
 
3.2 Generation of an antibody specifically detecting HPGD 
 
HPGD expression in Treg cells should be also assessed on protein level by Western blot 
analysis, immunofluorescence as well as flow cytometry. However, since no monoclonal 
antibody (mab) suitable for the above mentioned approaches was commercially available, 
mabs specific for human HPGD were generated in cooperation with Ravi Hingorani and 
Robert Balderas, both Becton Dickinson Biosciences. Part of this thesis was the analysis of 
binding specificity of the HPGD antibodies in flow cytometry, Western blot analysis and 
immunofluorescence while the generation, purification and labeling of the monoclonal 
antibodies was carried out by Ravi Hingorani. 
In the following paragraphs the transfection of HEK293 cells with HPGD will be described, 
which served for the subsequent analysis of binding specificity and application spectrum of 
the HPGD specific antibodies.  
 
3.2.1 Transfection of HEK293 cells with HPGD-GFP for the screening of HPGD antibodies 
 
Antibodies were produced using the classical approach of generating antibody-producing 
hybridomas after immunization of BALB/c mice with recombinant protein as antigen.             
The murine sera and later on the generated hybridoma clones were tested by Ravi Hingorani 
for production of the desired antibodies and for recognition of HPGD in vitro by ELISA and 
Western blot analysis. For the purpose of ELISA and Western blot analysis, we provided 
human embryonic kidney (HEK) 293 cells, which were transfected with a pLenti 6.2/V5-Dest 
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EF1α/HPGD-GFP vector encoding a fusion protein of the hydroxyprostaglandin 
dehydrogenase 15-(NAD) and 3’-green-fluorescent protein (GFP). Transfections with 
different vectors, which encode a fusion protein, consisting of HPGD and GFP, are 
abbreviated with the acronym HPGD-GFP throughout this thesis. Transfections with a GFP 
encoding vector will be abbreviated with GFP. The expression of recombinant eukaryotic 
HPGD protein was carried out in mammalian cells to minimize differences in 
posttranslational modifications and processing between recombinant and wildtype HPGD. 
Transfection efficiency was determined by flow cytometry (see Figure 9) and only cells with 
transfection efficiencies of at least 50 % were used for further processing. As a positive 
control for the transfection, HEK293 cells were transfected with pcDNA6/V5-His B/GFP 
vector, encoding GFP (see Figure 9). 
 
 
Figure 9: Control of transfection efficiency of HPGD-GFP or GFP transfected HEK293 cells 
HEK293 cells were transfected either with pLenti 6.2/V5-Dest EF1α/HPGD-GFP vector encoding a HPGD-
GFP fusion protein or with pcDNA6/V5-HisB/GFP vector encoding a GFP protein as positive control for 
transfection. Transfection efficiency was analyzed by flow cytometry and transfected HEK293 cells (open area) 
are depicted in a histogram in comparison to untransfected HEK293 cells (grey area). The numbers in the 
histograms indicate the percentage of transfected cells in the gate. One representative experiment out of three is 
shown. 
 
In addition to flow cytometric analysis, the protein expression of positive HPGD-GFP-
transfected HEK293 cells was assessed by Western blot analysis as a further quality control 
(Figure 10). The blot was incubated with an anti-GFP-antibody to determine the correct size 
of the over-expressed HPGD-GFP fusion protein in comparison to GFP-transfected cells. 
Untransfected cells served as negative control. The estimated band size of the HPGD-GFP 
fusion protein is 55.8 kDa (Figure 10) and only in HPGD-GFP transfected cells a respective 
band was detected. In contrast a band at 26.9 kDa was only detected in GFP-transfected 
HEK293 cells, indicating GFP protein expression. 
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Figure 10: Analysis of HPGD-GFP protein expression in 
HPGD-GFP-transfected HEK293 cells 
HEK293 cells were either left untransfected (Column 1: 
Control) or were transfected with GFP as control (Column 2: 
GFP) or with HPGD-GFP (Column 3: HPGD-GFP) 
respectively. The expression of the respective protein was 
detected with an anti-GFP antibody (red bands). The estimated 
band size of the fusion protein HPGD-GFP is 55.8 kDa and the 
band size of GFP is 26.9 kDa. β-actin (green bands; 42 k Da) 
was used as loading control. One representative experiment 
out of three is shown. 
 
HEK293 cells being at least 50 % positively transfected with HPGD-GFP and exhibiting the 
right band size on Western Blot were sent either as cell pellet or alive for further processing 
and subsequent testing of polyclonal and monoclonal antibodies to BD. Different hybridoma 
clones were tested for production of the desired antibodies and for recognition of HPGD in 
vitro by ELISA and Western blot analysis. The pre-screened hyridoma supernatants that 
showed positive results in both assays were then sent back to us for further tests determining 
binding specificity. 
 
3.2.2 Initial specificity tests on HPGD antibody containing hybridoma supernatants 
 
Initial quality experiments performed by BD with crude hybridoma supernatants had shown 
positive results in vitro in ELISA tests and Western blot analysis concerning antibody 
production and specific binding of the antibodies to HPGD antigen. These pre-screened 
antibody-containing hybridoma supernatants were used for further binding specificity tests in 
flow cytometry. HEK293 cells were therefore left untreated or transfected with HPGD-GFP. 
After 24 h the transfected and untransfected cells were used for candidate clone screening via 
flow cytometric analysis. For this purpose, the cells were fixated and permeabilized and then 
stained with the respective antibody containing hybridoma supernatants. In total 16 different 
hybridoma supernatants were tested. In Figure 11, the results of the flow cytometric analysis 
are shown. The staining quality of each HPGD antibody clone was determined by HPGD- and 
GFP-signal intensity. HPGD-GFP-transfected HEK293 cells are GFP positive and should 
therefore ideally show a linear correlation between the HPGD staining, visualized as HPGD 
signal intensity, and the GFP signal intensity. The supernatants of clone 1, 2 and 3 showed the 
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best staining performance in intracellular flow cytometric staining and were consequently 
used for further antibody screening. 
 
 
 
Figure 11: Binding specificity of HPGD antibodies on HPGD-GFP-transfected HEK293 cells 
HEK293 cells were left untransfected (Untransfected) or transfected with HPGD-GFP. HEK293 cells were 
stained with one of the supernatants 1-16 (S.1 - S.16) together with the secondary antibody (sec. ab). As control, 
cells were left untreated (Unstained), stained with the secondary antibody (sec. ab) alone or in combination with 
the isotype control (Isotype). The x-axis represents the GFP fluorescence intensity and the y-axis shows the 
HPGD fluorescence intensity. The numbers in the quadrants represent the percentage of cells. One 
representative experiment is shown. 
 
3.2.3 Optimization of the staining conditions for flow cytometric analysis 
 
Initial intracellular flow cytometric staining was performed with fixation and permeabilization 
buffers from the BD Cytofix/CytopermTM Fixation/Permeabilization kit. Most of the 
commercially available kits for intracellular flow cytometric stainings contain similar 
compounds, such as formaldehyde for fixation and saponine for permeabilization. However, 
differences in the concentrations of the chemicals can lead to varying staining results. Thus 
three different staining protocols were tested: 
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1. Protocol and staining buffers from the initially used BD Cytofix/CytopermTM 
Fixation/Permeabilization Kit 
2. Standard staining protocol with saponine and formaldehyde – based buffer (see 2.2.3.7 
Intracellular staining for FACS analysis and 2.1.8 Buffers and solutions – Saponine 
buffer) 
3. Protocol and staining buffers from eBioscience FOXP3-Staining Kit. 
 
HEK293 cells were transfected with HPGD-GFP and stained with the three supernatants (S.1, 
S.2 & S.3) that had performed best under 3.2.2. In Figure 12, it is shown that the initial 
conditions with the BD Cytofix/CytopermTM Fixation/Permeabilization kit performed best in 
intracellular HPGD staining. The standard protocol based on saponine and formaldehyde, 
however, showed poor staining results and the FOXP3 staining buffers from eBioscience even 
led to a loss of the HPGD signal. Therefore, the protocol and buffers from the BD 
Cytofix/CytopermTM Fixation/Permeabilization kit were used for subsequent intracellular 
flow cytometric stainings with the HPGD antibodies. 
 
 
Figure 12: Optimization of staining conditions for intracellular staining with HPGD antibodies  
HEK293 cells were transfected with HPGD-GFP and further processed with one of the following staining 
protocols: Cytofix/Cytoperm protocol, Saponine-Formaldehyd protocol or FOXP3 staining protocol. Cells were 
stained with one of three supernatants (S.1 - S.3) together with the secondary antibody (sec. ab). As control 
cells were stained with the secondary antibody (sec.ab) alone or in combination with the isotype control 
(Isotype). The x-axis represents the GFP fluorescence intensity. The y-axis shows the fluorescence intensity of 
the HPGD stained cells. The numbers in the quadrants represent the percentage of cells. One representative 
experiment is shown. 
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3.2.4 Specific binding of unlabeled HPGD antibodies 
 
As the initial screening mentioned above had identified 3 clones producing HPGD antibodies 
as being appropriate for flow cytometric applications, these three hybridoma clones were 
subcloned and the resulting antibodies were purified and concentrated by Ravi Hingorani. 
Subsequently, these concentrated antibodies (clone 1, 2 and 3) were tested for their binding 
specificity in flow cytometric applications. For this purpose HEK293 cells were left untreated 
or were transfected with either HPGD-GFP or with GFP as a control. Afterwards, intracellular 
staining with one of the three antibodies in different dilutions (1:100, 1:300, 1:500, 1:1.000 & 
1:3.000) was performed. In Figure 13, the staining with HPGD antibody clone 1 is shown, in 
Figure 14 the staining with HPGD antibody clone 2 and in Figure 15, the staining with HPGD 
antibody clone 3 is shown.  
All three HPGD antibody clones showed a linear increase in HPGD signal intensity with 
increasing GFP signal intensity for HPGD-GFP-transfected cells. For untransfected or GFP-
transfected cells, however, this was not observed, indicating good and specific staining of the 
HPGD antibodies and that the antibodies did not bind to the GFP part of the HPGD-GFP 
fusion protein. Appropriate staining results were obtained up to a dilution of 1:500 by all three 
clones and HPGD clone 2 even showed HPGD staining with a dilution of 1:1.000. With a 
dilution of 1:100, however, a high background staining and only a marginal increase in the 
HPGD staining were observed, compared to the staining results when a dilution of 1:300 was 
used. These results indicated an unspecific staining, which might be due to a highly 
concentrated antibody dilution. In contrast, good and specific HPGD staining results were 
obtained with a dilution of 1:300 and the background staining decreased to levels of the 
isotype control staining. Therefore, only dilutions below 1:100 were regarded as appropriate 
for further flow cytometric stainings. 
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Figure 13: Binding specificity of unconjugated HPGD antibody clone 1 to HEK293 cells.  
HEK293 cells were left untransfected (Untransfected cells) or were transfected with GFP (GFP transfected 
cells) or HPGD-GFP (HPGD-GFP transfected cells). Cells were stained with HPGD antibody clone 1 (S.1) in 
different dilutions (1:100, 1:300, 1:500, 1:1.000 & 1:3.000) and the secondary antibody (sec. ab). The stock 
solution was 0,25 mg/ml. As control, cells were left untreated (Unstained) or stained with the isotype control 
(Isotype) and the secondary antibody (sec.ab). FI (log10) GFP indicates the fluorescence intensity of the GFP 
signal, FI (log10) HPGD indicates the fluorescence intensity of the HPGD stained cells. The numbers in the 
quadrants represent the percentage of cells. One representative experiment out of three is shown. 
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Figure 14: Binding specificity of unconjugated HPGD antibody clone 2 to HEK293 cells.  
HEK293 cells were transfected, processed and analyzed as described in Figure 13. HPGD antibody clone 2 
(S.2) was used instead of clone 1. The stock solution was 0,25 mg/ml. The axis annotation is consistent with 
Figure 13. The numbers in the quadrants represent the percentage of cells. One representative experiment out of 
three is shown. 
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Figure 15: Binding specificity of unconjugated HPGD antibody clone 3 to HEK293 cells.  
HEK293 cells were transfected, processed and analyzed as described in Figure 13. HPGD antibody clone 3 
(S.3) was used instead of clone 1. The stock solution was 0,25 mg/ml. The axis annotation is consistent with 
Figure 13. The numbers in the quadrants represent the percentage of cells. One representative experiment out of 
three is shown. 
 
3.2.5 Endogenous HPGD mRNA expression in HEK293 cells 
 
HPGD expression can be found in various tissues and cell types 141. Jurkat cells for instance 
express HPGD mRNA at a level comparable with that seen in placenta 180. In the previous 
staining experiments a slight staining of untransfected, GFP- as well as HPGD-GFP-
transfected cells was observed when concentrated antibody solutions were used. Although the 
observed effects could represent background staining that was caused by an over-saturated 
antibody staining solution, the slight staining could be also due to endogenous HPGD 
expression in HEK293 cells. To test this hypothesis, the relative expression levels of HPGD 
in HEK293 cells were examined as a control experiment. HEK293 cells were left untreated 
(Control) or were transfected with HPGD-GFP or with GFP as a control. In Figure 16, the 
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relative HPGD mRNA expression, assessed by qRT-PCR in untransfected, GFP- or HPGD-
GFP-transfected cells is shown. Untransfected and GFP-transfected cells showed similar 
levels of endogenous HPGD expression, whereas HPGD-GFP-transfected cells demonstrated 
a strongly enhanced HPGD expression, that is over 100.000-fold higher compared to 
untransfected and GFP-transfected cells.  
Although these results demonstrate that HEK293 cells show HPGD mRNA expression, the 
observed background staining of untransfected or GFP-transfected cells in flow cytometry is 
rather not due to staining of HPGD protein. As HPGD-GFP transfected cells show a much 
higher HPGD mRNA expression than untransfected of GFP-transfected cells, it is unlikely to 
observe these differences likewise on protein level. Thus, the observed staining of 
untransfected or GFP-transfected HEK293 cells in flow cytometry is unspecific and due to an 
oversaturated antibody solution.  
 
 
Figure 16: Endogenous HPGD mRNA expression in 
HEK293 cells 
HEK293 cells were left untransfected (Control) or 
transfected either with GFP (GFP) or with HPGD-GFP-
(HPGD-GFP). Relative HPGD mRNA expression was 
assessed by qRT-PCR 24 h after transfection and is plotted 
compared to B2M. Mean values and standard deviations of 
one representative experiment are shown. 
 
3.2.6 Binding specificity of directly-conjugated HPGD antibodies 
 
In addition to the unconjugated HPGD antibodies also HPGD antibodies directly labeled with 
Alexa Fluor 647 were obtained from Beckton Dickinson Biosciences. These conjugated 
HPGD antibodies were also used for intracellular flow cytometric stainings to determine their 
binding specificity. For this purpose HEK293 cells were left untreated or were transfected 
with pcDNA6/myc-HisB/HPGD-GFP (HPGD-GFP), a further HPGD-GFP encoding vector, 
which gave better transfection efficiencies due to its smaller size. Furthermore, as control, 
cells were transfected with GFP or as additional control with the vector pIRES2-
AcGFP1/HPGD (HPGD-IRES-GFP), where HPGD is separated by an IRES-site (internal 
ribosome entry site) from AcGFP1 (a green fluorescent protein from Aequorea coerulescens). 
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This permits the simultaneous expression of the gene of interest (here: HPGD) and the 
fluorescent reporter gene (here: AcGFP1) from a single bicistronic mRNA. The control served 
to exclude unspecific binding of the HPGD antibody to an antigen specific for the HPGD-
GFP fusion protein. Following transfection after 24 h, cells were stained intracellularly with 
the conjugated HPGD antibodies clones 1, 2 and 3 in different dilutions (1:1.000, 1:2.000, 
1:5.000 and 1:10.000). In Figure 17, the staining for HPGD antibody clone 1 is shown, in 
Figure 18 the staining for HPGD antibody clone 2 and in Figure 19, the staining for HPGD 
antibody clone 3 is shown.  
Similar to the unconjugated antibodies tested before, the directly-conjugated HPGD 
antibodies showed specific staining of HPGD-GFP-transfected cells, whereas untransfected or 
GFP-transfected cells remained unstained. Also HPGD-IRES-GFP transfected cells were 
specifically stained and the intensity of the HPGD staining increased with the amount of GFP-
signal. However, the binding affinity of the three antibody clones strongly differed. With a 
dilution of 1:1.000 and 1:2.500 the HPGD antibodies clone 1 and clone 2 showed only a 
marginal staining for highly HPGD-GFP-transfected cells, which displayed a high GFP-
signal. In contrast, HPGD antibody clone 3 exhibited good and specific staining of HPGD-
GFP- and also HPGD-IRES-GFP-transfected cells, using these dilutions. Staining of HPGD-
GFP- and also HPGD-IRES-GFP-transfected cells was even observed with clone 3 for the 
dilutions of 1:5.000 and 1:10.000, whereas this was not achieved with the other HPGD 
antibodies clone 1 and clone 2, using these concentrations. For these reasons only HPGD 
antibody clone 3 was further used for the following experiments. 
 
 
   Results 
67 
 
Figure 17: Binding specificity of directly-conjugated HPGD antibody clone 1 to HEK293 cells.  
HEK293 cells were left untransfected (Untransfected cells) or were transfected with GFP (GFP transfected 
cells), pcDNA6/myc-HisB/HPGD-GFP (HPGD-GFP transfected cells) or pIRES2-AcGFP1/HPGD (HPGD-
IRES-GFP transfected cells). Cells were stained with HPGD antibody clone 1 (HPGD-ab) in different dilutions 
(1:1.000, 1:2.500, 1:5.000 and 1:10.000, stock solution 0,25 mg/ml). As control, cells were left untreated 
(Autofluorescence) or stained with the isotype control (Isotype). FI (log10) GFP indicates the fluorescence 
intensity of the GFP signal; FI (log10) HPGD indicates the fluorescence intensity of the HPGD stained cells. The 
numbers in the quadrants represent the percentage of cells. One representative experiment out of three is shown. 
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Figure 18: Binding specificity of directly-conjugated HPGD antibody clone 2 to HEK293 cells.  
HEK293 cells were transfected, processed and analyzed as described in Figure 17. HPGD antibody clone 2 was 
used instead of clone 1. The antibody stock solution was 0,25 mg/ml. The axis annotation is consistent with 
Figure 17. The numbers in the quadrants represent the percentage of cells. One representative experiment out of 
three is shown.  
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Figure 19: Binding specificity of directly-conjugated HPGD antibody clone 3 to HEK293 cells. 
HEK293 cells were transfected, processed and analyzed as described in Figure 17. HPGD antibody clone 3 was 
used instead of clone 1. The antibody stock solution was 0,25 mg/ml. The axis annotation is consistent with 
Figure 17. The numbers in the quadrants represent the percentage of cells. One representative experiment out of 
three is shown. 
 
3.2.7 HPGD staining of peripheral blood mononuclear cells 
3.2.7.1 Staining of peripheral blood mononuclear cells with a HPGD specific antibody 
 
HPGD antibody clone 3 had demonstrated specific and efficient staining of HEK293 cells, 
which were transfected with HPGD or HPGD-GFP, for flow cytometric experiments. In the 
following experiment, the binding of this antibody should be further tested in extracellular 
and intracellular staining of peripheral blood mononuclear cells (PBMC), to examine the 
binding intensity of the HPGD antibody towards different cell populations such as CD4+ or 
CD8+ T cells, B lymphocytes, natural killer (NK) cells or monocytes. Therefore, PBMC were 
isolated, pre-stained with different surface markers (CD3, CD4, CD8, CD14, CD16, CD19 
and CD56) and stained extra- or intracellularly with HPGD antibody clone 3 in different 
concentrations according to the concentration used in previous experiments (1:500, 1:1.000, 
1:2.500 and 1.5.000).  
In Figure 20, the extracellular staining of CD4+ and CD8+ T cells, B lymphocytes, NK cells or 
monocytes with HPGD antibody is shown. 5 % of the monocytes were stained with HPGD 
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antibody (dilution: 1:500), while other cell populations displayed only marginal extracellular 
staining with the HPGD antibody. These data show that the HPGD antibody does not bind 
unspecifically to CD4+ and CD8+ T cells. The slight staining of B cells, NK cells and 
monocytes could be due to antibody binding to Fc receptors that were not efficiently blocked. 
 
 
Figure 20: Extracellular HPGD staining of CD4+ T cells, CD8+ T cells, B cells, NK cells and monocytes. 
PBMC were isolated from human peripheral blood and stained with surface markers for CD3, CD4, CD8, CD14, 
CD16, CD19 and CD56 to distinguish between CD4+ T cells, CD8+ T cells, CD19+ B cells, CD56+ NK cells and 
CD14+ monocytes. Cells were stained with HPGD antibody clone 3 in varying concentrations (1:500 – 1:5.000, 
stock solution 0,25 mg/ml). The staining with HPGD antibody is depicted in a histogram (open area) in 
comparison to the isotype control (grey area). The numbers in the histograms indicate the percentage of HPGD 
stained cells. FI (log10) HPGD indicates the fluorescence intensity of the HPGD signal of HPGD stained cells. 
One representative experiment out of three is shown. 
 
In Figure 21, the intracellular HPGD staining of CD4+ and CD8+ T cells, B lymphocytes, NK 
cells or monocytes is shown. 4,5 % of the CD4+ T cells were positive for HPGD with an 
antibody dilution of 1:500. Also CD8+ T cells (10.1 %), B cells (30.5 %), NK cells (9.7 %) 
and monocytes (53.4 %) were stained by the HPGD antibody using a dilution of 1:500. The 
number of positively stained cells decreased with the next antibody dilution and cells were 
only stained marginally or not with higher dilutions than 1:1.000.  
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In addition to the intracellular HPGD staining, HPGD gene expression in different PBMC 
subsets was examined (see Appendix C), to determine whether HPGD expression can be 
observed in these cell populations and thus the observed HPGD signal in flow cytometry 
could be due to intracellular staining of HPGD. HPGD expression levels were compared with 
those of Treg cells, which show a high HPGD mRNA expression. It could be demonstrated 
that the mean HPGD expression values in the PBMC cell populations were below or near the 
background level compared to the high expression levels of Treg cells. Only NK cells showed 
a slightly enhanced HPGD expression. Therefore, the above mentioned results indicate that 
the observed HPGD signals in flow cytometry were unspecific and could be due to a highly 
concentrated antibody solution or binding of the HPGD antibodies to unblocked Fc receptors 
in monocytes, B lymphocytes and NK cells.  
 
 
Figure 21: Intracellular HPGD staining of CD4+ T cells, CD8+ T cells, B cells, NK cells and monocytes. 
PBMC were isolated from peripheral blood as described in Figure 20. Cells were stained intracellularly with 
HPGD antibody clone 3 in varying concentrations (1:500 – 1:5.000, stock solution 0,25 mg/ml). The staining 
with HPGD antibody is depicted in a histogram (open area) in comparison to the isotype control (grey area). 
The numbers in the histograms indicate the percentage of HPGD stained cells. FI (log10) HPGD indicates the 
fluorescence intensity of the HPGD signal of HPGD stained cells. One representative experiment out of three is 
shown. 
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3.2.7.2 Treg and Tconv cells are not differentially stained by the HPGD antibody in flow cytometry  
 
The previous results had demonstrated that HPGD antibody clone 3 specifically stains HPGD-
GFP- and HPGD-IRES-GFP-transfected cells in flow cytometric experiments. However, 
HPGD staining of CD4+ T cells was not observed, although differential HPGD expression in 
Treg compared to Tconv had been observed on mRNA level. To answer the questions whether 
Treg cells can be stained with the HPGD antibody and if this cell population was just missed 
among the CD4+ T cells, it was tested whether the HPGD antibody would show differential 
staining of Treg and Tconv cells. Therefore, CD4+ T lymphocytes were isolated from human 
peripheral blood as described in 2.2.2.4 and pre-stained with different surface markers (CD3, 
CD4, CD8, CD25 and CD127). Furthermore, cells were stained extra- or intracellularly with 
HPGD antibody clone 3 in different concentrations (1:500, 1:1.000, 1:2.500 and 1.5.000).    
The flow cytometric analysis revealed only marginal extracellular staining of Treg and Tconv 
cells with the HPGD antibody, as depicted in Figure 22. This result further demonstrates the 
specificity of the HPGD antibody, as surface molecules are not bound. 
 
 
Figure 22: Extracellular staining of Treg and Tconv cells with HPGD antibody clone 3 
CD4+ T lymphocytes were isolated from peripheral blood and stained with surface markers for CD3, CD4, 
CD8, CD25 and CD127 to distinguish between CD4+ CD25+ Treg cells and CD4+CD25- Tconv cells. Cells were 
stained with HPGD antibody clone 3 in varying concentrations (1:500 – 1:5.000, stock solution 0,25 mg/ml). 
The staining with HPGD antibody is depicted in a histogram (open area) in comparison to the isotype control 
(grey area). FI (log10) HPGD indicates the fluorescence intensity of the HPGD signal of the HPGD stained cells. 
The numbers in the histograms indicate the percentage of HPGD stained cells. One representative experiment is 
shown. 
 
The intracellular HPGD staining of Treg and Tconv is displayed in Figure 23. 13.4 % of the Treg 
cells were stained with HPGD antibody (dilution 1:500) compared to the isotype control, 
whereas only 3.4 % of the Tconv were stained. However, with increasing antibody dilution 
almost no HPGD stained cells were further detectable.  
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Figure 23: Intracellular HPGD staining of Treg and Tconv cells with HPGD antibody clone 3 
CD4+ T lymphocytes were isolated and treated as described in Figure 22. Cells were stained intracellularly with 
HPGD antibody clone 3 in varying concentrations (1:500 – 1:5.000, stock solution 0,25 mg/ml). The staining 
with HPGD antibody is depicted in a histogram (open area) in comparison to the isotype control (grey area). 
FI (log10) HPGD indicates the fluorescence intensity of the HPGD signal of the HPGD stained cells. The 
numbers in the histograms indicate the percentage of HPGD stained cells. One representative experiment is 
shown. 
 
Next, the mean fluorescence intensity (MFI) of HPGD in Tconv and Treg was assessed to 
determine whether the HPGD antibody staining would reflect the differences observed on 
mRNA level. However, no differences in the MFI between Treg and Tconv cells could be 
observed (Figure 24). Although the staining of the HPGD antibody was shown to be specific 
using, transfected cells, the HPGD staining could not distinguish HPGD stained Treg cells 
from Tconv cells. This suggests that the antibody probably has only a low affinity for the 
HPGD antigen and cannot be used to display differences when low protein amounts are 
present. Therefore, the HPGD antibody was not used for further flow cytometric staining of 
CD4+ T cells. 
 
 
Figure 24: The MFI of HPGD in Treg and Tconv cells is equal 
CD4+ T lymphocytes were isolated and further processed as 
described in Figure 23. Cells were stained with HPGD antibody 
clone 3 in a dilution of 1:500 (stock solution 0,25 mg/ml). 
Intracellular HPGD staining of Treg (grey area) and Tconv (open area) 
was analyzed by flow cytometry and is depicted in a histogram. 
FI (log10) HPGD indicates the fluorescence intensity of the HPGD 
signal of HPGD stained cells. One representative experiment is 
shown. 
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3.2.8 Application of the HPGD antibody for immunofluorescence staining 
 
Although, HPGD antibody clone 3 had demonstrated good staining results in flow cytometry, 
using HPGD-GFP- and HPGD-IRES-GFP-transfected HEK293 cells, the antibody showed 
poor staining results for primary cells. Only high protein amounts in HPGD overexpressing 
cells were sufficiently stained, indicating a low affinity of the antibody for HPGD. Thus, the 
HPGD antibody could not be used for flow cytometric stainings of primary cells. Despite the 
negative results in flow cytometry, the antibody was also tested for immunofluorescence 
staining. Different fixation and permeabilization procedures are used for immunofluorescence 
staining, which might change the confirmation of the HPGD protein, thereby enhancing the 
accessibility of the epitope and thus the staining result.  
HEK293 were therefore left untreated or transfected with HPGD-GFP or as control with GFP 
or HPGD-IRES-GFP, respectively. Cells were stained with the conjugated HPGD antibody 
clone 3 in different dilutions, decreasing from 1:50 to 1:1.000 (stock solution 0,25 mg/ml). 
Unstained cells served as autofluorescence control. Staining of HPGD-GFP transfected cells 
with the HPGD antibody is depicted in Figure 25. Only cells that displayed GFP fluorescence 
were also positive for HPGD staining and in addition the signal intensity for HPGD correlated 
with the GFP signal intensity. In contrast to flow cytometric staining, higher antibody 
dilutions were required for adequate immunofluorescence stainings of transfected HEK293 
cells. With decreasing antibody concentration the HPGD staining attenuated and was almost 
undetectable using a dilution of 1:500.  
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Figure 25: Immunofluorescence staining of HPGD-GFP transfected HEK293 cells with HPGD antibody 
clone 3.  
HEK293 cells were transfected with pcDNA6/myc-HisB/HPGD-GFP (HPGD-GFP). Cells were left unstained 
(Control) or were stained with HPGD antibody clone 3 in different dilutions (1:1.50, 1:100, 1:200, 1:500 and 
1:1.000, stock solution 0,25 mg/ml). The first row represents the GFP fluorescence, depicted in green for 
transfected cells (GFP signal). The middle row represents the HPGD fluorescence, depicted in red for HPGD 
stained cells (HPGD staining). The third row (Merge with DAPI) shows an overlay of both images together 
with DAPI, which visualizes the nucleus. Magnification for all pictures: 60x. One representative experiment out 
of two is shown. 
 
The staining of HPGD-GFP-transfected cells seemed to be specific as untransfected and GFP-
transfected HEK293 cells did not exhibit specific staining by the HPGD antibody even at high 
concentrations, as depicted in Figure 26 or Figure 27.  
 
 
Figure 26: Immunofluorescence staining of untransfected HEK293 cells with HPGD antibody clone 3  
Untransfected HEK293 cells were stained and analyzed as in Figure 25. The row annotation is consistent with 
Figure 25. Magnification for all pictures: 60x. One representative experiment out of two is shown. 
   Results 
76 
 
Figure 27: Immunofluorescence staining of GFP transfected HEK293 cells with HPGD antibody clone 3 
HEK293 cells were transfected with GFP and stained and analyzed as in Figure 25. The row annotation is 
consistent with Figure 25. Magnification for all pictures: 60x. One representative experiment out of two is 
shown. 
 
In addition, HPGD-IRES-GFP-transfected cells were used as further control for 
immunofluorescence staining, as depicted in Figure 28. This control allows the simultaneous 
expression of the two separate proteins HPGD and GFP. On the one hand this excludes that 
the antibody recognizes a HPGD-GFP fusion protein-specific epitope and thus leads to false 
positive binding results. On the other hand this rules out the possibility that the real epitope is 
hidden and not accessible due to a HPGD-GFP-specific protein confirmation. Besides that, 
the localization of HPGD protein in the cell can be examined, which may be different from 
that of the HPGD-GFP-protein. Similar to the observations made for HPGD-GFP-transfected 
cells, only HPGD-IRES-GFP-transfected cells that were GFP-positive cells were also stained 
for HPGD. The HPGD staining could thereby be merged with the GFP signal. With 
decreasing antibody concentration the HPGD staining attenuated and was almost undetectable 
at a dilution of 1:500. In comparison to HPGD-GFP-transfected cells the HPGD staining was 
weaker in HPGD-IRES-GFP-transfected cells, although cells were processed in parallel. An 
explanation for this phenomenon could be an enhanced degradation rate of HPGD compared 
to GFP. Moreover, the expression rates of the two genes might be different, as it was shown 
for example that the expression of the IRES-dependent second gene in a bicistronic vector can 
vary 209. In conclusion, the results show that the HPGD antibody specifically binds to HPGD 
in HPGD-GFP- and HPGD-IRES-GFP-transfected cells in immunofluorescence staining.  
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Figure 28: Immunofluorescence staining of HPGD-transfected HEK293 cells with HPGD antibody clone 
3. 
HEK293 cells were transfected with HPGD-IRES-GFP and stained and analyzed as in Figure 25. The row 
annotation is consistent with Figure 25. Magnification for all pictures: 60x. One representative experiment out 
of two is shown. 
 
Finally it was tested whether the differences in HPGD mRNA expression between Treg and 
Tconv could be also observed on protein level, using the HPGD antibody for 
immunofluorescence staining. Therefore, CD4+ T lymphocytes were isolated and stained 
intracellularly with FOXP3 antibody to distinguish Treg from Tconv cells. Furthermore, cells 
were stained with the HPGD antibody in two different concentrations (1:50 and 1:100) or left 
untreated (Control). In Figure 29, it is shown that both, Treg and Tconv cells were marginally 
stained with the HPGD antibody but no differences in the staining intensity between Treg and 
Tconv cells could be observed.  
This result indicates that the affinity of the HPGD antibody is too low for appropriate 
intracellular staining of HPGD in primary cells. Only high protein amounts in HPGD-
overexpressing cells, such as HPGD-GFP- or HPGD-IRES-GFP-transfected cells, were 
sufficiently stained. Therefore, the HPGD antibody was not used for immunofluorescence 
staining.  
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Figure 29: Similar staining of Treg and Tconv cells by the HPGD antibody in immunofluorescence.  
CD4+ T cells were isolated from human peripheral blood and stained intracellularly with HPGD antibody 
clone 3 in different dilutions (1:1.50, 1:100, stock solution 0,25 mg/ml) and with FOXP3 antibody (Fitc-
conjugated) to locate FOXP3+ Treg cells. As control, cells were stained with all antibodies except the HPGD 
antibody (Control). The first row (FOXP3 staining) shows the FOXP3 stained Treg cells displayed in green. The 
middle row (HPGD staining) displays the HPGD stained cells in red. The third row (Merge with DAPI) shows 
an overlay of both images together with DAPI, which visualizes the nucleus. Magnification for all pictures: 60x. 
One representative experiment out of two is shown. 
 
3.2.9 Application of the HPGD antibody for Western blot analysis 
3.2.9.1 Detection of HPGD in HPGD-transfected HEK293 cells 
 
Despite the poor staining results for Treg and Tconv cells in flow cytometry and 
immunofluorescence, HPGD antibody clone 3 should be also tested for Western blot analysis, 
to answer the question whether the differences of HPGD mRNA expression in Treg and Tconv 
cells would be also observed on protein level. In contrast to the previous methods, the protein 
is highly and irreversibly denaturated for Western blot analysis by the treatment with sodium 
dodecylsulfate (SDS). The epitope and its ability to interact with the HPGD antibody can be 
altered by this treatment and consequently change the staining result. Furthermore, additional 
epitopes may be uncovered, which can then be bound by the HPGD antibody.  
Therefore, HEK293 cells were left untransfected or were transfected with HPGD-GFP or with 
GFP as control. Protein lysates were prepared from cells showing a transfection rate above 
50 % as determined by flow cytometry. Subsequently, different HPGD antibody dilutions 
were tested in Western blot analysis with HPGD-GFP-transfected cells to determine the 
concentration range for specific binding of the HPGD antibody and define an optimal working 
concentration. The relative binding affinity for HPGD, normalized to β-actin is depicted in 
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Figure 30 and demonstrates a concentration dependent decrease in the detection of HPGD. 
Nevertheless, even minuscule amounts of antibody resulted in a clear signal. Taken together 
these results suggest that a dilution of 1:1.000 represents a convenient working concentration 
for the HPGD antibody.  
 
 
Figure 30: Low HPGD antibody concentrations detect 
HPGD-GFP protein by Western blotting. 
HEK293 cells were transfected with HPGD-GFP (vector 
pcDNA6/myc-HisB/HPGD-GFP) and equal amounts of 
protein were blotted on several blots. Different HPGD 
antibody dilutions were then tested for the detection of HPGD-
GFP protein on Western Blot. Antibody dilutions of 1:100 - 
1:20.000 (stock solution 0,25 mg/ml) were applied. The 
fluorescence intensity (FI) is shown for each HPGD antibody 
dilution. Samples were normalized to the FI of the loading 
control β-actin. One representative experiment of two is 
shown. 
 
In addition, also HPGD-IRES-GFP-transfected cells were used as control on Western Blot. 
This control should proof specific binding to an HPGD-specific epitope and exclude that the 
antibody unspecifically binds to an epitope specific for the HPGD-GFP fusion protein or 
GFP. Thus HEK239 cells were left untreated or were transfected either with HPGD-GFP, 
HPGD-IRES-GFP or GFP. HPGD antibody clone 3 was used in a dilution of 1:1.000, as this 
dilution had proven to be a convenient working solution for Western blot analysis for HPGD-
transfected cells. The HPGD antibody detected the expected size of HPGD (28,9 kDa) in 
HPGD-IRES-GFP-transfected cells as well as the HPGD-GFP fusion protein (55,8 kDa) in 
HPGD-GFP-transfected cells, but did not bind to GFP (26,9 kDa) in GFP-transfected cells as 
shown in Figure 31 A. Additionally, the Western Blot was incubated with an anti-GFP 
antibody to control the size of the HPGD-GFP fusion protein and display the GFP protein 
expressed by HPGD-IRES-GFP or GFP-transfected cells. The expected size of HPGD-GFP 
(55,8 kDa) in HPGD-GFP-transfected cells and GFP (26,9 kDa) in GFP- and HPGD-IRES-
GFP-transfected cells were detected by the anti-GFP antibody, as shown in Figure 31 B.  
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Figure 31: Detection of HPGD expression using the HPGD antibody clone 3 by Western blotting 
HEK293 cells were either left untransfected (Column 1: Control) or were transfected with pcDNA6/myc-His 
B/GFP as transfection efficiency control (Column 2: GFP), with pcDNA6/myc-His B/HPGD-GFP (Column 3: 
HPGD-GFP) or with pIRES2-AcGFP1/HPGD (HPGD-IRES-GFP) respectively. (A) The expression of HPGD 
(28,9 kDa) or HPGD-GFP fusion protein (55,8 kDa) was detected with the HPGD antibody (green bands) on 
Western Blot. Dilution of the antibody was 1:1.000 (stock solution 0,25 mg/ml). (B) As control anti-GFP 
antibody was applied (red bands) for detection of HPGD-GFP or GFP protein (26,9 kDa). β-actin (black bands; 
42 kDa) was used as loading control. One representative experiment out of two is shown. 
 
3.2.9.2 HPGD protein expression in human regulatory T cells 
 
The previous results had shown that relative HPGD mRNA expression is higher in human Treg 
cells in comparison to Tconv. Moreover, HPGD antibody clone 3 had demonstrated specific 
staining of HPGD in lysates of HPGD-transfected HEK293 cells. Consequently, this antibody 
was tested for Western blot analysis with Treg and Tconv cells to examine whether the 
differences in HPGD mRNA expression would be also observed on protein level.            
For this purpose HPGD expression of freshly isolated human Treg and Tconv cells was analyzed 
by Western blot analysis. HPGD protein expression was significantly higher in Treg than in 
Tconv cells, as shown in Figure 32 A. In Figure 32 B, it is shown that the HPGD antibody 
detected the expected size of HPGD (28,9 kDa) in Treg cells and that HPGD expression was 
less intensive in Tconv cells. However, a higher antibody concentration (1:200) had to be 
applied to visualize bands in T cells, than the initial concentration (dilution 1:1.000) that was 
used for HPGD-GFP-transfected HEK293 cells. Furthermore, more protein had to be 
subjected to the Western Blot (50 µg of T cell lysates compared to 15 µg of HEK cell lysates) 
to obtain good results. Taken together the results show that, consistent with the mRNA 
expression data, Treg cells also display a significantly higher HPGD protein expression 
compared to Tconv cells. Moreover, it was demonstrated that the HPGD antibody specifically 
detects HPGD protein on Western Blot and can be even used for analysis of primary cells. 
   Results 
81 
 
 
Figure 32: HPGD protein expression is higher in Treg cells than in Tconv  
Human CD4+CD25+ Treg cells and CD4+CD25- Tconv were purified and HPGD protein expression was assessed 
by Western blot analysis. (A) Relative amounts of HPGD were measured densitometrically in comparison to β-
actin. Data represent mean values and standard deviations of four independent experiments. Statistically 
significant differences are marked with an asterisk (* p < 0.01) (B) One representative Western blot experiment 
is shown.  
 
3.3 HPGD is expressed specifically in human natural regulatory T cells 
3.3.1 HPGD expression in T cell subsets 
 
Human Treg cells were shown to exhibit a higher expression of HPGD on mRNA and protein 
level than Tconv. Following that it was investigated whether HPGD expression was unique for 
Treg cells or if HPGD would be also expressed in other CD4+ T cell subsets, depending on 
their activation and differentiation state. The CD45RA surface molecule represents, for 
instance, a suitable marker to distinguish naïve from activated or memory T cells. The 
leukocyte specific transmembrane glycoprotein CD45 is a protein tyrosine phosphatase 
(PTP)210 and was shown to be required for efficient T and B cell antigen receptor signal 
transduction 211,212. Several isoforms of CD45 can be generated by alternative splicing of the 
exons 4 (A), 5 (B) and 6 (C) and expression of the respective isoforms is dependent on cell 
type, stage of differentiation and activation state of the cell 212,213. In humans, the isoform 
CD45RA is expressed on naïve T lymphocytes (Tnaive), which represent mature T cells that 
have not yet encountered antigen. Upon encounter of their cognate antigen Tnaive cells acquire 
an activated phenotype, characterized by upregulation of activation markers such as CD25, 
CD44, and CD69 and down-regulation of CD62L and CD45RA 214-216. The activated T cells 
may further differentiate into a memory T cell (Tmemory), which represents an ‘antigen-
experienced’ T cell that has already encountered and responded to its cognate antigen 216-218. 
Besides activated T cells also Tmemory are CD45RA- and express the shortest CD45 isoform 
CD45RO, which lacks RA, RB and RC exons 213,214. Thus CD45RA represents a suitable 
marker to distinguish naïve from activated or memory T cells. To address the question 
whether HPGD expression is enhanced during T cell activation and differentiation, Tconv cells 
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were isolated from human peripheral blood and further separated into CD4+CD25-CD45RA- 
Tmemory cells and CD4+CD25-CD45RA+ Tnaive cells. HPGD mRNA expression levels were 
assessed by qRT-PCR in freshly isolated Tmemory and Tnaive cells and compared to Treg cells. 
HPGD mRNA expression in Tmemory cells was slightly higher than in Tnaive, as depicted in 
Figure 33. However, HPGD expression was constantly lower for memory and naïve Tconv in 
comparison to natural Treg cells (see Figure 33).  
The differential HPGD mRNA expression in Tnaive compared to Tmemory cells indicates that 
HPGD expression might be upregulated during T cell differentiation. Furthermore, the results 
support that an enhanced HPGD expression might be specific for Treg cells. 
 
 
Figure 33: Tmemory cells reveal a higher HPGD 
expression than Tnaive cells 
Human natural Treg, Tconv, Tmemory & Tnaive cells were 
purified and relative HPGD mRNA expression, 
compared to B2M expression, was assessed by qRT-
PCR. Mean values and standard deviations of three 
independent experiments are shown. Data are 
normalized to Treg cells. Statistically significant 
differences (wilcoxon signed-rank test; p < 0.05) are 
marked with an asterisk. 
 
3.3.2 HPGD expression is not upregulated during T cell differentiation  
 
Human naïve CD4+ T cells can differentiate into a number of different T helper cell subsets 
with distinct effector cell functions, such as TH1, TH2, TH9 and TH17 219,220. TH1 cells, for 
instance, are characterized by production of high levels of IFNγ and are involved in cellular 
immunity against intracellular microorganisms 219-221. In contrast, TH2 cells produce IL-4, IL-
5, IL-9 and IL-13 and are required for humoral immunity to protect against parasitic 
helminthes and other extracellular pathogens 220,222. TH9 are characterized by production of 
IL-9 and IL-10 and are involved in allergic inflammation and defense against extracellular 
parasites as nematodes 223,224. TH17 cells produce IL-17A, IL-17F, IL-21, IL-22, IL-6, TNFα 
and CCL20 and play an important role in clearance of extracellular bacteria and fungi, mainly 
at mucosal surfaces 220,225,226. As higher expression levels of HPGD were detected in Tmemory 
cells in comparison to Tnaive, one could postulate that HPGD expression might increase during 
T cell differentiation. To test this hypothesis it was investigated whether HPGD expression is 
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upregulated during differentiation towards different T helper cell subsets such as TH1, TH2, 
TH9 or TH17. This question was addressed in the following experiment: CD4+CD25-
CD45RA+ naïve T cells were purified and differentiated towards the desired T cell subset by 
stimulation with CD3/CD28/MHC-I-coated beads together with the appropriate cytokines for 
5 days. Unstimulated Tnaive cells (Tunstim) as well as Tnaive cells only stimulated with 
CD3/CD28/MHC-I-coated beads (TH0) served as control. To monitor successful 
differentiation the expression of lineage specific transcription factors, such as T-bet for TH1 
cells, GATA-3 for TH2, PU.1 for TH9 and RORγt for TH17 cells were assessed by qRT-PCR 
(see Appendix D). HPGD expression was assessed in differentiated T cell subsets, as shown 
in Figure 34. Relative HPGD expression levels, assessed by qRT-PCR are presented in 
comparison to freshly isolated Tconv and Treg cells (time point 0 h). HPGD expression in TH0 
was equal to freshly isolated Tconv and Tunstim cells. Differentiation of naïve T cells into TH1, 
TH2, TH9 or TH17 cells did not result in the induction of HPGD. 
Taken together these results indicate that HPGD expression remains low in Tconv cells 
independent of TCR/CD28 stimulation and their polarization towards different TH cell 
lineages. Moreover, the enhanced HPGD expression seems to be specific for Treg cells.  
 
 
Figure 34: HPGD expression is not upregulated during T cell differentiation 
Human Tnaive cells were purified and differentiated with anti-CD3/CD28/MHC-I-coated beads together with the 
appropriate cytokines towards TH1, TH2, TH9 and TH17 cells. Unstimulated Tnaive cells (Tunstim) and Tnaive only 
stimulated with CD3/CD28/MHC-I-coated beads without additional cytokines (TH0) served as control. Freshly 
isolated Treg, (Treg 0h) and Tconv (Tconv 0h) served as additional controls. Relative HPGD mRNA expression, 
compared to B2M expression, was assessed by qRT-PCR. Mean values and standard deviations of three 
independent experiments are shown. Data were normalized to Tconv cells (time point 0 h). n.d.: no statistically 
significant differences (one-way ANOVA; p > 0.05) between the sample groups were observed.  
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3.3.3 HPGD expression is not upregulated in induced regulatory T cells  
 
Regulatory T cells are generated in the thymus as naturally occurring Treg cells (nTreg)1,16, but 
there also exist so called induced or adaptive Treg cells (iTreg) that are generated in the 
periphery 29,30,33. Similarly to nTreg cells these iTreg display high FOXP3 expression levels, 
anergy and suppressive function in vitro and in vivo 30,227. But on the other hand iTreg cells 
also differ from nTreg cells. Although they exhibit high FOXP3 expression levels, iTreg cells 
were shown to lack a part of the gene signature that is specific for nTreg cells 228. Still 
differences remain to be elucidated that are specific for nTreg or iTreg cells. 
In this context it was investigated whether HPGD expression would be upregulated in iTreg 
cells or whether HPGD expression is specific for nTreg cells. Therefore, naïve T cells were 
purified from human peripheral blood and differentiated into iTreg cells by stimulation with 
CD3/CD28/MHC-I-coated beads together with the appropriate cytokines for 5 days. Tunstim 
and TH0 cells served as control. To monitor successful induction of adaptive Treg cells the 
expression of the lineage specific transcription factor FOXP3 was assessed by qRT-PCR (see 
Appendix D). HPGD mRNA expression was assessed in iTreg cells, as shown in Figure 35. 
Relative HPGD mRNA expression levels, assessed by qRT-PCR are presented in comparison 
to freshly isolated Tconv and Treg cells (time point 0 h). HPGD expression in TH0 cells was 
equal to freshly isolated Tconv and Tunstim cells. Differentiation of naïve T cells into iTreg cells 
did not result in the induction of HPGD. Similar observations were made for gene expression 
profiling (see Figure 72, Appendix D), as Tconv, Tnaive and iTreg cells revealed low HPGD 
expression levels, whereas Treg cells displayed high HPGD expression levels. 
 
 
Figure 35: HPGD expression is not upregulated in 
induced Treg cells 
Human Tnaive cells were purified and differentiated 
with anti-CD3/CD28/MHC-I-coated beads together 
with the appropriate cytokines towards iTreg cells. 
Tunstim and TH0 cells as well as freshly isolated Treg, 
(Treg 0h) and Tconv (Tconv 0 h) served as controls. 
Relative HPGD mRNA expression, compared to 
B2M, was assessed by qRT-PCR. Mean values and 
standard deviations of three independent experiments 
are shown. Data were normalized to Tconv cells (time 
point 0 h). n.d.: no statistically significant differences 
(one-way ANOVA; p > 0.05) between the sample 
groups were observed. 
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Taken together, these results indicate that HPGD expression is specific for natural Treg cells 
and belongs to the nTreg specific gene expression program. HPGD expression levels seem to 
be settled during T cell maturation and can no longer be induced in Tnaive cells by extracellular 
stimulation. 
 
3.4 Influence of PGE2, TGF-β and IL-10 on HPGD expression in human Treg cells 
 
HPGD plays an important role in the metabolism of prostaglandins and is one of the major 
prostaglandin E2 (PGE2)-metabolizing enzymes 163,167. Furthermore, PGE2 is a known potent 
immunosuppressive, soluble molecule, which is produced by tumor cells 229 and cells of the 
immune system as for instance monocytes, macrophages or neutrophils 230. Moreover, tumor-
secreted PGE2 induces FOXP3 expression as well as a regulatory phenotype in Tconv cells 231. 
Notably, pre-incubation with PGE2 did also increase FOXP3 expression as well as the 
suppressive activity of Treg cells 232. For these reasons, a possible influence of PGE2 on the 
HPGD expression in Treg cells was investigated (Figure 35). Human Treg cells were isolated 
from peripheral blood and incubated for 72 h with PGE2 or left untreated. After 24, 48 and 
72 h cells were harvested. Expression of HPGD on mRNA levels was analyzed by qRT-PCR. 
Stimulation with PGE2 did not significantly influence HPGD expression compared to 
unstimulated Treg cells as depicted in Figure 35, suggesting that HPGD expression in Treg cells 
is independent of PGE2 signaling. 
 
 
Figure 36: HPGD expression is not influenced by 
stimulation with PGE2 
Human CD4+CD25+ Treg cells were purified and left 
untreated (Unstimulated) or stimulated with 1 µM 
PGE2 (PGE2). Relative HPGD mRNA expression, 
compared to B2M expression, was assessed by qRT-
PCR after 24 h, 48 h and 72 h. Samples are 
normalized to Treg cells (0 h). Data represent mean 
values and standard deviations of three independent 
experiments. 
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Besides that, tumor cells or cells in the tumor microenvironment can produce TGF-β and IL-
10 229, which were reported to induce Treg cells in the periphery 34,35. Consequently it was 
examined whether these factors might have an effect on HPGD expression in Treg cells. 
Therefore, Treg cells were isolated from human peripheral blood and incubated for 72 h with 
TGF-β or IL-10, respectively, or left untreated. HPGD mRNA expression was assessed by 
qRT-PCR after 24, 48 and 72 h. No significant influence could be observed when cells were 
stimulated with TGF-β, as shown in Figure 36. However, IL-10 stimulation did modulate 
HPGD expression, as HPGD expression was significantly higher after 24 h in IL-10 
stimulated cells compared to unstimulated cells.  
This result indicates that IL-10 receptor- signaling modulates HPGD expression, whereas 
TGF-β signaling has no influence on the HPGD expression in Treg cells. 
 
 
Figure 37: HPGD expression in human Treg cells is influenced by IL-10 but not TGF-β 
Human CD4+CD25+ Treg cells were purified and left untreated (Unstimulated) or stimulated with (A) 10 ng/ml 
TGF-β (TGF-β) or (B) 50 ng/ml IL-10 (IL-10). Relative HPGD mRNA expression, compared to B2M 
expression, was assessed by qRT-PCR after 24 h, 48 h and 72 h. Samples are normalized to Treg cells (0 h). Data 
represent mean values and standard deviations of at least three independent experiments. Statistically significant 
differences (p < 0.05) are marked with an asterisk. 
 
3.5 Influence of interleukin-2 on HPGD expression in human regulatory T cells 
3.5.1 TCR activation in the presence of IL-2 enhances HPGD expression in Treg cells 
 
Regulatory T cells require previous activation for the induction of their suppressor function in 
vitro, as it was shown by Thornton et al. 2004 233. Best induction results were achieved when 
Treg cells were pre-cultured for at least 24 h with anti-CD3-antibody (0.5-1 µg/ml) in the 
presence of IL-2 (at least 12.5 U/ml) and the absence of Tconv cells 233. Since the previous 
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results of this study had shown that HPGD expression decreases in unstimulated Treg cells, it 
was consequently investigated whether this pre-activation with TCR signaling and activation 
of the IL-2 receptor would influence HPGD expression in Treg cells. 
To address this question, human Treg and Tconv cells were isolated from peripheral blood and 
incubated for 24 h in medium supplemented with IL-2 and anti-CD3 antibody. HPGD mRNA 
expression was assessed by qRT-PCR. TCR stimulation in the presence of IL-2 significantly 
upregulated HPGD mRNA expression in Treg cells, as shown in Figure 38 A. In contrast, 
HPGD mRNA expression in Tconv cells was unchanged (Figure 38 B). These results show that 
HPGD expression in Treg cells is differentially regulated than in Tconv and can be influenced 
by TCR/IL-2R activation. Furthermore, these results support that HPGD expression in Treg 
cells is dependent on extracellular stimuli. 
 
 
Figure 38: HPGD expression is specifically upregulated in Treg cells upon IL-2/anti-CD3 stimulation. 
(A) Human Treg (grey columns) and (B) Tconv cells (black columns) were purified from human peripheral blood 
and left untreated (-) or stimulated with 1.0 µg/ml anti-CD3 antibody and 20 U/ml IL-2 (IL-2 & α-CD3) for 
24 h (+). HPGD mRNA expression, compared to B2M expression, was assessed by qRT-PCR. Samples are 
normalized to Treg cells (0 h). Data represent mean values and standard deviations of three independent 
experiments. Statistically significant differences (p < 0.05) are marked with an asterisk. 
 
The inducing effects of CD3/IL-2-stimulation on expression of HPGD in Treg cells were 
further examined over time. Therefore, human Treg and Tconv cells were isolated and 
stimulated for 12 h, 24 h, 48 h and 72 h with IL-2 and anti-CD3. HPGD mRNA expression 
was assessed by qRT-PCR and it could be established that HPGD is significantly upregulated 
approximately 2-fold in Treg cells already after 12 h (Figure 39). This upregulation remained 
relatively stable over a period of 72 h. In contrast, HPGD mRNA expression was not 
enhanced in Tconv cells upon the stimulation with anti-CD3 and IL-2. 
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This result shows that HPGD expression in Treg cells is differentially regulated than in Tconv 
cells, as TCR activation and IL-2R signaling specifically enhance HPGD mRNA expression 
in Treg cells. Moreover, these data show that HPGD expression in Treg cells can be modulated 
by extracellular stimuli. 
 
 
Figure 39: HPGD is specifically upregulated in regulatory T cells upon CD3 & IL-2 stimulation. 
(A) Human Treg  and (B)Tconv cells were purified from human peripheral blood and left untreated (Unstimulated) 
or stimulated with 1 µg/ml anti-CD3 antibody and 20 U/ml IL-2 (α-CD3 & IL-2) for 12 h, 24 h, 48 h and 72 h. 
HPGD mRNA expression, compared to B2M expression, was assessed by qRT-PCR. Samples are normalized 
to Treg cells (0 h). Mean values and standard deviations represent four independent experiments. Statistically 
significant differences between unstimulated and α-CD3/IL-2-stimulated samples are marked with an asterisk (* 
p < 0.05). 
 
3.5.2 HPGD upregulation is IL-2 dependent and independent of TCR signaling 
 
Activating pre-culture of Treg cells with anti-CD3-antibody in the presence of IL-2 was shown 
to specifically induce HPGD expression in Treg cells. However, it might be possible that the 
observed upregulation of HPGD was induced, for instance, by stimulation with IL-2 alone. 
This assumption is supported by the observations that the transcription factor activating 
protein-1 (AP-1) that can be activated by IL-2R signaling via MAPK signaling pathways 
136,139
, has potential binding sites in the promoter of HPGD 180. It was therefore investigated 
whether induction of HPGD expression in Treg cells was a result of TCR or IL-2R activation 
or due to synergistic effects of both signaling pathways. To assess the relevance of IL-2R 
signaling for HPGD expression in Treg cells it was investigated whether HPGD expression 
could be upregulated by IL-2 stimulation alone. Therefore, Treg and Tconv cells were isolated 
from human peripheral blood and stimulated for 12 h, 24 h, 48 h and 72 h with IL-2. The 
analysis revealed that HPGD was upregulated 2-fold in Treg cells upon stimulation with IL-2 
alone after 12 h with a maximum of 2.5-fold expression after 48 h (Figure 40). HPGD 
   Results 
89 
expression in Tconv cells on the other hand was not influenced by IL-2 stimulation. This result 
shows that HPGD expression in Treg cells is dependent on IL-2 signaling and HPGD 
upregulation can be also mediated by IL-2R signaling alone. 
 
 
Figure 40: IL-2 stimulation specifically upregulates HPGD expression in regulatory T cells. 
(A) Human Treg and (B) Tconv cells were purified from peripheral blood and left untreated (Unstimulated) or 
stimulated with 20 U/ml IL-2 (IL-2) for 12 h, 24 h, 48 h and 72 h. HPGD mRNA expression, compared to B2M 
expression, was assessed by qRT-PCR. Samples are normalized to Treg cells (0 h). Data represent mean values 
and standard deviations of four independent experiments. Statistically significant differences between 
unstimulated and IL-2 stimulated samples are marked with an asterisk (* p < 0.05). 
 
HPGD mRNA expression values of Treg cells, stimulated with IL-2 alone or in the presence of 
anti-CD3 antibody were compared with each other, but no significant differences between the 
two different stimulations were observed, as all expression values were relatively similar 
(Figure 41). This result further supports that IL-2 is important for the induction of HPGD and 
shows that HPGD upregulation can be also mediated by IL-2 stimulation alone and is not 
exclusively dependent on the combined effects of TCR and IL-2R signaling. 
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Figure 41: Induction of HPGD mRNA expression is equal after IL-2 or IL-2/ anti-CD3 stimulation.  
Human Treg cells were purified from peripheral blood and stimulated with 20 U/ml IL-2 alone (IL-2) or together 
with1 µg/ml anti-CD3 antibody (IL-2/ α-CD3) for 12 h, 24 h, 48 h and 72 h. HPGD mRNA expression, 
compared to B2M expression, was assessed by qRT-PCR. Samples are normalized to Treg cells (0 h). Mean 
values and standard deviations of four independent experiments are shown. n.d.: no statistically significant 
differences (one-way ANOVA; p > 0.05) between sample groups were observed. 
 
In the previous experiments it was shown that IL-2 receptor signaling alone was sufficient to 
upregulate HPGD expression in Treg cells. In the following part it was therefore tested 
whether TCR activation alone would be also able to induce HPGD expression in Treg cells.    
To answer the question whether TCR signaling can induce HPGD mRNA expression, human 
Treg and Tconv cells were isolated from peripheral blood and anti-CD3-antibody was 
administered over a period of 72 h. Cells were incubated either with soluble anti-CD3-
antibody or CD3-conjugated beads, which represents a more physiological way of inducing 
TCR signaling, as they mimic the contact of T cells with antigen-presenting cells, to 
determine possible differences between the two stimulation methods. After 12 h, 24 h, 48 h 
and 72 h cells were harvested and HPGD mRNA expression was assessed by qRT-PCR. As 
shown in Figure 42, HPGD expression was not upregulated in Treg cells by any stimulation 
over a period of 72 h. As expected Tconv cells showed no enhanced HPGD expression upon 
TCR stimulation with soluble or bead coupled anti-CD3-antibody. This result suggests that 
HPGD expression is not influenced by TCR signaling and further supports that HPGD 
expression in Treg cells is only dependent on IL-2 signaling. 
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Figure 42: HPGD is not upregulated in Treg or Tconv cells upon TCR stimulation.  
(A) & (C) Human Treg and (B) & (D) Tconv cells were purified from peripheral blood and were left untreated 
(Unstimulated) or stimulated with 1 µg/ml soluble anti-CD3 antibody (α-CD3 soluble) or with bead coupled 
anti-CD3 antibody (α-CD3-Bead; 2 beads: 1 cell) for 12 h, 24 h, 48 h and 72 h. HPGD mRNA expression, 
compared to B2M expression, was assessed by qRT-PCR. Samples are normalized to Treg cells (0 h). Data 
represent mean values and standard deviations of at least three independent experiments.  
 
In addition to TCR activation the influence of costimulation on HPGD expression in Treg and 
Tconv cells was examined. Previous studies had demonstrated that T cell proliferation is 
differentially regulated in Treg and Tconv cells and this could apply likewise to HPGD 
expression. Thornton et al. 2004 for example had shown that activation of Treg cells was 
independent of CD80/CD86 costimulation and the additional stimulation with exogenous IL-2 
could replace costimulation233. However, this observation was different for activation of Tconv 
cells, where IL-2 was not sufficient as a substitute for costimulation, demonstrating that the 
induction of T cell proliferation, even in the presence of IL-2, is different for Treg and Tconv 
cells 233. To examine a potential influence of costimulation on HPGD expression, Treg and 
Tconv cells were purified from human peripheral blood and stimulated with anti-
CD3/CD28/MHC-I-coated beads for 72 h. Cells were harvested after 12 h, 24 h, 48 h and 72 h 
and HPGD mRNA expression was assessed by qRT-PCR. Stimulation with 
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CD3/CD28/MHC-I – coated beads did not enhance HPGD mRNA expression neither in Treg 
nor in Tconv cells, as shown in Figure 43 A and B. 
These data suggest that HPGD expression is independent of TCR signaling and costimulation 
in Treg as well as Tconv cells and further support that HPGD expression in Treg cells is only 
dependent on IL-2R signaling. 
 
 
Figure 43: Costimulation via CD28 does not enhance HPGD expression in TCR-stimulated Treg or Tconv 
cells. 
(A) Human Treg and (B) Tconv cells were purified from human peripheral blood and left untreated (Unstimulated) 
or stimulated with CD3/CD28/MHC-I-coated beads (CD3/CD28-Bead; 3 beads: 1 cell) for 12 h, 24 h, 48 h and 
72 h. HPGD mRNA expression, compared to B2M expression, was assessed by qRT-PCR. Samples are 
normalized to Treg cells (0 h). Mean values and standard deviations of at least three independent experiments are 
shown.  
 
Next, HPGD mRNA expression levels of Treg cells were compared after stimulation for 24 h 
with the previously mentioned stimuli, to further demonstrate that HPGD mRNA expression 
in Treg cells is dependent on IL-2 signaling but not TCR signaling with or without 
costimulation (Figure 44 A). In contrast, HPGD mRNA expression in Tconv cells is 
independent of any of these stimulations, as IL-2 treatment and also TCR ligation with 
costimulation cannot induce HPGD expression in Tconv cells (Figure 44 B).  
Taken together these results clearly illustrate that HPGD mRNA expression is differentially 
regulated in Treg and Tconv cells and that IL-2 signaling plays an important role for HPGD 
expression in Treg cells.  
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Figure 44: Influence of TCR ligation, costimulation and IL-2 on HPGD expression in Treg and Tconv after 
24 h stimulation  
(A) Human Treg and (B) Tconv cells were purified from peripheral blood and left untreated (Unst.) or stimulated 
for 24 h with 20 U/ml IL-2 (IL-2) alone or in combination with 1 µg/ml anti-CD3 antibody (IL2/CD3), with 
1 µg/ml soluble anti-CD3 antibody (CD3 sol.), with bead bound anti-CD3 antibody (CD3-Bead; 3 beads:1 cell) 
or with CD3/CD28/MHC-I-coated beads (CD3CD28, 3 beads: 1cell). HPGD mRNA expression, compared to 
B2M expression, was assessed by qRT-PCR. Samples are normalized to Treg cells (0 h). Data represent mean 
values and standard deviations of four independent experiments. Statistically significant differences are marked 
with an asterisk (* p < 0.05). 
 
3.5.3 HPGD protein expression after stimulation with IL-2 
 
HPGD mRNA expression was shown to be significantly upregulated upon stimulation with 
IL-2 in human Treg cells. To determine if the upregulation of HPGD on mRNA level also 
resulted in an increase of HPGD protein expression, Treg and Tconv cells were purified from 
human peripheral blood and stimulated with IL-2 or left untreated. After 48 h and 72 h cells 
were harvested and HPGD protein levels were investigated by Western blotting. Assessment 
of HPGD protein expression in Treg and Tconv cells after 48 h and 72 h showed an enhanced 
HPGD expression upon IL-2 stimulation in Treg whereas this effect could not be observed for 
Tconv cells, depicted in Figure 45. 
These results show that HPGD expression in Treg cells is highly dependent of IL-2R signaling, 
as both HPGD mRNA and protein expression are significantly enhanced after stimulation 
with IL-2. 
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Figure 45: HPGD protein expression is specifically upregulated in Treg cells upon IL-2 stimulation. 
Human Treg and Tconv cells were purified from peripheral blood and left untreated (-) or stimulated with 20 U/ml 
IL-2 (+). Cells were harvested after 48 h and 72 h and protein expression of HPGD and β-actin as loading 
control was analyzed by Western blotting. (A) The relative HPGD protein amounts, compared to β-actin, were 
measured densitometrically. Data represent mean values and standard deviations of at least three independent 
experiments. Data were normalized to Treg 0 h. Statistically significant differences are marked with an asterisk (* 
p < 0.05). (B) One representative Western Blot is shown. 
 
3.5.4 HPGD expression in regulatory T cells is even induced by very low levels of IL-2 
 
The cytokine IL-2 is vitally important for Treg cells because on the one hand they are unable to 
produce IL-2 themselves 27 and on the other hand they are highly dependable of IL-2, in terms 
of their development and function 234,235. Moreover, it was recently shown that also low IL-2 
concentrations were sufficient to maintain gene expression of IL-2-dependent target genes in 
Treg cells 236. In view of these observations it is of high interest to determine the effects of 
different IL-2 concentrations on the HPGD expression. To elucidate whether increasing IL-2 
concentrations would further enhance HPGD expression and define in addition a minimum 
IL-2 concentration that would still be able to upregulate HPGD expression, Treg cells were 
stimulated with different IL-2 concentrations, varying from 1.000 – 0.5 U IL-2/ ml and 
relative HPGD mRNA expression was analyzed by qRT-PCR after 12 h, 24 h, 48 h and 72 h. 
Even very low IL-2 concentrations were able to enhance HPGD expression in Treg cells 
(Figure 46). Notably, maximum HPGD expression was induced using as low as 5-10 U IL-2 
per ml while no further increase in HPGD expression was observed when higher IL-2 
concentrations were used. 
This result suggests that HPGD expression in Treg cells is coupled to a low IL-2R signaling 
threshold and only low amounts of IL-2 are required to saturate the signaling pathways that 
lead to HPGD upregulation. 
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Figure 46: Influence of different IL-2 concentrations on the relative HPGD mRNA expression in Treg cells 
Human Treg cells were purified from peripheral blood and left untreated (Unstimulated) or stimulated with 
different IL-2 concentrations (IL-2). Cells were incubated with concentrations of 1.000, 200, 100, 40, 20, 10, 5, 
1 and 0.5 U/ml IL-2. HPGD mRNA expression was assessed by qRT-PCR, compared to B2M expression. 
Samples are normalized to Treg cells (0 h). Data represent mean values and standard deviations of five 
independent experiments in row 1-2 and two independent experiments in row 3. Statistically significant 
differences are marked with an asterisk (* p < 0.05). 
 
In addition the HPGD expression at 24 h for all tested IL-2 concentrations is depicted in 
Figure 47. No further increase in HPGD expression using IL-2 concentrations higher than 
5 U/ml could be observed. These data further illustrate that even low IL-2 amounts can 
enhance HPGD expression in Treg cells and a minimum of 5 U/ml IL-2 is required to induce 
the maximum of HPGD expression in Treg cells. 
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Figure 47: HPGD expression at 24 h in Treg cells stimulated with increasing IL-2 concentrations 
Cells were treated and assessed as described for Figure 48 Data represent mean values and standard deviations 
of five independent experiments for 10 – 1.000 U/ml, and two independent experiments for 0.5-5 U/ml. n.d.: no 
statistically significant differences (one-way ANOVA; p > 0.05) between the sample groups were observed. 
 
3.5.5 IL-2 stimulation does not upregulate HPGD expression in differentiated T cells  
 
Previous results had demonstrated that HPGD expression was not upregulated during T cell 
differentiation. As HPGD expression in Treg cells was shown to be induced by IL-2R 
signaling, the question was whether IL-2 stimulation would also have an influence on HPGD 
in TH cell subsets. To answer the question whether IL-2R signaling would similarly induce 
HPGD expression in differentiated T cells, various TH cell subsets were stimulated with IL-2 
to investigate the effect on HPGD expression. 
For this purpose Tnaive cells were differentiated towards TH1, TH2, TH9 and TH17, as 
previously described (see section 3.3.2) and then stimulated with IL-2. Relative HPGD 
mRNA expression was determined by qRT-PCR in the TH cell subsets after 48 h with or 
without IL-2 stimulation. Relative HPGD expression levels are presented in comparison to 
Tconv and Treg cells with or without IL-2 stimulation. HPGD expression was not significantly 
altered upon IL-2 stimulation in the differentiated T cell subsets and HPGD expression levels 
were comparable to Tconv cells, as shown in Figure 48. In contrast, Treg cells displayed a 
significantly higher HPGD expression upon IL-2 treatment. 
Taken together these data show that regulation of HPGD expression is distinct in Treg cells 
compared to TH cell lineages and that IL-2R signaling does not enhance HPGD expression in 
differentiated T cells. Furthermore, the results support the hypothesis that elevated HPGD 
expression levels are specific for Treg cells. 
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Figure 48: IL-2 stimulation does not enhance HPGD expression in different T helper cell subsets. 
Human CD4+CD25-CD45RA+ Tnaive cells were purified and differentiated with CD3/CD28/MHC-I-coated 
beads together with the appropriate cytokines towards TH1, TH2, TH9 and TH17 cells. Tunstim represent 
unstimulated Tnaive and served as control together with TH0 cells which were only stimulated with 
CD3/CD28/MHC-I-coated beads without additional cytokines. TH cells were left untreated (-) or stimulated 
with 20 U/ml IL-2 (+) for 48 h. Relative HPGD mRNA expression, compared to B2M expression, was assessed 
by qRT-PCR and data are plotted compared to Treg, (48 h) and Tconv (48 h). Mean values and standard deviations 
of three independent experiments after normalization to unstimulated Tconv cells (48 h) are shown. n.d.: no 
statistically significant differences (one-way ANOVA; p > 0.05) between the sample groups were observed. 
 
3.5.6 HPGD expression is not enhanced in iTreg cells upon IL-2R signaling 
 
Similarly to TH cell subsets also iTreg cells did not displayed an enhanced HPGD expression, 
comparable to Treg cells. On the one hand iTreg cells were shown to lack a part of the gene 
signature, which is specific for nTreg cells 228. On the other hand they display Treg specific 
characteristics such as high a FOXP3 expression, anergy and suppressive function in vitro and 
in vivo 30,227. Although iTreg cells did not show enhanced HPGD expression they might still 
upregulate HPGD upon activation with IL-2. To answer the question whether HPGD 
expression can be induced in iTreg upon IL-2R signaling, Tnaive were differentiated towards 
iTreg cells, as previously described (see section 3.3.3) and stimulated with IL-2 for 48 h. 
Relative HPGD mRNA expression was determined by qRT-PCR after 48 h with or without 
IL-2 stimulation. Relative HPGD expression levels are presented in comparison to Tconv and 
Treg cells with or without IL-2 stimulation. Notably, stimulation with IL-2 did not result in the 
induction of HPGD mRNA expression in iTreg cells, as it was observed for Treg cells, shown in 
Figure 49. In fact HPGD expression levels of iTreg cells, with or without IL-2 stimulation, 
were comparable with those of Tunstim, TH0 and Tconv cells. 
Apparently, polarization towards an induced regulatory phenotype was not sufficient to 
activate the essential gene expression programs, which lead to enhanced HPGD expression in 
Treg cells and thus IL-2R signaling could also not induce HPGD expression. Obviously, 
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HPGD expression and regulation in Treg cells are distinct from iTreg cells and HPGD seems to 
belong to the natural Treg-specific gene signature. Taken together these data indicate that a 
high HPGD expression is specific for natural Treg cells. 
 
 
Figure 49: IL-2 stimulation does not 
enhance HPGD expression in iTreg 
cells. 
Cells were treated and assessed as 
described for Figure 48. Tunstim 
represent unstimulated Tnaive and 
served as control together with TH0 
cells, which were only stimulated with 
CD3/CD28/MHC-I-coated beads 
without additional cytokines. HPGD 
mRNA expression was assessed, 
compared to B2M, by qRT-PCR. Data 
are shown compared to Treg (48 h) and 
Tconv (48 h) cells. Mean values and 
standard deviations of three 
independent experiments are shown 
after normalization to unstimulated 
Tconv cells (48 h). n.d.: no statistically 
significant differences (one-way 
ANOVA; p > 0.05) between the 
sample groups were observed. 
 
 
3.6 HPGD is enzymatically active in human regulatory T cells 
 
The HPGD is one of the major enzymes that metabolize prostaglandin E2 141,237. The critical 
step is thereby the β-oxidation of the 15-hydroxyl group of PGE2 into a 15-keto group. The 
conversion into the 15-keto-metabolite thereby represents the first step in the biological 
inactivation of PGE2 141,163. Enzymatically active HPGD degrades PGE2, which leads to 
accumulation of PGE2-metabolites. However, expression of the HPGD protein does not 
necessarily result in functional enzymatic activity. To prove that HPGD is functional in Treg 
cells, the enzymatic activity of HPGD was tested in human Treg and also Tconv cells. 
Therefore, these cells were isolated from human peripheral blood and stimulated with IL-2 for 
48 h in order to upregulate HPGD expression in Treg cells prior to further processing. 
Successful HPGD upregulation was confirmed by qRT-PCR (Figure 50). Enzymatic activity 
of HPGD was determined in cellular lysates by an radioactive assay, which measures the 
transfer of tritium from 15(S)-[15-3H]PGE2 to glutamate by coupling HPGD with glutamate 
dehydrogenase 178,205. Treg cells show a high enzymatic activity of HPGD in comparison to 
Tconv cells (Figure 50). The levels of enzymatic activity thereby reflect the differences 
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between Treg and Tconv cells in HPGD mRNA expression, as Tconv cells with a low HPGD 
mRNA expression also display a low enzymatic activity, whereas high HPGD mRNA 
expression and high enzymatic activity are observed in Treg cells. These data show that human 
Treg cell express an active and functional enzyme with specific activity. 
 
 
Figure 50: HPGD is enzymatically active in human Treg cells. 
Human Treg and Tconv cells were purified and stimulated with 20 U/ml IL-2 for 48 h prior to assessment of 
enzymatic activity. (A) Enzymatic activity of HPGD was measured by an radioactive assay that measures the 
transfer of 15(S)-[15-3H]PGE2 to glutamate by coupling HPGD with glutamate dehydrogenase. The specific 
activity of HPGD is depicted as pmol/min/mg protein. (B) Relative HPGD expression was assessed by qRT-
PCR in Treg and Tconv cells and data are normalized to the house keeping control β2M. One representative 
experiment of two is shown. 
 
3.7 Increased HPGD expression in Treg by IL-2 is dependent on JAK3/STAT5 and 
PI3K/NF-κB signaling 
 
In the previous experiments it was demonstrated that HPGD expression was significantly 
enhanced in Treg cells upon stimulation with IL-2. Binding of IL-2 to its receptor leads to 
activation of different signaling cascades, such as the MAPK and PI3K pathways or 
JAK/STAT signaling (see also 1.2 Interleukin-2 receptor signaling pathways)238-242. The 
contribution of the above mentioned signaling cascades to upregulation of HPGD in Treg cells 
was examined by targeting key molecules of the respective pathways with specific inhibitors 
to elucidate which signaling cascades are in particular involved in IL-2-mediated upregulation 
of HPGD. 
 
3.7.1 MAPK signaling is not involved in IL-2 mediated HPGD upregulation 
 
To test if signaling events via mitogen-activated protein kinases (MAPK) were involved in 
IL-2 mediated HPGD upregulation, human Treg cells, were treated with increasing doses of a 
MEK1 inhibitor (PD98059) with or without additional IL-2 stimulation. Treg cells were pre-
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incubated with the inhibitors for 1 h before additional costimulation with IL-2 was initiated. 
Thus an activation of the IL-2 signaling pathway was avoided before the inhibitor could attain 
its complete inhibitory effect. HPGD mRNA expression was assessed by qRT-PCR after 24 h. 
In addition, to exclude effects by the inhibitor on cell death and apoptosis rate, cell viability of 
human CD4+ T lymphocytes was assessed by measuring incorporation of propidium iodide 
(PI), after incubation with the inhibitor for of 24 h. Thereby, no toxic effects were observed at 
the indicated concentrations (see Figure 73, Appendix E). No reduction in the IL-2-mediated 
upregulation of HPGD was observed upon treatment with the MEK1 inhibitor (Figure 51). 
Although incubation with the MEK1 inhibitor together with IL-2 slightly enhanced HPGD 
expression in comparison to DMSO-treated control cells, this increase was not statistically 
significant. These results therefore suggest that induction of HPGD expression in Treg cells by 
IL-2 is independent of MAPK signaling. 
 
 
Figure 51: Unchanged upregulation of HPGD in Treg cells 
after MEK1 inhibition. 
Human CD4+CD25+ T cells were purified from peripheral 
blood and pre-treated with 50 or 100 µM MEK1 inhibitor 
(PD98059) or with the respective amount of DMSO (Control) 
for 1 h. Then 20 U/ml IL-2 (IL-2 stimulated) or medium 
(Unstimulated) was added. Relative HPGD mRNA expression, 
compared to B2M expression, was assessed by qRT-PCR 24 h 
after inhibitor treatment. Mean values and standard deviations 
of three individual experiments are presented, after 
normalization to unstimulated control cells. 
 
3.7.2 Inhibition of PI3K and NF-κB decreases IL-2 mediated HPGD upregulation 
 
In the experiments described above it was shown that MAPK signaling was not involved in 
IL-2-mediated HPGD upregulation. However, upon IL-2R activation besides activation of 
MAPK also signaling molecules such as the Janus kinase-1 and -3 are activated, which lead to 
subsequent activation and recruitment of the phosphatidylinositol 3-kinase (PI3K) 126,243. 
Therefore, a potential role of the PI3K pathway was investigated. Human Treg cells were 
treated with increasing doses of a PI3K inhibitor (LY294002) with or without additional IL-2 
stimulation. To avoid effects of IL-2 signaling before the inhibitor could mediate its inhibitory 
effect, Treg cells were pre-incubated with the inhibitor for 1 h before additional costimulation 
with IL-2 was initiated. HPGD mRNA expression was assessed by qRT-PCR after 24 h of 
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inhibitor treatment. Moreover, human CD4+ T lymphocytes were stained with PI, after 
incubation with the inhibitor for 24 h, to test and exclude effects of the inhibitor concerning 
cell death and apoptosis rate. No toxic effects were observed at the indicated concentrations 
(see Figure 73, Appendix E). In Figure 52, it is shown that inhibition of PI3K blocks IL-2 
mediated HPGD upregulation, as a concentration of 20 µM PI3K inhibitor significantly 
reduced IL-2-mediated HPGD upregulation. These results indicate a potential role for the 
PI3K signaling pathway in IL-2-mediated upregulation of HPGD. 
 
 
Figure 52: Inhibition of PI3K decreases IL-2 
mediated upregulation of HPGD in Treg cells.  
Human CD4+CD25+ T cells were purified from 
peripheral blood and pre-treated with 10 or 20 µM 
PI3K inhibitor (LY249002) or with the respective 
amount of DMSO (Control) for 1 h. Then 20 U/ml IL-
2 (IL-2 stimulated) or medium (Unstimulated) were 
added. Relative HPGD mRNA expression, compared 
to B2M expression, was assessed by qRT-PCR 24 h 
after inhibitor treatment. Data are shown as mean 
values and standard deviations of four individual 
experiments. Statistical significant differences (p < 
0.01) are marked with an asterisk. 
 
The activation of PI3K upon IL-2R signaling leads to production of inositol phospholipids 
PtdIns (3,4,5)P3 and PtdIns(3,4)P2, which attract Akt (also known as Protein Kinase B, PKB) 
to the plasma membrane where it is phosphorylated130. Akt in turn phosphorylates and thus 
activates IκB kinase (IKK), which is comprised of the catalytic subunits IKK-α and IKK-β 
and the regulatory subunit IKK-γ (NEMO)131-133. IKK phosphorylates the inhibitor of κBα 
protein (IκBα), which leads to ubiquitination of IκBα, its dissociation from nuclear factor κB 
(NF-κB, subunits p50 and p65) and eventual degradation of IκBα by the proteasome. The 
release of NF-κB allows its translocation to the nucleus where it initializes transcription132-134. 
As IL-2-mediated upregulation of HPGD in Treg cells was shown to be dependent of PI3K 
signaling, the next question was whether NF-κB inhibition would impair the inducing effect 
of IL-2 on HPGD expression. To answer this question Treg cells were purified from human 
peripheral blood and treated with increasing doses of NF-κB inhibitor BAY11-7082 or with 
an alternative NF-κB activation inhibitor. As described above, Treg cells were pre-incubated 
with the inhibitors for 1 h before additional costimulation with IL-2 was initiated, to avoid 
activation of the IL-2 signaling pathway before the inhibitor could mediate its inhibitory 
   Results 
102 
effect. HPGD mRNA expression was assessed by qRT-PCR after 24 h. Incubation with 1 µM 
of NF-κB inhibitor BAY11-7082 did reduce IL-2-mediated upregulation of HPGD, although 
this effect was not statistically significant. However, incubation with 20 µM of the NF-κB 
activation inhibitor did significantly reduce the IL-2 induced upregulation of HPGD 
expression. To exclude toxic effects of the inhibitors with regard to cell death and apoptosis 
rate, human CD4+ T lymphocytes were incubated with the inhibitor for 24 h and the 
percentage of dead cells was analyzed by (PI) staining. The inhibitors did not show toxic 
effects at the indicated concentrations (see Figure 73, Appendix E). Taken together, these 
results point to a potential role of the PI3K pathway in IL-2 mediated HPGD upregulation, as 
both blockade of PI3K and NF-κB signaling resulted in a significantly impaired upregulation 
of HPGD expression after IL-2 administration. 
 
 
Figure 53: Inhibition of NF-κB blocks IL-2 mediated upregulation of HPGD in Treg cells. 
Human CD4+CD25+ T cells were purified from peripheral blood and pre-treated with different concentrations of 
one NF-κB inhibitor or with the respective amount of DMSO (Control) for 1 h. Then 20 U/ml IL-2 (IL-2 
stimulated) or medium (Unstimulated) was added. Relative HPGD mRNA expression, compared to B2M, was 
assessed by qRT-PCR 24 h after inhibitor treatment. (A) Relative HPGD mRNA expression after treatment with 
NF-κB inhibitor BAY11-7082. (B) Relative HPGD mRNA expression after treatment with NF-κB activation 
inhibitor. Data represent mean values and standard deviations of four individual experiments. Statistical 
significant differences (p < 0.05) are marked with an asterisk.  
 
3.7.3 JAK3 and STAT5 signaling are involved in IL-2 mediated HPGD upregulation 
 
Besides activation of the PI3K or MAPK pathways, activation of the IL-2 receptor also 
initiates subsequent activation of JAK3 which in turn activates STAT5. This leads to 
dimerisation and nuclear translocation of STAT5 where it influences the expression of various 
genes 129. To address how JAK3 and STAT5 signaling contributes to the upregulation of 
HPGD after IL-2 stimulation, Treg cells were treated with specific inhibitors of JAK3 or 
STAT5 before stimulation with IL-2 was conducted. To exclude toxic effects of the inhibitor, 
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regarding cell death and apoptosis, human CD4+ T lymphocytes were stained with PI, after 
incubation with the inhibitor for 24 h. Both inhibitors revealed no toxic effects at the indicated 
concentrations (see Figure 73, Appendix E). To avoid effects of IL-2 signaling before the 
inhibitor could mediate its inhibitory effect, Treg cells were pre-incubated with the inhibitor 
for 1 h before additional costimulation with IL-2 was initiated. HPGD mRNA expression was 
assessed by qRT-PCR after 24 h of inhibitor treatment. 
In Figure 54, it is shown that the stimulating effects of IL-2 on HPGD expression were 
significantly reduced by inhibition of JAK3 using the selective JAK3 inhibitor Janex-1. 
HPGD was not upregulated upon IL-2 stimulation when cells were incubated with 100 or 
150 µM JAK3 inhibitor.  
 
 
Figure 54: Inhibition of JAK3 decreases IL-2 mediated 
upregulation of HPGD in Treg cells. 
Human CD4+CD25+ T cells were purified from peripheral 
blood and pre-treated with 100 or 150 µM JAK3 inhibitor 
Janex-1 or with the respective amount of DMSO (Control) for 
1 h. Then IL-2 (20 U/ml) (IL-2 stimulated) or medium 
(Unstimulated) was added. Relative HPGD mRNA expression, 
compared to B2M expression, was assessed by qRT-PCR 24 h 
after inhibitor treatment. Data are shown as mean values and 
standard deviations of four individual experiments. Statistical 
significant differences (p < 0.01) are marked with an asterisk.  
 
As JAK3 signaling was shown to be involved in IL-2-mediated HPGD upregulation, we next 
asked whether inhibition of STAT5 might impair IL-2-induced upregulation of HPGD 
expression in Treg cells. To answer this question Treg cells were treated with increasing doses 
of a STAT5-specific inhibitor. Treg cells were pre-incubated with the inhibitors for 1 h before 
additional costimulation with IL-2 was initiated, to avoid activation of the IL-2 signaling 
pathway until the inhibitor could mediate its inhibitory effect. HPGD mRNA expression was 
assessed by qRT-PCR after 24 h. 
Similar effects as for experiments with JAK3 inhibitor were obtained when Treg cells were 
treated with the STAT5 inhibitor. The STAT5 inhibitor blocked IL-2-mediated HPGD 
upregulation, as cells treated with 300 µM STAT5 inhibitor significantly reduced IL-2-
mediated induction of HPGD (Figure 55), while lower concentrations of the inhibitor even 
resulted in a minor increase of HPGD expression.  
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These results confirm that JAK3/STAT5 signaling plays a role in IL-2 induced upregulation 
of HPGD expression in Treg cells. Taken together the experiments addressing the three 
different signaling pathways for IL-2 signaling could show that the induction of HPGD in Treg 
cells is dependent upon PI3K/NF-κB and JAK3/STAT5 signaling but MAPK signaling is not 
involved. 
 
 
Figure 55: STAT5 inhibition decreases IL-2 
mediated upregulation of HPGD in Treg cells. 
Human CD4+CD25+ T cells were purified from 
peripheral blood and pre-treated with 100, 200 or 
300 µM JAK3 inhibitor or with the respective amount 
of DMSO (Control) for 1 h. Then 20 U/ml IL-2 (IL-2 
stimulated) or medium (Unstimulated) was added. 
Relative HPGD mRNA expression was assessed by 
qRT-PCR 24 h after inhibitor treatment. Mean and 
standard deviations of four individual experiments are 
presented. Statistical significant differences (p < 0.05) 
are marked with an asterisk. 
 
3.8 IL-10 and PGE2 can augment the IL-2 dependent upregulation of HPGD 
 
It could be demonstrated that IL-2 stimulation enhances HPGD expression. Besides that, also 
IL-10 stimulation did modulate HPGD expression, as HPGD expression was significantly 
higher after 24 h in IL-10 stimulated Treg cells compared to unstimulated cells. In contrast, 
stimulation with PGE2 or TGF-β did not influence HPGD expression in Treg cells, suggesting 
that HPGD expression in Treg cells is independent of PGE2 and TGF-β signaling. In the 
following it was investigated whether the upregulation of HPGD expression in Treg cells after 
IL-2 treatment would be influenced by costimulation with IL-10, PGE2 or TGF-β over time. 
Human Treg cells were therefore stimulated with IL-2 and incubated with the respective 
molecules. After 24 h, 48 h and 72 h HPGD mRNA expression was measured by qRT-PCR. 
Additional stimulation with PGE2 or IL-10 further enhanced HPGD expression in comparison 
to Treg cells treated with IL-2 alone, as shown in Figure 56. In contrast, co-stimulation with 
TGF-β decreased HPGD expression.  
These rather unexpected results suggest that IL-10 and PGE2 in combination with IL-2 
costimulation have positive synergistic effects on HPGD mRNA expression in Treg cells, as no 
or only slight effects were observed when cells are stimulated with IL-10 or PGE2 alone. On 
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the contrary, TGF-β revealed a negative effect on IL-2 mediated upregulation of HPGD 
mRNA expression in Treg cells, despite that no effect was observed when cells were 
stimulated with TGF-β alone. These data indicate that TGF-β partially blocks IL-2R signaling 
and thus attenuates the inducing effects of IL-2 on HPGD expression in Treg cells. 
Furthermore, these results indicate that TGF-β signaling might interfere with HPGD 
upregulation during the induction of an iTreg cell phenotype and represent a reason for a low 
HPGD expression in iTreg cells compared to nTreg cells. 
 
 
Figure 56: Stimulation with PGE2 or IL-10 further enhances IL-2 mediated HPGD upregulation  
Human CD4+CD25+ T cells were purified from peripheral blood and incubated with 20 U/ml IL-2 alone or in 
combination with (A) 30 ng/ml TGF-β, (B) 1 µM PGE2 or (C) 50 ng/ml IL-10 for 24 h, 48 h and 72 h. Relative 
HPGD mRNA expression, compared to B2M expression, was assessed by qRT-PCR. Mean values and standard 
deviations of one representative experiment of three are presented, after normalization to Treg cells 0h. Statistical 
significant differences (p < 0.05) between IL-2 stimulated cells and cells treated with IL-2 in combination with 
TGF-β, PGE2 or IL-10 are marked with an asterisk. 
 
3.9 Murine regulatory T cells show no upregulation of HPGD 
3.9.1 HPGD is expressed at similar levels in mouse Tconv and Treg cells from C57BL/6 or BALB/c 
mice  
3.9.1.1 Low HPGD expression in Treg cells from C57BL/6 mice compared to Tconv cells 
 
After characterizing expression of HPGD in human Treg cells, we wanted to determine its 
expression in murine Treg cells, to see if the observations made in the human could be 
transferred to the murine system. Therefore, murine Treg and Tconv cells were isolated from 
spleens of C57BL/6 mice and relative HPGD mRNA expression was assessed by qRT-PCR 
analysis. Remarkably, murine Treg showed a lower HPGD expression compared to Tconv cells 
(Figure 57). This stands in sharp contrast to previous observations made in the human system, 
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as human Treg cells showed a significantly higher HPGD mRNA and protein expression than 
Tconv cells. This result therefore suggests that HPGD expression in human Treg cells differs 
from that in murine cells. 
 
 
Figure 57: HPGD expression in murine Treg from C57BL/6 
mice is lower compared to Tconv cells. 
Murine Treg (white column) and Tconv (grey column) cells were 
isolated from spleens of C57BL/6 mice. Relative HPGD mRNA 
expression, compared to B2M expression, was assessed by qRT-
PCR. Samples were normalized to Tconv cells (0 h). Data 
represent mean values and standard deviations of four 
independent experiments. n.s. – not significant. 
 
3.9.1.2 Comparable HPGD expression levels in Treg and Tconv cells from BALB/c mice 
 
Next, expression levels of HPGD were investigated in murine T cells from BALB/c mice to 
exclude that low HPGD expression in Treg cells was due to the genetic background of 
C57BL/6 mice. Therefore, Treg and Tconv cells were isolated from spleens of BALB/c mice 
and relative HPGD mRNA expression was assessed by qRT-PCR analysis. HPGD mRNA 
expression was slightly higher in Treg cells compared to Tconv cells, as shown in Figure 58. 
Although this result differs from the observations made in T cells from C57BL/6 mice, the 
differences in HPGD expression between Treg and Tconv cells from BALB/c mice were not 
statistically significant, but expression levels were rather comparable. These results further 
support a differential expression of HPGD in murine Treg cells compared to human Treg cells.  
 
 
Figure 58: Comparable HPGD expression levels in 
murine Treg and Tconv cells from BALB/c mice 
Murine Treg (white column) and Tconv (grey column) 
cells were obtained from spleen of BALB/c mice and 
relative HPGD mRNA expression, compared to B2M 
expression, was assessed by qRT-PCR. Samples were 
normalized to Tconv cells (0 h). Data represent mean 
values and standard deviations of three independent 
experiments. n.s. – not significant. 
 
 
   Results 
107 
3.9.2 Interleukin-2 does not increase HPGD expression in murine Treg cells 
3.9.2.1 HPGD expression is not induced upon IL-2R signaling in Treg cells from C57BL/6 mice 
 
In the previous experiments, it could be demonstrated that IL-2 receptor signaling alone was 
sufficient to upregulate HPGD expression in human Treg cells. Therefore, it was tested 
whether the same could be observed in murine Treg cells. For this purpose Treg and Tconv cells 
were purified from spleens of C57BL/6 mice and cells were either left untreated or were 
stimulated with IL-2. After 24 h cells were harvested and HPGD mRNA expression was 
assessed by qRT-PCR. In Figure 59, it is depicted that IL-2R signaling did not induce HPGD 
expression in murine Treg cells. IL-2 stimulated Treg cells showed only a slight but not 
significant increase in HPGD expression, compared to freshly isolated and untreated Treg 
cells. As expected, IL-2 stimulation did also not upregulate HPGD expression in Tconv cells. 
These results show that IL-2R signaling is insufficient to enhance HPGD expression in 
murine T cells and further support that expression and regulation of HPGD in murine Treg 
cells differ from the human system. 
 
 
Figure 59: IL-2R signaling does not enhance HPGD expression in murine Treg from C57BL/6 mice. 
Murine Treg (white columns) and Tconv (grey columns) cells were isolated from spleens of C57BL/6 mice. Cells 
were either left untreated or stimulated with 20 U/ml IL-2 for 24 h. Relative HPGD mRNA expression, 
compared to B2M expression, was assessed by qRT-PCR. Samples were normalized to Tconv cells (0 h). Data 
represent mean values and standard deviations of four independent experiments. 
 
3.9.2.2 IL-2R signaling does not enhance HPGD expression in Treg cells from BALB/c mice  
 
In contrast to the observations made for human Treg cells, IL-2 stimulation is insufficient to 
induce HPGD expression in murine Treg cells. Next, HPGD expression levels of murine T 
cells from BALB/c mice were investigated after IL-2 treatment to exclude that low HPGD 
expression and unresponsiveness to IL-2 stimulation were due to the genetic background of 
C57BL/6 mice. Therefore, Treg and Tconv cells were isolated from spleens of BALB/c mice 
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and cells were either left untreated or were stimulated with IL-2 for 24 h. HPGD expression 
was not upregulated upon IL-2 treatment neither in Treg nor Tconv cells (Figure 60). These 
results show that the regulation of HPGD expression in murine Treg cells is independent of IL-
2 and that the IL-2-mediated upregulation of HPGD, observed in human Treg cells, cannot be 
confirmed in the murine system.  
 
 
Figure 60: HPGD expression is not enhanced in murine Treg from BALB/c mice upon IL-2 stimulation. 
Murine Treg (white columns) and Tconv (grey columns) cells were isolated from spleen of BALB/c mice. Cells 
were either left untreated or stimulated with 20 U/ml IL-2 for 24 h. Relative HPGD mRNA expression, 
compared to B2M expression, was assessed by qRT-PCR. Samples were normalized to Tconv cells (0 h). Data 
represent mean values and standard deviations of three independent experiments. 
 
3.10 Transcriptional regulation of HPGD expression 
 
Regulatory CD4+CD25+ T cells express the transcription factor FOXP3 (forkhead box P3), a 
member of the forkhead/winged helix family of transcription factors. FOXP3 not only is a 
specific marker for Treg cells, but FOXP3 plays an important role as master regulator in the 
expression of various important Treg-cell associated genes and is crucial for the development 
and functional phenotype of Treg cells 59-62. Moreover, FOXP3 is sufficient to induce a Treg 
phenotype in conventional CD4+CD25- T cells 59-61. FOXP3 modulates the expression of 
various target genes in Treg cells, as it can repress as well as induce gene expression 244-246.   
For this purpose FOXP3 can bind to the promoter and enhancer regions of the respective 
genes 247, either alone but it can also form a DNA-binding complex together with other 
transcription factors, for example NFAT (Nuclear Factor of Activated T cells) 248, 
AML/Runx1 (Runt-related transcription factor 1) 249 or NF-κB (Nuclear Factor κB) 250. In a 
complex with NFAT, FOXP3 negatively regulates transcription of IL-2, but positively 
regulates other genes, such as CD25 and CTLA4 251. Furthermore, FOXP3 can influence gene 
expression through epigenetic mechanisms, such as chromatin remodeling and histone 
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deacetylation247,252. In the following section the influence of FOXP3 on the expression of 
HPGD in human Treg cells was investigated and whether FOXP3 can bind to the HPGD locus 
to modulate gene expression. 
 
3.10.1 Silencing of FOXP3 in human Treg cells enhances HPGD expression 
 
As HPGD expression was shown to be specifically enhanced in human Treg cells compared to 
Tconv, it was of interest to determine whether HPGD is a target gene of FOXP3. To answer the 
question whether HPGD expression is under the control of FOXP3, it was investigated 
whether HPGD expression in human Treg cells would be changed after silencing of FOXP3 
expression. Therefore, human Treg cells were isolated from peripheral blood and siRNA-
mediated knockdown of FOXP3 in Treg cells was performed. Relative HPGD mRNA 
expression was assessed by qRT-PCR 48 h after the FOXP3 knockdown. The efficiency of 
the FOXP3 knockdown was assessed by analysis of FOXP3 mRNA expression in qRT-PCR 
analysis and protein expression in flow cytometry and a reduction of FOXP3 expression could 
be observed 24 h after knockdown (see Appendix F). In Figure 61, it is shown that HPGD 
expression is significantly enhanced in Treg cells after silencing of FOXP3 in comparison to 
Treg cells treated with control siRNA. This result shows that FOXP3 partially blocks HPGD 
transcription, either by directly or indirectly regulating HPGD expression. 
 
 
Figure 61: HPGD expression is augmented after silencing 
of FOXP3 in Treg cells. 
Human CD4+CD25+ Treg cells were isolated from peripheral 
blood and electroporated with 10 µg control siRNA or FOXP3 
siRNA. After 24 h relative HPGD mRNA expression was 
assessed by qRT-PCR, compared to B2M expression. Data 
were normalized to control siRNA transfected Treg cells. Mean 
values and standard deviations of at least three independent 
experiments are shown. Statistical significant differences (p < 
0.05) are marked with an asterisk.  
 
3.10.2 FOXP3 can bind to the HPGD promoter 
 
FOXP3 can influence gene expression either by direct interaction with the DNA alone or in a 
complex with other transcriptional factors 244-247 or by indirect mechanisms, such as chromatin 
remodeling and histone deacetylation247,252. Previous experiments had shown that HPGD 
expression increases in Treg cells, after silencing of FOXP3, indicating regulation of HPGD by 
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FOXP3. Therefore, it was tested whether FOXP3 can bind to the HPGD locus and HPGD 
represents a direct target gene of FOXP3. 
To answer the question whether FOXP3 can bind to the HPGD locus, the sequence of the 
HPGD locus was screened for binding sites of FOXP3 using bioinformatic in silico 
approaches and several potential FOXP3 binding sites were predicted upstream of the 
transcription start site (TSS) as well as in the genomic locus of HPGD. Five of the predicted 
binding sites are depicted in an overview of the HPGD locus in Figure 62. In addition, the 
location of HPGD on chromosome 4, the exon structure of HPGD, a CpG island identified at 
the HPGD locus, as well as promoter- and enhancer-associated histone modifications are 
displayed. The promoter of HPGD was identified by the presence of the CpG island and the 
promoter specific histone modification H3K4Me3 (trimethylation of lysine 4 on histone 
H3)253, which was assessed in 9 different cell lines, for example the lymphoblastoid cell line 
Gm12878, human mammary epithelial cells (HMEC) or normal human epidermal 
keratinocytes. An enhancer area was identified by the enhancer-associated histone 
modification H3K3Me1 (Monomethylation of lysine 3 on histone H3)253, which was also 
assessed in different cell lines. The above mentioned data were obtained from the UCSC web 
site. FOXP3 binding to the HPGD locus was assessed by promoter arrays (Prof. Simon C. 
Barry, unpublished data) and notably four of the predicted FOXP3 binding sites could be 
verified by FOXP3 ChiP tiling arrays (Figure 62) in human expanded Treg cells, see therefore 
also Sadlon et al. 2010 244.  
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Figure 62: FOXP3 binding sites within the HPGD locus.  
The location of the human HPGD gene on chromosome 4 (Chr4 q34.1) is illustrated at the top of the figure. The 
HPGD gene with exon 1 to 7 was obtained from the University of California Santa Cruz (UCSC) genome 
assembly web site (http://genome.ucsc.edu), hg18. Visualized are the predicted FOXP3 binding sites S1 to S5 
(red bars), the CpG island (green bar), FOXP3 binding sites in the locus of HPGD were obtained from promoter 
tiling arrays (orange bar) and from FOXP3 ChiP tiling arrays (blue bars B1 to B4) in expanded Treg cells, which 
confirmed four of the predicted FOXP3 binding sites. Furthermore, histone modifications that are promoter-
associated (H3K4Me3) or enhancer-associated (H3K3Me1), assessed in different cell lines (for example 
Gm12878, HMEC or NHEK cells), are shown. These data were obtained from the UCSC web site. 
 
One of the FOXP3 binding sites was predicted -15kb 5’ of the transcription start site in the 
potential enhancer area. This respective FOXP3 binding site was selected to exemplify that 
FOXP3 can bind to the HPGD locus, using an electrophoretic mobility shift assay (EMSA). 
FOXP3 protein bound to the selected FOXP3 binding motif (HPGD) as depicted in Figure 63, 
illustrated by the shift in fluorescence intensity in lane 2. To test if the binding is specific a 
mutated HPGD (mut-HPGD) oligonucleotide was used and no binding of this oligonucleotide 
to FOXP3 could be detected (lane 6). Furthermore, the signal intensity was reduced in the 
presence of an oligonucleotide with a known FOXP3 binding motif (FKH), which was used as 
a competitor (lane 3). In the presence of the mut-HPGD oligonucleotide, however, signal 
intensity was not reduced (lane 4). As further control to proof specific FOXP3 binding, an 
histidin-specific antibody was included in the binding reaction of HPGD oligonucleotide and 
FOXP3 protein (Figure 76, lane 2 Appendix H). Binding of the histidin antibody to the His-
tag within the recombinant FOXP3 protein, resulted into a second, supershifted band, which 
indicated specific binding of FOXP3 to the HPGD oligonucleotide. Taken together the results 
show that the binding of FOXP3 to the HPGD oligonucleotide was specific. Moreover, this 
analysis shows that FOXP3 can bind to the HPGD locus and thus might influence the 
expression of HPGD. 
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Figure 63: Specific binding of FOXP3 to the HPGD gene. 
An EMSA was performed with recombinant FOXP3 protein (Protein) and the following oligonucleotides: 
(HPGD): a dimer of the HPGD gene with a FOXP3 binding motif, labeled with the infrared dye DY-681 
(shown in red, lanes 1-3 & 4). (mut.-HPGD): a dimer of the HPGD gene with the mutated FOXP3 binding 
motif, labeled with infrared dye DY-781 (shown in green, lanes 4 & 6). (FKH): a dimer of the forkhead FKH 
binding motif in the GM-CSF enhancer, labeled with the infrared dye DY-781 (shown in green, lanes 3 & 5). 
One representative experiment out of three is shown. 
 
3.11 HPGD plays no role for the expression of FOXP3 or the suppressive function 
of human Treg cells 
3.11.1 FOXP3 expression in Treg cells is not influenced by silencing of HPGD 
 
The role of HPGD for the Treg cell function was examined in the following section, as 
significantly higher HPGD expression was found in human Treg cells compared to Tconv, TH 
cell subsets and iTreg cells, which indicated a specific function in the Treg cell. Although 
FOXP3 was shown to partially block HPGD expression in Treg cells and FOXP3 binding to 
the HPGD locus was demonstrated, we examined the possibility that HPGD could regulate 
the expression of FOXP3. To answer this question, FOXP3 expression levels in human Treg 
cells were examined after silencing of HPGD. Therefore, human Treg cells were isolated from 
peripheral blood and siRNA-mediated knockdown of HPGD in Treg cells was performed. 
Relative FOXP3 mRNA expression was assessed by qRT-PCR and FOXP3 protein 
expression was examined by flow cytometric analysis of intracellular FOXP3 staining, 24 h 
after the knockdown of HPGD. The efficiency of the HPGD knockdown was assessed by 
analysis of HPGD mRNA expression and a significant reduction of HPGD expression could 
be observed 24 h after knockdown (Figure 64). 
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Figure 64: Efficiency of the HPGD knockdown in 
human Treg cells. 
Human CD4+CD25+ T cells were purified from 
peripheral blood and treated with control siRNA or 
HPGD siRNA. Knockdown efficiency was assessed 
by qRT-PCR in comparison to B2M expression 24 h 
after knockdown. Mean values and standard 
deviations of seven individual experiments are 
presented. Data were normalized to Treg cells treated 
with control siRNA. Statistical significant differences 
are marked with an asterisk (* p < 0.05). 
 
Silencing of HPGD did not significantly influence FOXP3 expression on mRNA and protein 
level, as Treg cells displayed comparable FOXP3 expression levels after the HPGD 
knockdown compared to Treg cells treated with control siRNA, shown in Figure 65. 
These results suggest that HPGD has no influence on FOXP3 expression in human Treg cells. 
 
 
Figure 65: Relative FOXP3 mRNA and protein expression after HPGD knockdown in human Treg cells. 
Human CD4+CD25+ T cells were purified from peripheral blood and treated with control siRNA or HPGD 
siRNA. (A) Relative FOXP3 mRNA expression, compared to B2M expression, was assessed by qRT-PCR 24 h 
after knockdown. (B) Relative FOXP3 protein expression was assessed by intracellular FOXP3 flow cytometric 
staining 24 h after HPGD knockdown. Data are shown as mean and standard deviations of seven individual 
experiments. 
 
3.11.2 Silencing of HPGD does not influence the suppressive function of Treg cells 
 
One characteristic of regulatory T cells is their suppressive function in vitro and in vivo 18,79,80. 
Thus, a possible role of HPGD for Treg cells might be that HPGD expression is critical for 
their suppressive function. To answer the question whether HPGD is crucial for the 
suppressive function of Treg cells, the suppressive activity was examined after silencing 
HPGD by siRNA-mediated knockdown in Treg cells. The suppressive activity of Treg cells was 
examined in a suppression assay, which represents a method to determine their functional 
status. In brief, human Treg cells were purified from peripheral blood, treated with HPGD 
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siRNA or control siRNA, respectively, and 24 h after the knockdown these Treg cells were 
further used for a suppression assay. Therefore, CFSE-labeled Tconv cells were stimulated with 
anti-CD3/CD28/MHC-I-coated beads (3 beads per 1 cell) and siRNA-treated Treg cells were 
titrated to the Tconv cells in different ratios. Proliferation of Tconv cells was assessed by flow 
cytometry after 72 h. Silencing of HPGD in Treg cells did not influence their suppressive 
capacity, as Treg cells displayed a similar suppressive capacity after treatment with control 
siRNA as well as HPGD siRNA (Figure 66). This result indicates that HPGD plays no 
important role for the suppressive function of Treg cells at least in vitro. 
 
 
Figure 66: Knockdown of HPGD in human Treg cells does not 
influence their suppressive capacity.  
Human CD4+CD25+ T cells were purified from peripheral blood 
and a siRNA-mediated HPGD or control knockdown was 
performed. Suppressive function of human Treg was assessed 24 h 
after knockdown in a suppression assay. Therefore, siRNA-treated 
Treg cells were titrated in different ratios to CFSE-labeled Tconv cells, 
which were stimulated with anti-CD3/CD28/MHC-I coated beads (3 
beads: 1 T cell). Proliferation of Tconv cells was assessed after 72 h 
by flow cytometry. Data are presented after normalization to Tconv 
cells, which were incubated with beads but without Treg cells. Data 
are shown as mean values and standard deviations of at least three 
individual experiments. 
 
3.11.3 Chemical inhibition of HPGD has no significant effect on HPGD mRNA expression in Treg 
cells 
 
The role of HPGD for the regulatory phenotype of Treg cells was further investigated when 
HPGD was chemically inhibited. Chemical inhibition of HPGD was tested as an alternative 
approach to the siRNA mediated knockdown of HPGD. Therefore, the inhibitor CK47A (5-
[[4-(ethoxycyrbonyl)phenyl]azo]-2-hydroxy-benzeneacetic acid; CAY10397) was used. 
CK47A is a potent, selective inhibitor of HPGD with an IC50 of approximately 10 µM. The 
inhibitor was pretested on CD4+ T cells to define an optimal concentration, which results in 
no unspecific side effects. 20 µM was found to be a suitable concentration that did not have 
toxic effects on CD4+ T cells, as shown in Figure 67, and was used as appropriate working 
concentrations for the following experiments. 
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Figure 67: An HPGD inhibitor concentration of 
20 µM represents a suitable working 
concentration. 
Human CD4+ T cells were purified from peripheral 
blood and treated with different HPGD inhibitor 
concentrations for 24 h or DMSO (control). 
Consequently cell viability was measured by 
propidium iodide incorporation in flow cytometry. 
Data are shown as mean values and standard 
deviations of three individual experiments after 
normalization to DMSO treated control cells. 
 
Next, it was examined whether chemical inhibition of HPGD in human Treg cells would 
influence HPGD expression. The inhibition of HPGD did not significantly change HPGD 
mRNA expression in Treg cells, compared to DMSO treated control cells (Figure 68). HPGD 
mRNA expression showed a slight positive tendency after HPGD inhibitor treatment, which 
might indicate that HPGD expression is regulated via a feedback loop in human Treg cells. 
However, further experiments would be necessary to address this in more detail. 
 
 
Figure 68: HPGD expression is enhanced upon 
chemical inhibition of HPGD in human Treg cells.  
Human CD4+CD25+ T cells were purified from 
peripheral blood and treated with 20 µM HPGD 
inhibitor CK47A (20 µM inhibitor) or with the 
respective amount of DMSO (Control) for 24 h. 
Relative HPGD mRNA expression, compared to B2M 
expression, was assessed by qRT-PCR. Data are 
normalized to DMSO treated Treg cells. Standard 
deviations and mean values of three individual 
experiments are shown. 
 
3.11.3.1 FOXP3 expression in Treg cells is not influenced by chemical inhibition of HPGD 
 
The previous results had demonstrated that FOXP3 expression was not influenced by 
silencing of HPGD. As an alternative approach to the siRNA mediated knockdown, HPGD 
was chemically inhibited to determine a potential influence on FOXP3 expression in Treg 
cells. Human Treg cells were isolated from peripheral blood and incubated with 20 µM HPGD 
inhibitor or the respective amount of DMSO for 24 h. Relative FOXP3 mRNA expression 
was assessed by qRT-PCR and FOXP3 protein expression was examined by flow cytometric 
analysis of intracellular FOXP3 staining, after chemical inhibition of HPGD. In Figure 69 it is 
shown that FOXP3 mRNA and protein expression were unchanged in Treg cells after 
inhibition of HPGD.  
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This result indicates that HPGD has no influence on FOXP3 expression in human Treg cells. 
 
 
Figure 69: FOXP3 expression is not influenced by chemical inhibition of HPGD in Treg cells. 
Human CD4+CD25+ T cells were purified from peripheral blood and treated with 20 µM HPGD inhibitor 
CK47A (20 µM inhibitor) or with the respective amount of DMSO (Control). (A) Relative FOXP3 mRNA 
expression, compared to B2M expression, was assessed by qRT-PCR 24 h after inhibitor treatment. (B) 
Relative FOXP3 protein expression was assessed by intracellular FOXP3 staining 24 h after inhibitor treatment. 
Data are normalized to control cells and are shown as mean values and standard deviations of three individual 
experiments. 
 
3.11.3.2 No change in suppressive function of Treg after chemical inhibition of HPGD 
 
Although the former results had shown that silencing of HPGD in Treg cells does not influence 
their suppressive function, the suppressive activity of Treg cells was also examined after 
chemical inhibition of HPGD, to answer the question whether the enzymatic function of 
HPGD is crucial for the suppressive activity of Treg cells. Chemical inhibition should 
guarantee the complete blockade of the enzymatic function of HPGD. In brief, human Treg 
cells were isolated from peripheral blood and treated with 20 µM HPGD inhibitor CK47A 
(20 µM inhibitor) or with the respective amount of DMSO (control) for 24 h. Following this 
treatment the suppressive activity of these Treg cells was examined in a suppression assay, in 
which these Treg cells were titrated in different ratios to CFSE-labeled Tconv cells, stimulated 
with anti-CD3/CD28/MHC-I coated beads (3 beads per 1 cell). The proliferation of Tconv cells 
was assessed after 72 h by flow cytometry. In Figure 71, it is shown that chemical inhibition 
of HPGD in Treg cells did only slightly enhance their suppressive activity compared to DMSO 
treated control Treg cells. These results therefore indicate that the suppressive capacity of Treg 
cells is not dependent of the enzymatic activity of HPGD. This result is further supported by 
the observations of the previous siRNA-mediated silencing of HPGD in Treg cells, which did 
not significantly affect their suppressive activity.  
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Figure 70: Chemical inhibition of HPGD in human 
Treg cells does not significantly change their 
suppressive capacity.  
Human CD4+CD25+ T cells were purified from 
peripheral blood and were treated with 20 µM HPGD 
inhibitor CK47A (20 µM inhibitor) or with the 
respective amount of DMSO (Control) for 24 h. 
Subsequently the suppressive activity of Treg was 
assessed in a suppression assay. Data were analyzed 
and processed as described in Figure 66. The 
presented data are mean values and standard 
deviations of three individual experiments. 
 
Taken together, the experiments addressing the role of HPGD for the Treg cell illustrate that 
HPGD and its enzymatic activity seem to be neither necessary for the FOXP3 expression in 
Treg cells nor for their suppressive function at least in vitro. However, the enzymatic activity 
of HPGD may still mediate other important functions within the cell or might be required for 
the suppressive activity of Treg cells in vivo and could not yet be elucidated with the present 
experiments. 
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4 Discussion 
4.1 Specific expression of HPGD in human regulatory T cells 
 
The characteristics and functions of CD4+CD25+ regulatory T cells have been extensively 
studied – yet further investigation is required to completely determine how Treg cells mediate 
their suppressive activity especially in vivo and which molecules are actually involved. Up to 
now various molecules have been identified to be crucial for the function and development of 
Treg cells and to serve as marker molecules 254. Among these is the lineage specific 
transcription factor FOXP3 that influences as a master regulator the transcription of many 
target genes in humans and mice 244-246. However, there are still unknown genes that are 
required for a complete phenotype of Treg cells with full regulatory function.  
In order to identify novel target molecules involved in the development and function of 
human regulatory T cells, global gene expression profiling was carried out. Therefore, Treg 
and Tconv cells from healthy individuals as well as patients suffering from chronic 
lymphocytic leukemia (CLL), under resting as well as cells under activating or inhibiting 
conditions, were integrated. This approach should designate novel genes specifically 
expressed in Treg cells in comparison to Tconv cells. In contrast to previous approaches from 
other groups 206,207, the use of Tconv cells, kept under a wide variety of different conditions, 
should exclude genes that are unspecifically regulated in Tconv and Treg cells. In this context 
HPGD was identified as a gene that was highly expressed in Treg cells in comparison to Tconv 
cells. HPGD represents a key enzyme in the metabolism of prostaglandins and is one of the 
major PGE2-metabolizing enzymes 163,167. Remarkably, the expression pattern of HPGD was 
similar to that of the transcription factor FOXP3, with a high expression specifically in Treg 
cells and a low expression in Tconv cells (Figure 5). This stands in contrast to other molecules 
such as CTLA4 and CD127, which are commonly used to describe and distinguish Treg from 
Tconv cells. In fact, CTLA4 and CD127 displayed even high expression levels for Tconv cells 
and did not reveal the same Treg- or Tconv-restricted expression pattern, as it was the case for 
HPGD (Figure 6). Moreover, these molecules are not strictly Treg-specifically expressed, as 
CTLA4 is transiently upregulated on CD4+ and CD8+ T cells, 2-3 days following 
activation68,255 and CD127 was recently shown to be downregulated on CD4+ T cells in 
general upon activation68,256. For these reasons CTLA4 and CD127 are insufficient in their 
qualities as Treg-specific marker molecules.  
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Consistent with the gene expression data relative HPGD mRNA expression was shown to be 
significantly higher expressed in human Treg cells than in human Tconv cells (Figure 7). The 
differential expression of HPGD in Treg cells compared to Tconv cells was also validated on 
protein level by Western blot analysis (Figure 32). With these results it was demonstrated that 
Treg cells express the enzyme HPGD, which might maintain specific functions within the Treg 
cell.  
Since no monoclonal antibody for detection of HPGD protein was commercially available at 
the time the thesis was conducted, a monoclonal antibody specific for human HPGD was 
generated in cooperation with Ravi Hingorani and Robert Balderas, both Becton Dickinson 
Biosciences. Within this context several antibody clones were tested, concerning their binding 
specificity and staining performance in flow cytometry, Western blot analysis and 
immunofluorescence staining. For all three methods, best results were achieved with HPGD 
antibody clone 3 that demonstrated specific and efficient staining of cells transfected with 
HPGD or a HPGD-GFP fusion protein. However, the HPGD antibody appeared to be not 
suitable for flow cytometric and immunofluorescence stainings of primary cells, because Treg 
and Tconv cells did not appear to be differentially stained by the antibody and HPGD staining 
was either absent or equally distributed in all cells. One reason we might not have detected 
staining of HPGD in primary cells, could be that the primary cells do not express HPGD 
protein. This hypothesis, however, stands in contrast to the results of Western blot analysis, 
which detected HPGD protein in Treg cell lysates (Figure 32). Furthermore, enzymatic activity 
of HPGD was demonstrated in Treg cells during this study which also nicely reflected the 
differences between Treg and Tconv cells, concerning their relative HPGD mRNA expression 
(Figure 50). High enzymatic activity in Treg cells was accompanied by high HPGD mRNA 
expression and vice versa in Tconv cells. Another reason for the absence of HPGD staining 
might be low affinity of the HPGD antibody. This would be supported by the fact that only 
highly transfected HEK293 cells, overexpressing HPGD protein, were sufficiently stained. In 
addition, high protein amounts of Treg cell lysates had to be subjected to Western blotting in 
order to efficiently detect HPGD on Western Blot. Although, HPGD expression in 
untransfected HEK293 cells could be detected by qRT-PCR data (Figure 16) and in addition 
these cells were slightly stained in flow cytometry with high HPGD antibody concentrations 
(dilution 1:100, Figures 13-15), this staining cannot be considered as evidence for endogenous 
staining of HPGD in these cells. One argument against this is the 100.000 fold higher HPGD 
mRNA expression in HPGD-GFP transfected cells compared to untransfected cells. It is 
rather unlikely that these differences might be also observed on protein level. Even more so as 
  Discussion 
120 
highly HPGD-GFP transfected cells, visualized by GFP signal intensity, were only 
appropriately stained with the HPGD antibody. Another argument is that HPGD was likewise 
undetectable in untransfected HEK293 cells on Western Blot. These results, therefore, 
indicate that the observed slight background staining, observed in flow cytometry, was rather 
caused by unspecific staining due to an oversaturated antibody solution and support the 
hypothesis of a low affinity of the HPGD antibody. Similarly, the results obtained from 
immunofluorescence support a low affinity of the HPGD antibody, as FOXP3 positive CD4+ 
T cells showed no differential HPGD staining compared to FOXP3 negative CD4+ T cells. A 
third reason for the unsatisfying HPGD staining results of primary cells in flow cytometry and 
immunofluorescence might be the differential treatment of the cells. For Western blot analysis 
the protein is treated with SDS, which leads to irreversible denaturation of the protein 
structure. This may alter the structure and availability of the epitope and thus its ability to 
interact with the HPGD antibody, consequently changing the staining result. On the contrary, 
in flow cytometry and immunofluorescence the three-dimensional protein structure is 
conserved by the treatment for instance with formaldehyde. Potential epitopes might thereby 
be covered or less accessible, which impairs the interaction with the HPGD antibody and in 
turn the staining result. Supporting this hypothesis is the fact that HPGD protein expression in 
Treg cells was only detected by Western blotting. The epitopes might have become better 
accessible for the HPGD antibody on Western Blot, resulting in an improved detection. In 
conclusion, the analysis frame of the HPGD protein expression was very limited due to a low 
affinity of the HPGD antibody. The antibody was used in Western blot analysis for the 
detection of HPGD in primary cells. For flow cytometric or immunofluorescence staining, 
however, it was uneligible, because only HPGD-overexpressing cells were appropriately 
stained. 
Although HPGD expression was shown to be higher in Treg cells on mRNA as well as protein 
level than in Tconv cells, we wanted to determine whether HPGD expression was specific for 
Treg cells or could be also found in other CD4+ T cell subsets, with regard to their activation 
state and differentiation stage. Therefore HPGD mRNA expression was assessed in Tmemory 
and Tnaive cells, which were distinguished during this study by their differential expression of 
the leukocyte specific transmembrane glycoprotein CD45. The isoform CD45RA allows the 
discrimination of naïve from activated or memory T cells 210, as the isoform CD45RA is 
expressed on human naïve T lymphocytes. Upon encounter of their cognate antigen Tnaive 
cells acquire an activated phenotype. They upregulate activation markers such as CD25, 
CD44, and CD69 but down-regulate CD62L and CD45RA 214-216. These activated, ‘antigen-
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experienced’ T cells can further differentiate into a memory T cell 216-218, which is also 
CD45RA- and expresses the shortest CD45 isoform CD45RO 213,214. First examinations had 
revealed a higher HPGD expression level in Tmemory cells than in Tnaive cells, indicating that 
HPGD expression might be upregulated during T cell activation and differentiation. However, 
when the assumption was tested whether HPGD expression would be upregulated during T 
cell activation or differentiation, enhanced HPGD expression was neither detected in activated 
T cells (TH0 cells, Figure 34) nor in the different T helper cell subsets, TH1, TH2, TH9 as well 
as TH17 cells (Figure 34). Instead, HPGD expression levels did not increase but remained 
constantly lower compared to Treg cells. This result indicated a Treg cell specific HPGD 
expression, which seems to be fixated already during early thymic differentiation and 
establishment of the Treg cell phenotype. The polarization of the Tconv cells seemed to be 
already so strong and established that even the culture conditions that induce an iTreg cell 
phenotype were not sufficient to induce HPGD expression in vitro.  
Remarkably, also induced Treg cells did not upregulate HPGD expression, as shown by gene 
expression profiling and qRT-PCR data (Figure 35 and 72). This is of special interest as on 
the one hand induced Treg and naturally occurring Treg cells have certain characteristics in 
common, such as a high FOXP3 expression and suppressive function in vitro and in vivo 
30,227
. On the other hand iTreg cells also strongly differ from nTreg and differences in gene 
expression between iTreg and nTreg still remain to be elucidated. A study by Hill et al. 2007 
demonstrated for instance that iTreg cells lack a part of the gene signature, specific for nTreg 
cells, despite their high FOXP3 expression 228. Thus, the specific HPGD expression in nTreg 
cells indicates that HPGD represents a novel marker molecule for nTreg cells. Over the last 
years several molecules were proposed as potential marker molecules to differentiate nTreg 
from iTreg cells and different marker molecules for human and murine nTreg cells were 
summarized by Yi et al. 257. However, these potential markers failed as real nTreg cell markers, 
as they were either upregulated on activated Tconv cells or expressed by naïve or other 
regulatory T cell subsets 257. Nonetheless, it is of high interest to distinguish between nTreg 
from iTreg cells, to designate the origin of the enhanced Treg numbers that are found, for 
instance, in the tumor microenvironment 109,112,113(see also Introduction 1.1.5). Up to now it 
remains unclear whether these Treg cells are induced from non-Treg cells, promoted by tumor-
secreted cytokines, or if pre-existing Treg cells migrate into the tumor tissue and eventually 
proliferate there. Besides that, a specific marker for nTreg cells would be beneficial for their 
detection in various disease models. Moreover, a marker molecule specific for nTreg cells 
could help to define a cell population with a stable regulatory phenotype that is not lost during 
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the following Treg cell expansion, because large cell amounts of a pure Treg cell population are 
required in clinical trials for cell-based tolerogenic therapy of autoimmune diseases, graft 
rejection or graft versus host disease 258,259. Although, highly purified human Treg cell 
populations (greater than 90% CD4+FOXP3+ cells) can be obtained by fluorescence-activated 
cells sorting on CD25high, the percentage of FOXP3+ cells decreases already after 2 weeks of 
expansion to 50% 260. Moreover, FOXP3 expression can be induced in FOXP3+ Tconv cells by 
stimulation of the TCR in the presence of TGF-β, without inducing suppressive activity in 
these cells 261. Thus even highly purified FOXP3+ cell populations may represent a mixture of 
Treg and non-Treg cells. For these reasons a nTreg cell specific molecule could help to define a 
pure Treg cell population with a stable regulatory phenotype. Recently, the transcription factor 
Helios was identified as specifically expressed in thymic derived Treg cells and was therefore 
proposed to be a nTreg specific marker 206,262. Notably, Helios expression was absent in 
induced Treg cells and was shown to influence FOXP3 expression and suppressive activity in 
Treg cells 262,263. However, this statement was soon challenged by another study, which 
demonstrated coexpression of Helios in induced Treg cells and claimed that Helios expression 
is dependent on the method of activation and not on the origin of the cell 264. Therefore, a true 
nTreg cell specific marker still remains to be identified. Although HPGD expression in thymic-
derived Treg cells needs to be examined, we might have identified such a novel molecule that 
is specific for nTreg cells, as the present study demonstrates an high HPGD expression in nTreg 
cells but low expression in iTreg, activated Tconv and T helper cell subsets. 
 
4.2 Regulatory function of Treg cells in vitro is independent of HPGD  
 
Since HPGD was specifically expressed in nTreg cells, compared to iTreg, Tconv and TH cell 
subsets, various questions arose from these findings, for instance, what function HPGD 
fulfills in Treg cells. As pre-incubation with PGE2 upregulates FOXP3 expression and even 
enhances the suppressive function of Treg cells 232, the high expression levels of a PGE2 
metabolizing enzymes 141 in Treg cells seem to be contradictory. However, the enzymatic 
activity of HPGD might be involved in the regulation of various signaling pathways, which in 
turn might influence FOXP3 expression. For this reason FOXP3 expression was examined 
after silencing HPGD in human Treg cells by siRNA knockdown. Alternatively, the enzymatic 
function of HPGD was chemically inhibited by the specific HPGD inhibitor CK47A, which is 
a potent, selective inhibitor of HPGD. First we observed that HPGD knockdown did not 
influence FOXP3 mRNA and protein expression in comparison to control knockdown 
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(Figure 65). Also chemical inhibition of HPGD did not alter FOXP3 mRNA or protein 
expression in comparison to DMSO treated control cells (Figure 69). Hence, FOXP3 
expression in Treg cells seemed to be independent of the enzymatic function of HPGD. Yet, 
the enzymatic function of HPGD might still be required for the regulatory phenotype of the 
Treg cell. Baratelli et al. 2005 reported PGE2 pre-treated Treg cells could still suppress 
proliferation of Tconv cells, which were separated by trans-well inserts. Notably, neither anti-
IL-10 nor anti-TGF-β neutralizing antibodies did reverse these effects, suggesting the 
contribution of additional soluble factors other than IL-10 or TGF-β 232. As PGE2 can be 
metabolized by HPGD, these soluble factors might represent metabolites of PGE2 that might 
be secreted and also have immunosuppressive properties. Moreover, PGE2 secretion was 
suggested to be a suppressive mechanism used by Treg cells 265,266 and PGE2 inhibits the 
proliferation of CD4+ T cells 267,268. Thus HPGD might repel the suppressive effects of PGE2 
in the Treg cell, while at the same time an effective suppression of Tconv is guaranteed. For 
these reasons we sought to investigate the contribution of HPGD to the suppressive phenotype 
of Treg cells in vitro. However, silencing of HPGD by siRNA knockdown in Treg cells did not 
affect their suppressive activity (Figure 66), as Treg cells treated with control siRNA equally 
inhibited proliferation of Tconv cells. Similar results were obtained for chemical inhibition of 
HPGD, which did not significantly change the suppressive function of Treg cells (Figure 70). 
Although these observations suggest that suppression by Treg cells is independent of the 
enzymatic activity of HPGD, it might be still required for an in vivo function. Moreover, the 
in vitro measurement of suppressive activity might not represent the optimal read-out, to 
determine a potential role of HPGD for the regulatory function of Treg cells. For instance, cell-
contact dependency was postulated for Treg cells, as indicated by in vitro assays 19,72, but at the 
same time several cell-contact-independent suppression mechanisms have been described to 
be used by Treg cells in vivo (see Introduction 1.1.4). Besides, blocking one of these 
mechanisms might not necessarily increase or impair the complete suppressive capacity and 
so the contribution of HPGD to the regulatory phenotype of Treg cells remains to be 
elucidated. 
 
4.3 Influence of extracellular stimuli on the HPGD expression in human Treg cells 
 
Regulatory T cells can be influenced by various stimuli, for example by TCR stimulation and 
additional signals via costimulatory and cytokine receptors are also involved 19. Especially the 
cytokine IL-2 was shown to be important for the development and function of Treg cells. Mice 
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deficient in IL-2, IL-2Rα or IL-2Rβ have strongly reduced numbers of Treg cells and die 
prematurely from a severe lymphoproliferative and autoimmune syndrome 234,235 
Furthermore, it was shown that blocking the IL-2R on Treg cells leads to a loss of their 
regulatory activity, suggesting a possible role of IL-2 for suppressor function 91. Treg cells 
were further shown to require previous activation for the induction of their suppressor 
function in vitro 233. Pre-cultured for at least 24 h with anti-CD3-antibody (0.5-1 µg/ml) in the 
presence of IL-2 (at least 12.5 U/ml) and the absence of Tconv cells guaranteed best induction 
results 233. Since unstimulated human Treg cells in the present study downregulated HPGD 
mRNA expression already after 12 h, indicating a dependency on extracellular stimuli, the 
influence of TCR ligation in the presence of IL-2 or CD28 costimulation on HPGD 
expression were consequently examined. Notably, TCR ligation in the presence of IL-2 did 
significantly upregulate HPGD expression in Treg but not in Tconv cells (Figures 38 & 39). 
Moreover, the enzymatic activity of HPGD was also enhanced by IL-2 stimulation and a high 
enzymatic activity in Treg cells was accompanied by a high HPGD mRNA expression in 
comparison to the low activity and HPGD mRNA expression in Tconv cells (Figure 50). As the 
suppressive function and FOXP3 expression of Treg cells can be also induced upon TCR/ IL-2 
stimulation 233, these findings indicate a potential role of HPGD for the Treg cell function, 
despite the previous negative results from the in vitro suppression assays. Soon it became 
evident that HPGD upregulation was due to IL-2 but not TCR stimulation. Notably, the 
inducing effect of IL-2 on HPGD expression seemed to be restricted to Treg cells as TH1, TH2, 
TH9 or TH17 did not upregulate HPGD expression upon IL-2 stimulation (Figure 48). Even 
induced Treg cells did not enhance HPGD expression upon IL-2R signaling, as it was observed 
for nTreg cells (Figure 49). These results show that IL-2R signaling in Treg cells is 
differentially regulated than in other T cell subsets. Moreover, these results once more 
demonstrate that HPGD expression seems to be specific for naturally occurring Treg cells, in 
comparison to other CD4+ T cell subsets and further indicate a Treg cell specific function for 
HPGD. 
Remarkably the effects of IL-2 on HPGD expression were even observed at low IL-2 
concentrations (10 U IL-2/ml) (Figure 46). This result corresponds to earlier studies, which 
demonstrated that IL-2-dependent targets in Treg cells are coupled to a low IL-2R signaling 
threshold 236. As Treg cells are unable to secrete IL-2 27 and only few IL-2 producing cells are 
in the thymus and these cells are furthermore not abundant in the periphery 269-271, Treg cells 
need to utilize IL-2 effectively in an environment where this essential cytokine is only 
transiently and minimally expressed. Additionally, the grade of IL-2R signaling is associated 
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with different functional activities of nTreg cells, as for instance low IL-2R signaling supports 
thymic development or the induction of FoxP3, whereas high IL-2R signaling is required for 
Treg cell growth 272. These observations explain why even low IL-2 concentrations did 
upregulate HPGD expression. Moreover, no correlation between the HPGD expression level 
and the amount of IL-2 was observed, as increasing concentrations of IL-2 (10 U – 
1.000 U/ml) led to similar HPGD expression levels in Treg cells. This indicates that only low 
amounts of IL-2 are required to saturate signaling pathways that lead to an upregulation of the 
HPGD expression and no further HPGD increase can be achieved by increasing amounts of 
IL-2.  
Besides TCR/IL-2R activation the influence of costimulation on HPGD expression in Treg and 
Tconv cells was examined, as T cell proliferation was shown to be differentially regulated in 
Treg and Tconv cells and this could be likewise for the HPGD expression. The activation of Treg 
cells was shown to be independent of CD80/CD86 costimulation, as stimulation with 
exogenous IL-2 could replace costimulation233. However, this observation was different for 
the activation of Tconv cells, where IL-2 was not sufficient as a substitute for costimulation, to 
induce T cell proliferation 233. Thus, HPGD expression in Tconv cells might be influenced by 
TCR/CD28 activation. However, stimulation with anti-CD3/CD28/MHC-I-coated beads did 
not affect HPGD mRNA expression in Tconv cells (Figure 43). Treg cells did also not enhance 
HPGD expression upon this stimulation. This result was expected and is in line with the 
observation that Treg cells are unable to produce IL-2 even after TCR/CD28 activation 27. 
Investigations into the underlying pathways of IL-2R signaling revealed a crucial role of PI3K 
and NF-κB signaling for the IL-2 mediated upregulation of HPGD (Figures 52 & 53). This 
was demonstrated by incubation with inhibitors specifically targeting these signaling 
molecules, which in turn impaired IL-2 mediated HPGD upregulation in Treg cells. However, 
this observation is in contrast to a study by Bensinger et al. 2004 demonstrating that 
CD4+CD25+ Treg cells stimulated with exogenous IL-2 failed to activate the PI3K-Akt 
pathway and exclusively activated STAT5, because activation (phosphorylation) was not 
observed for Akt and only for STAT5 273. In addition, the same study also shows that 
proximal IL-2R signaling in CD4+CD25+ Treg cells is sufficient to activate PI3K and that the 
negative regulation lies downstream of PI3K and is due to the lipid phosphatases PTEN and 
Src homology 2-containing inositol polyphosphate 5-phosphatase (SHIP)-1 273. Therefore, it 
can be speculated that PI3K could still activate other targets than Akt, thus leading to the 
observed effects. Another explanation for the observed results could be that other signaling 
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molecules than PI3K were inhibited by the PI3K inhibitor. Although the PI3K inhibitor 
LY294002 used in this study is reported to be a highly selective one that does not inhibit other 
lipid and protein kinases such as PI4 kinase, PKC, MAP kinase or c-Src, it cannot be excluded 
that the observed results with the PI3K inhibitor are caused by inhibition of signaling 
molecules other than PI3K. Similar events can be assumed for NF-κB. On the one hand NF-
κB could be activated by other IL-2-dependent signaling events and inhibition of NF-κB 
downmodulated IL-2-dependent HPGD expression. On the other hand inhibition of NF-κB 
might also have targeted other signaling events connected with IL-2-mediated HPGD 
upregulation.  
Nonetheless, in accordance with the study of Bensinger et al. 2004 is the observation that 
inhibition of JAK3 and STAT5-signaling did down-modulate IL-2 mediated HPGD 
upregulation (Figures 54 & 55). This result indicates an important role of STAT5 in the 
regulation of HPGD expression. Potential binding sites for STAT5 were predicted in the 
HPGD promoter area and future experiments should investigate whether STAT5 binds to 
these sites in the HPGD promoter and directly acts on HPGD expression. In contrast to these 
findings, MAPK signaling was not required for the IL-2 dependent induction of HPGD in Treg 
cells. As expected, chemical inhibition of MEK1 did not significantly change the IL-2 
influenced HPGD expression (Figure 51). This result is in line with the above mentioned 
observation of Bensinger and colleagues 273 that IL-2 stimulation does not activate the 
MAPK- pathway in Treg cells. 
In addition to IL-2 the influence of PGE2 on HPGD expression in Treg cells was investigated. 
Prostaglandin E2 is a soluble, immune suppressive molecule that is produced by many 
different cell types including cells of the immune system, such as monocytes, macrophages 
and neutrophils 230, but also by tumor cells 229. PGE2 plays thereby an important role in 
carcinogenesis as it inhibits for instance tumor cell apoptosis, induces tumor-cell proliferation 
and increases tumor progression 274,275. Furthermore, PGE2 inhibits the proliferation of CD4+ 
T cells 267,268 and notably, pre-incubation with PGE2 did increase FOXP3 expression as well 
as the suppressive activity of Treg cells 232. In addition, tumor-secreted PGE2 was shown to 
induce FOXP3 expression as well as a regulatory phenotype in CD4+CD25-T cells 231,232. 
Human CD4+CD25+ adaptive Treg cells that were induced by PGE2 in vitro, did express 
cyclooxygenase 2 (COX-2) and FOXP3 and produced PGE2 to suppress effector T cell 
responses 266. For these reasons the enhanced expression of the PGE2-metabolizing enzyme 
HPGD in Treg cells seems to be counterintuitive. It could be hypothesized that HPGD is 
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required to protect the Treg cell from T cell inhibitory effects of PGE2 by inactivating PGE2, 
while at the same time this would enable the activation of Treg specific functions. PGE2 
signaling occurs through 4 classes of receptors, the E prostanoid receptors EP1 to EP4, which 
have been reported to be expressed on T cells 276,277. It was shown that EP2 and EP4 were 
required for PGE2-mediated induction of Treg cell FOXP3 gene expression 231. Furthermore, 
EP3 and EP4 were recently identified in the nuclear envelope of porcine cerebral 
microvascular endothelial cells, suggesting the presence of functional nuclear receptors for 
PGE2 278, although these receptors have not yet been shown on the nuclear envelope in Treg 
cells to my knowledge. For these reasons it could be speculated that PGE2 signaling might 
influence HPGD expression in the Treg cell. Therefore, we investigated whether incubation 
with PGE2 would influence HPGD expression in Treg cells. However, the treatment of human 
Treg cells with PGE2 alone did not significantly modulate the HPGD mRNA expression in Treg 
cells in comparison to unstimulated Treg cells, as HPGD expression decreased under both 
conditions to 40 – 30 % over a period of 72 h (Figure 36). In addition to the EP receptors also 
prostaglandin specific transporters (PGT) have been described 279-281, however, PGT have not 
been specifically shown on Treg cells. Assuming that PGE2 could enter the Treg cell via PGT 
the present HPGD expression level seems to be sufficient to prevent suppressive effects of 
PGE2 on the Treg cell. 
Other immune suppressive molecules such as TGF-β 282,283 or IL-10 284-286 have also been 
detected in several tumors or tumor cell lines and were reported to induce Treg cells in the 
periphery 34,35. In addition, IL-10 was shown to maintain FOXP3 expression and suppressive 
capacity of regulatory T cells287 and is produced by Treg cells and Tr1 cells35. Similarly, TGF-
β was also shown to induce FOXP3 expression and the conversion of CD4+CD25- T cells into 
regulatory CD4+CD25+ T cells (TH3) 34,104. Furthermore, secretion of TGF-β 45 and 
membrane-tethered TGF-β on Treg cells were shown to be involved in suppression of Tconv 
cells 54,89. Therefore, an influence of TGF-β and IL-10 on the HPGD expression in Treg cells 
cannot be excluded and the importance of these molecules for the HPGD expression in Treg 
cells was consequently investigated. Similar to the results obtained by PGE2 stimulation, 
TGF-β alone did not reveal a significant influence on HPGD expression in Treg cells compared 
to unstimulated cells (Figure 37). However, IL-10 stimulation positively influenced HPGD 
expression, as the HPGD expression was still significantly higher after 24 h with IL-10 
stimulation in comparison to unstimulated cells (Figure 37). These results indicate that HPGD 
in Treg cells is responsive to IL-10 signaling. Positive effects of IL-10 were also previously 
demonstrated with villous trophoblasts that showed decreased HPGD expression in the 
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presence of IL-1β but effects were antagonized by IL-10 stimulation176. IL-10 receptor 
signaling activates the Janus tyrosine kinases JAK1 and Tyk2 that lead to an activation of the 
transcription factor STAT3 288, and in mice it was shown that selective deletion of STAT3 in 
Treg cells led to spontaneous intestinal inflammation, which was associated with TH17 cell 
increase 289. Therefore, it is possible that IL-10 acts on HPGD expression via STAT3. With 
specific inhibition of STAT3 in Treg cells this issue could be investigated. Moreover, EMSA 
and ChiP assays could provide further evidence for direct binding of STAT3 to the HPGD 
promoter. 
In addition to these experiments, it was examined whether stimulation with TGF-β, IL-10 or 
PGE2 would impair or reverse the inducing effects of IL-2 on HPGD expression in Treg cells. 
TGF-β thereby significantly reduced IL-2-mediated HPGD upregulation after 24 h, 
suggesting a negative regulatory role of TGF-β (Figure 56). Besides that TGF-β plays an 
important role in the induction of regulatory T cells and participates in the suppression of 
Tconv cells (as mentioned before), it was also reported that TGF-β together with IL-2 enhances 
the suppressive effects of nTreg cells 290,291. The observation that TGF-β impairs the IL-2-
mediated upregulation of HPGD expression might therefore indicate that HPGD is not 
necessary for the suppressive capacity of Treg cells but maintains another function. Otherwise 
HPGD expression would be further enhanced, due to the activation of the respective 
suppression programs. In contrast to TGF-β, the presence of PGE2 and especially IL-10 did 
further increase IL-2-induced HPGD expression (Figure 56), compared to cells stimulated 
with IL-2 only (Figure 40). These rather unexpected results suggested that IL-10 and PGE2 in 
combination with IL-2 costimulation have positive synergistic effects on HPGD mRNA 
expression in Treg cells, as no effect on HPGD expression was observed when cells were 
stimulated with IL-10 or PGE2 alone and also IL-2 stimulation alone resulted in lower HPGD 
expression levels than in combination with IL-10 or PGE2. One explanation for this 
phenomenon could be that negative signaling pathways, which partially block HPGD 
expression, are compensated by IL-10 or PGE2 signaling and consequently HPGD expression 
is further enhanced. Moreover, IL-10 signaling alone had already demonstrated positive 
effects on HPGD expression. As mentioned above, HPGD expression might be regulated by 
IL-10R signaling via for example STAT3. Assuming that both, the induction of STAT5 by 
IL-2 and STAT3 by IL-10R signaling, lead to upregulation of HPGD expression, the inducing 
effects of these two signaling pathways might potentiate.  
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Besides that STAT5 and STAT3 could directly bind to HPGD, IL-2R and IL-10R signaling 
might alternatively activate the same target genes, distinct from HPGD, which in turn 
upregulate HPGD expression. AP-1 represents such a candidate, for which potential binding 
sites were identified and validated in the promoter of HPGD 180. Notably, AP-1 can be 
activated not only by IL-2R signaling 136-138 but JunB, a potential AP-1 component 292, was 
shown to be also a target gene of STAT3 293.  
In conclusion these results demonstrate that HPGD expression is dependent on extracellular 
stimuli and further indicate that HPGD expression in Treg cells is adapted to the present 
microenvironment in which the cells remain. Thus, HPGD might be necessary for tissue-
specific or disease-associated functions of the Treg cell (see therefore Discussion 4.6). 
 
4.4 Transcriptional regulation of HPGD expression in Treg cells 
 
In context with the above mentioned studies we also sought to investigate the influence of 
FOXP3 on HPGD expression in human Treg cells. With FOXP3 being the lineage marker of 
Treg cells and controlling their development and function via regulating the expression of 
many target genes 59-62, FOXP3 might similarly control the expression of HPGD. Silencing of 
FOXP3 by siRNA- knockdown in Treg cells resulted in significantly enhanced HPGD 
expression levels, indicating that HPGD expression is partially blocked by FOXP3 
(Figure 61). These results were rather unexpected, as HPGD expression was significantly 
higher in Treg than in Tconv, similarly to FOXP3 expression. Therefore, it could be assumed 
that the knockdown of FOXP3 should lead to the down-modulation of HPGD, in case that 
HPGD would be a direct target of FOXP3. However, we observed the contrary as HPGD 
expression was upregulated upon FOXP3 knockdown. Furthermore, the fact that HPGD is 
upregulated after a FOXP3 knockdown would rather indicate that FOXP3 negatively regulates 
HPGD expression. But this does not explain the significantly higher HPGD expression in Treg 
compared to Tconv, which show a low FOXP3 and HPGD expression. A possible explanation 
for the observed effects could be that FOXP3 has no direct influence on HPGD in Treg cells 
but regulates other factors, which in turn influence HPGD expression. Knockdown of FOXP3 
might lead to an imbalance in the expression of these other factors and consequently HPGD is 
upregulated. IL-2 expression in Treg cells, for instance, is repressed by a complex of FOXP3 
and NFAT 248. Upon silencing of FOXP3, this blockade is abandoned and IL-2 can now be 
activated by a newly formed complex, consisting of NFAT-AP1 248. IL-2 is transcribed and 
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consequently induces upregulation of HPGD expression, as demonstrated above. Moreover, it 
cannot be excluded that the siRNA-mediated FOXP3 knockdown did also affect other genes 
than FOXP3 and thus HPGD expression was enhanced. A further reason could be that FOXP3 
keeps the HPGD expression on a fine regulated optimal expression level, which is disturbed 
by the loss of FOXP3 and thus leads to enhanced HPGD expression. 
To further elucidate the observed effects we investigated whether FOXP3 can bind to the 
HPGD locus and thus directly influence HPGD expression. Transcription factor binding site 
prediction identified several potential FOXP3 binding sites upstream of the transcription start 
site (TSS) as well as in the genomic locus of HPGD (Figure 62). We could confirm binding of 
FOXP3 to a potential enhancer area at the HPGD locus. In addition to EMSA (Figure 63), 
further FOXP3 binding sites were confirmed in the HPGD locus by FOXP3 ChiP tiling arrays 
(Figure 62). Taken together, these findings indicate that FOXP3 can bind to the HPGD locus 
and could thus influence HPGD expression by direct interaction. The data obtained from the 
FOXP3 ChiP tiling arrays were, however, generated on basis of expanded Treg cells and 
therefore differences to naturally occurring Treg cells cannot be excluded. Although it was 
demonstrated that FOXP3 can bind to the HPGD locus further experiments are required to 
clarify whether binding of FOXP3 to HPGD consequently leads to gene transcription or not. 
Thus a luciferase reporter assay should be performed for the identified FOXP3 binding 
regions to prove functional consequences of FOXP3 binding to the HPGD locus. 
Besides the regulation of gene expression by FOXP3 also other transcription factors and 
control mechanisms should be closer examined to gain further insight into the differential 
HPGD expression between Treg and Tconv cells. Gene expression in eukaryotic cells is a well-
regulated process and can be controlled on different levels, such as transcription, RNA 
splicing, translation and post-translational modification of the protein. The transcriptional 
processes are thereby highly dependent of the interactions of transcription factors with their 
cognate regulatory sequences but also epigenetic mechanisms influence gene expression. For 
instance, Baron et al. 2007 had demonstrated that CpG islands were specifically demethylated 
in Treg cells within the gene locus of the human FOXP3 gene, in particular in an evolutionary 
conserved element in the 5’ untranslated region, which they named ‘Treg-specific 
demethylated region’ (TSDR), while this region was methylated in naïve CD4+ T cells. 
Notably, when the authors analyzed the methylation status of the FOXP3 TSDR of activated 
Tconv and TGF-β-induced Treg cells, the selected CpG motif remained completely methylated, 
despite that cells upregulated CD25 and displayed high FOXP3 expression levels 294. In 
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addition, they could further demonstrate that the DNA methylation status in TSDR not only 
regulated FOXP3 gene transcription but was also critical for a stable FOXP3 expression 295. 
Similarly, a methylation-specific PCR with bisulfite-treated DNA could be performed to 
examine the methylation status of the HPGD locus of Treg cells and compared it with those of 
Tconv and iTreg cells. Demethylated CpG islands in the HPGD body of nTreg cells in 
comparison to methylated regions of iTreg or Tconv cells would provide an explanation for the 
lower HPGD expression in these cells.  
Moreover remodeling of the chromatin structure for instance by modification of histone tails 
plays an important role in gene expression 296. Trimethylation of lysine 4 on histone H3 
(H3K4me3) thereby represents a permissive histone modification, which marks active 
promoters 253. The same can be observed for acetylation of histone H4 (H4Ac), which was 
shown to enhance transcription factor binding to nucleosomal DNA 297. In contrast di- and 
trimethylation of lysine 27 or 9 on histone H3 (H3K27Me2/3 or H3K9Me2/3) and 
trimethylation of lysine 20 on histone 4 (H4K20Me3), however, are associated with gene 
silencing 298,299. Permissive and repressive histone modifications at the HPGD locus should be 
compared between Treg and Tconv, as this could provide further explanations for differences in 
gene expression. Therefore, a chromatin immunoprecipitation with specific antibodies for the 
respective histone modifications could be conducted, combined with a subsequent qPCR 
(ChIP-qPCR) which overspans the promoter area with specific primer pairs. Alternatively to 
the qPCR, the immunoprecipitated DNA fragments could be sequenced (ChIP-Seq) 299,300. 
Preliminary ChIP-Seq data generated by our group point towards no significant differences 
between Treg and Tconv concerning the permissive histone modifications H3K4me3 and H4Ac 
and the repressive modification H3K27me3. However, differences in histone modifications 
can only give an indication for a possible regulatory scenario. A permissive histone 
modification does not necessarily correlate with the level of gene expression 296. Both cell 
types may show the same permissive histone modification, regardless of their differences in 
gene expression 296. Further insight into the regulation of HPGD gene transcription could be 
provided by another approach, combining chromatin immunoprecipitation with an antibody 
specific for RNA polymerase II (RNAPII) with following ChIP-Seq. RNAPII is essential for 
DNA transcription as it catalyzes the synthesis of mRNA precursors 301. Interestingly, stalled 
RNAPII at the promoter region of many genes was observed and it was suggested that this 
served to facilitate rapid gene expression 302. Notably, the level of RNAPII occupancy at the 
promoter region could be correlated with the activity of the respective gene. Genes that either 
lack RNAPII binding or show an high enrichment of RNAPII at the transcription site, were 
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found to be silent or weakly expressed 303. In contrast, genes that show a distribution of 
RNAPII throughout the transcription unit are highly expressed 303. RNAPII occupancy at the 
HPGD promoter region could therefore provide further insight into transcriptional regulation 
of HPGD. Regulatory T cells might show RNAPII occupancy throughout the transcriptional 
unit whereas no RNAPII binding or only occupancy at the transcription start site of HPGD 
would be expected for Tconv or iTreg cells. Additionally, DNase I hypersensitive sites could be 
examined at the HPGD locus of Treg and Tconv, as these sites also indicate active gene loci, 
similar to DNA methylation and histone modifications 296. 
In conclusion the following model of HPGD regulation in Treg could be proposed: Constant 
IL-2 signaling, which is essential for the Treg cell, is required for an enhanced HPGD 
expression in Treg. Thereby, FOXP3 maintains HPGD expression in a fine-regulated balance. 
Upon silencing of FOXP3, however, this balance is irritated. Other transcription factors that 
were previously blocked by FOXP3 may now have a stimulating effect on HPGD expression, 
with the consequence that HPGD expression is upregulated. Moreover, IL-2 expression that 
was previously repressed by the FOXP3-NFAT complex can now be activated by the newly 
formed NFAT-AP1 complex 248, resulting into enhanced IL-2 expression levels and possibly 
IL-2 secretion. Extracellular IL-2 increases until a critical level of 5 to 10 U/ml is reached, 
which is sufficient for upregulation of HPGD. The enhanced IL-2 concentration activates 
signaling cascades, such as JAK3/STAT5 signaling, which in turn overrule the influence of 
FOXP3 and activate gene transcription. HPGD expression is consequently upregulated. 
Further studies, however, are required to completely elucidate, which transcription factors and 
signaling events are actually involved in the regulation of the HPGD expression in Treg cells 
under resting as well as activating conditions. 
 
4.5 Differences of HPGD expression between human and murine Treg cells 
 
After characterizing expression of HPGD in human Treg cells, HPGD expression was also 
assessed in murine Treg cells in comparison to Tconv cells, to see if the observations made in 
the human could be transferred to the murine system. Remarkably, a lower HPGD expression 
was found in murine Treg cells in comparison to Tconv isolated from C57BL/6 mice 
(Figure 57). Although Treg cells from BALB/c mice displayed a slightly higher HPGD 
expression compared to Tconv, the expression levels were not significantly higher (Figure 58). 
Furthermore, HPGD expression in murine T cells was not specifically upregulated in Treg cells 
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upon IL-2 stimulation, independent of C57BL/6 or a BALB/c genetic background (Figures 59 
& 60). On the one hand these results demonstrate that gene expression in murine and human 
Treg cells is not necessarily congruent and that species specific differences may exist. This was 
already observed for other molecules, which showed specific and constitutive expression in 
murine or human Treg cells, but were not expressed at all or only in a subset of human or 
murine Treg cells. Expression of neuropilin-1 (Nrp-1) was shown, for instance, to be 
specifically and constitutively expressed on murine nTreg cells, independent of their activation 
status 304, whereas human Treg cells did not express Nrp-1, regardless of their origins 305. 
Another example is the ectoenzyme CD39 that is uniformly expressed on murine Treg cells, 
but is only expressed by a subset of human Treg cells with an effector/memory-like phenotype 
51
. 
On the other hand murine cells for the present study were isolated from spleen, whereas 
human cells were isolated from peripheral blood. Therefore, one could hypothesize that 
HPGD expression in Treg cells is dependent on the tissue and its particular microenvironment. 
This assumption is supported by a study of Feuerer et al. 2009, which demonstrated that 
murine fat tissue-derived Treg cells displayed a distinct and specific gene expression profile, 
which clearly differed from the expression pattern of Treg cells derived from spleen or lymph 
nodes, with HPGD being one of the transcripts that was specifically enhanced in fat-derived 
Treg cells 306. Future experiments should focus on HPGD expression of murine and human Treg 
cells derived from various tissues to answer the question of a tissue-specific HPGD 
expression in Treg cells. Moreover, the results obtained from these studies would elucidate 
differences between murine Treg and human Treg cells concerning their HPGD expression 
levels. Assuming that Treg cells exhibit a tissue-specific expression pattern for HPGD, the 
contribution of HPGD to a potential tissue-specific and also disease-associated role of Treg 
cells needs to be investigated (see therefore also next section 4.6). 
 
4.6 Role of HPGD for tissue specific functions of Treg cells 
 
Taken together, in the present study it was shown that HPGD represents a novel gene, which 
is specific for human naturally occurring Treg cells. Although the relevance of HPGD for the 
Treg cell function remains to be elucidated, the present study indicates a tissue-specific 
expression and thus a potential tissue-specific role of HPGD for Treg cells. Tissue-specific 
expression was indicated by the observation that spleen derived murine Treg cells did not show 
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a higher HPGD expression compared to murine Tconv cells as it was observed for human T 
cells, which were purified from peripheral blood. Moreover, it was clearly demonstrated that 
HPGD mRNA expression of human Treg cells can be modulated by various extracellular 
stimuli, such as the cytokines IL-2 and IL-10 or PGE2 in combination with IL-2, while HPGD 
mRNA expression levels decreased in the absence of any stimulus. HPGD expression may be 
adapted in vivo, depending on the particular microenvironment of each tissue in which the Treg 
cell resides. To elucidate whether HPGD expression in Treg cells is tissue-dependent and 
facilitates a tissue-specific role of the Treg cells, different questions have to be answered: First 
the expression levels of Treg cells derived from different tissues need to be assessed. As 
mentioned earlier, differences in HPGD expression between the murine and human system 
could thereby be investigated, to determine potential species specific differences. In this 
context HPGD expression levels of thymus derived Treg cells would throw further light on 
whether HPGD expression is indeed specific for thymic derived nTreg cells.  
Depending on these results, the next step should be to examine whether HPGD expression in 
Treg cells is modified in certain disease models. Differential expression of a PGE2 
metabolizing enzyme in Treg cells might be of interest especially in the tumor 
microenvironment, as on the one hand increased colonic mucosal levels of PGE2 were 
reported in patients with adenomatous polyps and colorectal carcinomas 307,308 and on the 
other hand increased numbers of Treg cells were observed in various tumors (see also 
introduction 1.1.5) 109,112,113. Notably, HPGD seems to play an important role in cancer as a 
tumor suppressor, because a loss of HPGD expression in various tissues was associated with 
the progression of the particular tumor, whereas over-expression of HPGD in these cells could 
reverse tumor progression 183-187 (see also introduction 1.3.5).  
Besides, PGE2 was reported to inhibit the proliferation of CD4+ T cells 267,268. Hence, in a 
microenvironment enriched with PGE2, HPGD might protect the Treg cell from the negative 
effects of PGE2. Moreover, Treg cells were suggested to exert their suppressive function also 
by PGE2 secretion 265,266. Thus, the protective effect of HPGD might be a prerequisite for 
efficient suppression of T cell proliferation by the Treg cell. In addition to that, the enzymatic 
activity of HPGD might play a role for the suppressive function of Treg cells in vivo, despite 
the negative results in the present in vitro experiments. As HPGD was shown to be functional 
in Treg cells it could be investigated whether PGE2 metabolites are generated in Treg cells and 
whether these metabolites maintain certain functions for the cell itself. These PGE2 
metabolites, for instance, might be secreted and exhibit immunosuppressive characteristics or 
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maintain other functions. Preliminary data generated from our group with 13,14-dihydro-15-
keto PGE2 indicated that this PGE2 metabolite also inhibits proliferation of Tconv cells 
similarly to PGE2. Since PGE2 is rapidly converted in vivo into 13,14-dihydro-15-keto PGE2 
309,310
, secretion of PGE2 metabolites might represent a further mechanism that Treg cells might 
use to suppress the proliferation of Tconv cells. Unfortunately, the metabolite 13,14-dihydro-
15-keto PGE2 is not very stable and a variable amount of non-enzymatic degradation is 
observed resulting into 13,14-dihydro-15-keto PGA2 311,312. Thus, it is rather unlikely that the 
metabolite 13,14-dihydro-15-keto PGE2 maintains an immunosuppressive function, but that 
other, more stable metabolites might be involved.  
Besides various prostaglandins, such as PGE1, PGE2, PGF1α, PGF2α, PGI2 and 6-keto-PGF1α, 
HPGD can also use other molecules as substrates, such as lipoxin A4 or unsaturated fatty 
acids, for instance 12-HHT or 15-HETE (see also Introduction 1.3.3) 168-170. The metabolites 
of these lipid mediators might be also important for the Treg cell itself or be involved in tissue-
specific functions. Furthermore, HPGD expression might be also important for a potential role 
of Treg cells in the adipose tissue and in obesity. Adipose tissue of lean individuals was found 
to be highly enriched with Treg cells with a specific gene expression profile and HPGD being 
one of the transcripts that were specifically enhanced 306. However, an altered constitution of 
T cells, resident in the adipose tissue, was observed during obesity, with reduced Treg cell 
numbers 306, whereas enhanced numbers of TH1 cells and CD8+ T cells were reported 313. 
Notably, obesity and metabolic dysfunction are associated with a low-grade chronic 
inflammation. Thereby, evidence is accumulating, that lipid mediators (mentioned above) 
play an important role in the induction of low-grade inflammation 314. This assumption is 
supported by the observation of high levels of arachidonate in adipose tissue of obese human 
individuals 315,316. Moreover, lipid mediators can activate immune receptors, such as G-
protein-coupled receptors and Toll-like receptors (TLR) and might induce low-grade 
inflammation 317. Thus, HPGD expression might be required for Treg cells to control and 
suppress inflammatory reactions in the adipose tissue and thus prevent adipocyte and 
metabolic dysfunction, which causes obesity and diabetes. In addition, lipid mediators are also 
involved in other human diseases, including rheumatoid arthritis, multiple sclerosis and 
various chronic inflammatory diseases 317 and HPGD might similarly play a role for the 
maintenance of immune homeostasis in the respective tissues. 
Finally, to gain further insight into the function of HPGD for the Treg cell and its relevance for 
the regulatory phenotype, Tconv cells could be transduced lentivirally with HPGD. Due to 
  Discussion 
136 
over-expression of HPGD, Tconv cells might gain Treg-associated features, such as an anergic 
and suppressive phenotype or the upregulation of characteristic marker molecules. 
In summary the results of the present study provide a basis for future experiments to examine 
the role of HPGD for a potential tissue-specific function of Treg cells and moreover could help 
to determine their function in the tumor microenvironment and in other diseases.  
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5 Zusammenfassung 
 
Fokus dieser Studie war die Charakterisierung der Hydroxyprostaglandin dehydrogenase 15-
(NAD) (HPGD) in CD4+CD25+ regulatorischen T-Zellen (Treg) im Hinblick auf die 
Regulation von HPGD und seine Rolle für die suppressive Funktion von Tregs. Auf der einen 
Seite übernimmt HPGD eine essentielle Funktion im Prostaglandin-Metabolismus und ist 
dabei eines der Hauptenzyme, die Prostaglandin E2 (PGE2) verstoffwechseln. Auf der anderen 
Seite wurde gezeigt, dass HPGD ein Tumor Suppressor ist. Die Expression von HPGD in 
regulatorischen T Zellen ist von speziellem Interesse, da erhöhte Mengen von Tregs im 
Tumorgewebe gefunden werden können und PGE2 diese Zellen aktiviert und zudem zur 
Karzinogenese beiträgt. 
Die vorliegende Studie zeigt, dass HPGD signifikant höher in Tregs exprimiert wird als im 
Vergleich in CD4+CD25- T-Zellen (Tconv). Insbesondere war die HPGD Expression spezifisch 
für natürlich vorkommenden Tregs (nTregs), da HPGD während der T-Zelldifferenzierung nicht 
hochreguliert wurde und auch induzierte regulatorische T-Zellen (iTreg) 
bemerkenswerterweise keine erhöhte HPGD Expression zeigten. Des Weiteren konnte die 
HPGD Expression ausschließlich in nTregs durch verschiedene extrazelluläre Stimuli 
spezifisch moduliert werden. Sogar kleinste Mengen an Interleukin 2 (IL-2) waren 
ausreichend die HPGD Expression stark zu erhöhen. Diese Daten weisen daraufhin, dass 
HPGD zum spezifischen Genrepertoire von nTregs gehört, da eine niedrige IL-2 Rezeptor-
Signaltransduktion auch die Entwicklung von Tregs im Thymus fördert. HPGD stellt daher ein 
neues Treg-spezifisches Molekül dar, das zur Unterscheidung zwischen nTregs und iTregs 
verwendet werden kann. Zusätzlich weist die Abhängigkeit der HPGD Expression vom 
extrazellulären Mikromilieu auch auf eine Gewebe-spezifische Expression und potentielle 
Funktion von HPGD in der Treg Zelle hin. 
Zusammengefasst zeigen die Ergebnisse dieser Studie, dass HPGD ein neues Gen 
repräsentiert, das spezifisch in natürlich vorkommenden regulatorischen Zellen exprimiert 
wird. Obwohl die Bedeutung von HPGD für die Funktion von Tregs noch unklar ist, liefert die 
vorliegende Studie eine Basis für nachfolgende Experimente, die eine Gewebe-spezifische 
Funktion von Tregs als auch deren Rolle im Tumormikromilieu aufklären kann.  
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Appendix 
A. Vector charts 
 
Vector charts of plasmids that were used and generated during this work are listed in Table 6 
and 7.  
 
Table 6: Vector charts of plasmids used during the present study 
1. pcDNA6/V5-His B (Invitrogen Life 
Technologies, Karlsruhe (DE)) 
2. pENTR4 GFP 3’ (Invitrogen Life 
Technologies, Karlsruhe (DE)) 
 
 
3. pLenti6.2/V5-Dest EF1α (Invitrogen 
Life Technologies, Karlsruhe (DE)) 
4. pIRES2-AcGFP1 (Clontech 
Laboratories, US) 
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Table 7: Vector charts of plasmids generated during the present study 
5. pLenti6.2/V5-Dest EF1α/HPGD-GFP 
(generated during the present study) 
6. pcDNA6/V5-His B/HPGD (generated 
during the present study) 
 
 
7. pcDNA6/V5-His B/HPGD-GFP 
(generated during the present study) 
8. pcDNA6/V5-His B/eGFP 
 
 
 
B. Experimental conditions for the gene expression profiling approach 
 
CD4+ T cells were isolated from human peripheral blood of healthy individuals or cancer 
patients (CLL). The cells were either left untreated (resting) or were incubated with different 
stimuli up to 24 h. The experimental conditions are listed in Table 8. Details concerning 
stimulation, coating and generation of the beads (also aAPCs) can be found under 2.2.2.8. In 
general the beads were used at a ratio of 3 beads: 1 T cell. 
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Table 8: Different experimental conditions for gene expression profiling 
Condition Abbreviation Cell type Treatment Donor 
1 Teff-H-0h-unstim CD4+ T cell Rested for 0 h Healthy 
2 Teff-H-8h-unstim CD4+ T cell Rested for 8 h Healthy 
3 Teff-H-12h-unstim CD4+ T cell Rested for 12 h Healthy 
4 Teff-H-18h-unstim CD4+ T cell Rested for 18 h Healthy 
5 Teff-H-19h-unstim CD4+ T cell Rested for 19 h Healthy 
6 Teff-H-20h-unstim CD4+ T cell Rested for 20 h Healthy 
7 Teff-H-26h-unstim CD4+ T cell Rested for 26 h Healthy 
8 Teff-H-8h-CD3 CD4+ T cell CD3/MHC-I-beads for 8 h Healthy 
9 Teff-H-8h-
CD3/CD28 
CD4+ T cell CD3/CD28/MHC-I-beads for 8 h Healthy 
10 Teff-H-20h-
CD3/CD28 
CD4+ T cell CD3/CD28/MHC-I-beads for 20 h Healthy 
11 Teff-H-8h-
CD3/CD28/PD1 
CD4+ T cell CD3/CD28/PD1-beads for 8 h Healthy 
12 Teff-H-8h- 
CD3/CD28/CTLA4 
CD4+ T cell CD3/CD28/CTLA4-beads for 8 h Healthy 
13 Teff-H-8h-
CD3/CD28+TGF-β 
CD4+ T cell CD3/CD28/MHC-I-beads 
+ TGF-β (30 ng/ml) for 8 h 
Healthy 
14 Teff-H-8h-
CD3/CD28+PGE2 
CD4+ T cell CD3/CD28/MHC-I-beads 
+ PGE2 (1 µM) for 8 h 
Healthy 
15 Teff-H-8h-
CD3/CD28+IL10 
CD4+ T cell CD3/CD28/MHC-I-beads 
+ IL-10 (50 ng/ml) for 8 h 
Healthy 
16 Teff-H-A-0h-unstim CD4+CD25lowT 
cell 
Rested for 0 h Healthy 
17 Teff-H-B-0h-unstim CD4+CD25int T 
cell 
Rested for 0 h Healthy 
18 Teff-H-C-0h-unstim CD4+CD25low-int T 
cell 
Rested for 0 h Healthy 
19 Teff-H-D-0h-unstim CD4+CD25- T cell Rested for 0 h Healthy 
20 Teff-CLL-D-0h-
unstim 
CD4+CD25- T cell Rested for 0 h CLL 
21 Teff-H-D-24h-
unstim 
CD4+CD25- T cell Rested for 24 h Healthy 
22 Teff-H-D-24h-
CD3+IL2 
CD4+CD25- T cell CD3(1µg/ml) + IL2(20U/ml) for 24 h Healthy 
23 Teff-CLL-D-24h-
CD3+IL2 
CD4+CD25- T cell CD3(1µg/ml) + IL2(20U/ml) for 24 h CLL 
24 Teff-H-D-24h- CD4+CD25- T cell CD3(1µg/ml) + IL2(20U/ml) for 24 h Healthy 
  Appendix 
156 
CD3+IL2 
25 Treg-H-0h-unstim CD4+CD25+T cell Rested for 0 h Healthy 
26 Treg-H-6h-unstim CD4+CD25+T cell Rested for 6 h Healthy 
27 Treg-H-0h-unstim CD4+CD25+T cell Rested for 0 h Healthy 
28 Treg-CLL-0h-unstim CD4+CD25+T cell Rested for 0 h CLL 
29 Treg-H-24h-
CD3+IL2 
CD4+CD25+T cell CD3(1µg/ml) + IL2(20U/ml) for 24 h Healthy 
30 Treg-CLL-24h-
CD3+IL2 
CD4+CD25+T cell CD3(1µg/ml) + IL2(20U/ml) for 24 h CLL 
31 Treg-H-24h-unstim CD4+CD25+T cell Rested for 24 h Healthy 
32 Treg-H-exp CD4+CD25+T cell Treg expanded (CD3/CD28/MHC-I-
beads + IL2(300U/ml))  
Healthy 
33 Treg-H-exp-Rapa CD4+CD25+T cell Treg expanded with Rapamycin 
(CD3/CD28/MHC-I-beads + 
IL2(300U/ml) + Rapamycin (100ng/ml))  
Healthy 
34 Treg-H-exp-24h-
CD3/CD28 
CD4+CD25+T cell Treg expanded (CD3/CD28/MHC-I-
beads + IL2(300U/ml)) and additionally 
stimulated with CD3/CD28/MHC-I-
beads for 24 h 
Healthy 
 
C. HPGD gene expression in Treg cells is higher compared to other PBMC 
subpopulations 
 
HPGD expression levels in CD14+ monocytes, CD19+ B lymphocytes, CD3+ T lymphocytes 
and CD56+ NK cells were examined to answer the question whether these PBMC subsets 
show HPGD expression and on account of this the observed HPGD staining in flow 
cytometry might be due to intracellular staining of HPGD. In addition, HPGD expression 
levels in the PBMC subsets were compared with those of Treg and Tconv cells. PBMC were 
isolated from human peripheral blood as described in 2.2.2.3 and separated into CD14+ 
monocytes, CD19+ B lymphocytes, CD3+ T lymphocytes and CD56+ NK cells. Furthermore, 
CD4+ T cells were isolated as described in 2.2.2.4 and separated into CD4+CD25+ Treg and 
CD4+CD25- Tconv as described in 2.2.2.5. In Figure 71, it is shown that the mean HPGD 
expression values in the different cell populations were below or near the background level 
(dotted line) compared to the high expression levels of Treg cells. Only NK cells showed a 
slightly enhanced HPGD expression. This result indicates that the observed HPGD signals in 
flow cytometry were unspecific and due to binding of the HPGD antibodies to unblocked Fc 
receptors.  
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Figure 71: Differential HPGD expression in different PBMC populations  
The average gene expression of HPGD in different PBMC populations was obtained by DNA microarray 
experiments. Therefore, CD4+ T cells and PBMC were isolated from human peripheral blood. CD4+ T cells 
were separated into CD4+CD25+ Treg and CD4+CD25- Tconv cells, PBMC into CD14+ monocytes, CD19+ B 
lymphocytes, CD3+ T lymphocytes and CD56+ NK cells. The graphic was created with pre-analyzed data, 
which was normalized with the quantile method. Mean values and standard deviations of three individual 
experiments are shown. The dotted line indicates the background level of 72.56 arbitrary units, which was 
calculated with the R statistical software package, using the quantile normalized data. 
 
 
D. HPGD gene expression is not upregulated during iTreg cell differentiation 
 
HPGD expression levels of induced regulatory T cells were compared with those of different 
CD4+ T cell subsets. Therefore CD4+ T cells were isolated as described in 2.2.2.4 and were 
left untreated (Tunstim) or stimulated with anti-CD3/CD28/MHC-I coated beads (Tstim). CD4+ T 
cells were further separated into CD4+CD25+ Treg, CD4+CD25- Tconv, CD4+CD25-CD45RA+ 
Tnaive and CD4+CD25-CD45RA- Tmemory cells as described in 2.2.2.5 and Tnaive were 
differentiated towards iTreg cells as described in 2.2.2.6. In Figure 72, it is shown that the 
mean HPGD expression values in the various cell populations was below or near the 
background level compared to high expression levels of Treg cells. This result further supports 
the assumption that HPGD expression is specific for Treg cells. 
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Figure 72: HPGD expression is not upregulated during differentiation towards iTreg cells  
The average gene expression of HPGD in different PBMC populations was obtained by DNA microarray 
experiments. Therefore CD4+ T cells were isolated from human peripheral blood and left untreated (Tunstim), 
stimulated with anti-CD3/CD28/MHC-I coated beads (Tstim) or separated into CD4+CD25+ Treg, CD4+CD25- 
Tconv, CD4+CD25-CD45RA+ Tnaive and CD4+CD25-CD45RA- Tmemory cells. Tnaive were differentiated into iTreg 
cells. The graphic was created with pre-analyzed data, which was normalized with the quantile method. Mean 
values and standard deviations of three individual experiments are shown. The dotted line indicates the 
background level of 72.56 arbitrary units, which was calculated with the R statistical software package, using 
the quantile normalized data. 
. 
 
E. Expression of lineage specific transcription factors as read out for successful 
T-cell differentiation 
 
Successful differentiation towards different T helper cell subsets was controlled by 
upregulation of lineage specific transcription factors, depicted in Figure 73. 
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Figure 73: Upregulated expression of lineage specific transcription factors as read out for successful T 
cell differentiation towards a TH1, TH2, TH9, TH17 and iTreg cell phenotype                     
Human CD4+CD25-CD45RA+ Tnaive cells were purified and stimulated with anti-CD3/CD28/MHC-I-coated 
beads and the appropriate cytokines to induce differentiation towards TH1, TH2, TH9, TH17 or iTreg cells. TH0 
cells represent control cells that were only stimulated with anti-CD3/CD28/MHC-I-coated beads. Tunstim 
represent unstimulated control cells. Relative mRNA expression was assessed by qRT-PCR after 7 days of 
T cell differentiation in comparison to B2M expression. (A) Relative T-bet mRNA expression in TH1, TH0 and 
Tunstim cells. (B) Relative GATA-3 mRNA expression in TH2, TH0 and Tunstim cells. (C) Relative PU.1 mRNA 
expression in TH9, TH0 and Tunstim cells. (D) Relative RORγt mRNA expression in TH17, TH0 and Tunstim cells. 
(E) Relative FOXP3 mRNA expression in iTreg, TH0 and Tunstim cells. Mean values and standard deviations of 
three independent experiments are shown. Data were normalized to the respective T cell subset. 
 
F. Test of toxic effects of different inhibitors on CD4+ T lymphocytes 
 
In the previous experiments it was shown that HPGD expression was significantly enhanced 
in Treg cells upon stimulation with IL-2. Binding of IL-2 to the IL-2 receptor leads to 
activation of different signaling cascades, such as the MAPK and PI3K pathways or 
JAK/STAT signaling. The contribution of the above mentioned signaling cascades to 
upregulation of HPGD in Treg cells was examined by targeting key molecules of the respective 
pathways with specific inhibitors to elucidate which signaling molecules are involved in IL-2-
mediated HPGD upregulation. To exclude effects by the respective inhibitors on cell death 
and apoptosis rate, the different inhibitors were tested on cell toxicity by assessment of cell 
viability of CD4+ T lymphocytes. Therefore, CD4+ T cells were purified from human 
peripheral blood and incubated for 24 h with the different inhibitors in increasing 
concentrations (see Figure 74). After 24 h cell viability was measured by means of propidium 
iodide incorporation in flow cytometry. The inhibitors showed no toxic effects at the indicated 
concentrations, as shown in Figure 74. 
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Figure 74: Cell viability of CD4+ T cells after treatment with different inhibitors in different 
concentrations  
Human CD4+ T cells were purified and stimulated for 24 h with different inhibitors or the respective amount of 
DMSO. Following inhibitors were used: (A) JAK3 inhibitor (Janex-1) as 100 & 150µM, (B) STAT5 inhibitor 
as 100, 200 & 300µM, (C) PI3K inhibitor (LY249002) as 10 & 20µM, (D) MEK1 inhibitor (PD98059) as 50 & 
100µM, (E) NF-κB inhibitor BAY11-7082 as 0.5 & 1µM and (F) NF-κB activation inhibitor as 1, 10 & 20µM. 
The percentage of dead cells was analyzed by propidium iodide (PI) staining. Data represent mean values and 
standard deviations of three experiments. 
 
G. Control of the siRNA mediated FOXP3 knockdown in human regulatory T 
cells  
 
The transcription factor FOXP3 can influence the expression of various target genes in Treg 
cells, as it can repress as well as induce gene expression.244-246 As HPGD expression was 
shown to be specifically enhanced in human Treg cells compared to Tconv, it was of interest to 
determine whether HPGD is a target gene of FOXP3. To answer the question whether HPGD 
expression is under the control of FOXP3, it was tested whether HPGD expression in human 
Treg cells would be changed after silencing FOXP3 by a siRNA knockdown. Therefore, 
human Treg cells were isolated from peripheral blood and siRNA-mediated knockdown of 
FOXP3 or a control knockdown in Treg cells was performed. FOXP3 mRNA expression was 
assessed by qRT-PCR analysis and protein expression by intracellular flow cytometric 
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staining 48 h after the knockdown, to examine the efficiency of the knockdown. A reduction 
of FOXP3 expression could be observed on mRNA as well as protein level after knockdown, 
as shown in Figure 75 A and B, indicating efficient knockdown of FOXP3. 
 
 
Figure 75: Efficiency of siRNA-mediated FOXP3 knockdown in Treg cells  
Human CD4+CD25+ T cells were purified from peripheral blood and treated with control siRNA or FOXP3 
siRNA. (A) Relative FOXP3 mRNA expression was assessed by qRT-PCR in comparison to B2M expression 
48 h after the control or FOXP3 knockdown. (B). Relative FOXP3 protein expression was assessed by 
intracellular FOXP3 staining 48 h after the control or FOXP3 knockdown. Data were normalized to control 
siRNA transfected cells and are shown as mean and standard deviations of at least three individual experiments. 
 
H. Electrophoretic mobility shift Assay – Supershift 
 
Previous experiments had shown that HPGD expression increases in Treg cells, after silencing 
of FOXP3, indicating regulation of HPGD by FOXP3. Therefore, it was tested whether 
FOXP3 can bind to the HPGD locus and HPGD represents a direct target gene of FOXP3. To 
answer the question whether FOXP3 can bind to the HPGD locus, the sequence of the HPGD 
locus was screened for binding sites of FOXP3 using bioinformatic in silico approaches and 
several potential FOXP3 binding sites were predicted upstream of the transcription start site 
(TSS) as well as in the genomic locus of HPGD. One of the FOXP3 binding sites, which was 
predicted -15kb 5’ of the transcription start site in a potential enhancer area, was selected to 
exemplify that FOXP3 can bind to the HPGD locus, using an electrophoretic mobility shift 
assay (EMSA). FOXP3 protein bound to the selected FOXP3 binding motif (HPGD), as 
depicted above in Figure 63. The binding was specific as a mutated HPGD (mut-HPGD) 
oligonucleotide showed no binding to FOXP3 and moreover the signal intensity was reduced 
in the presence of an oligonucleotide with a known FOXP3 binding motif (FKH), which was 
used as a competitor. The recombinant FOXP3 protein used for these experiments has a 
histidin tag. As a further control experiment an anti-histidin antibody was therefore added to 
the reaction mix. As control an isotype control antibody was used. Incubation with the anti-
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histidin antibody led to a shift in fluorescence intensity of a part of the band, as shown in 
Figure 76 (lane 2), which was not observed for incubation with isotype control antibody 
(lane 3) or when no histidin-antibody was added (lane 1). This result further shows that 
FOXP3 bound specifically to the HPGD oligonucleotide and that FOXP3 can bind to the 
HPGD locus. 
 
 
Figure 76: Specific binding of FOXP3 to the HPGD 
gene.  
An EMSA was performed with recombinant FOXP3 
protein (Protein) and a dimer of the HPGD gene with 
a FOXP3 binding motif (HPGD), labeled with the 
infrared dye DY-681 (Lane 1). An anti-histidin 
antibody (His-ab, Lane 2) or isotype control antibody 
(Isotype control-ab, Lane 3) were added to the 
reaction mix. One representative experiment out of 
two is shown. 
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